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1. Introduction 
 
1.1 Vascular remodeling 
 
The integrity of the vessel wall is a prerequisite for vascular function. The vessel wall 
normally consists of three well-defined concentric layers that surround the lumen1.  
The intima is the innermost monolayer of endothelial cells (EC) that lines the inside of the 
vessel wall being in direct contact with the flowing blood. The endothelium primarily functions 
as a selective barrier between blood and underlying vascular tissues and as the regulator of 
blood vessel diameter. It releases different growth factors and vasoactive mediators, which 
regulate the physical and biochemical properties of the vessels and affect vascular 
contractility and cell growth. Endothelial cells are in contact with the underlying middle layer 
(or media) composed of vascular smooth muscle cells (VSMC). 
The medial layer as the 'muscle' of the blood vessel maintains the vascular tone and 
regulates contraction, blood vessel tone and diameter, blood pressure, and blood flow 
distribution. VSMC within blood vessels proliferate at an extremely low rate and exhibit very 
low synthetic activity.  
The outer-most layer, also termed adventitia, mainly contains fibroblasts which form a fibrous 
connective tissue. This tissue is very strong, and helps to prevent the rupture or bursting of 
larger arteries that carry blood under high pressure. 
In addition to hemodynamic factors, such as flow and pressure, the vascular wall is 
constantly exposed to a variety of humoral factors, including coagulation factors, vasoactive 
peptides, cytokines, growth factors and certain hormones. Changes in the homeostatic 
balance between these factors can induce adaptive alterations of the vessel structure, 
architecture and function. These processes are known as vascular remodeling.  
The main features of remodeling are hypertrophy (cell growth) and/or hyperplasia 
(proliferation) of the predominant cell type within each of these layers, as well as increased 
deposition of extracellular matrix components and fibrin. During vascular remodeling 
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“activated” EC may express adhesion molecules recruiting leucocytes which promote 
inflammatory responses and aggregation of platelets. In addition, increased permeability of 
EC and endothelial injury expose the underlying medial layer to blood-borne factors. Altered 
production of various vasoactive factors affects the contractile responses, gene expression 
and growth of the vascular smooth muscle cells and facilitate their proliferation as well as 
migration from the media to the subendothelial layer2. Moreover, VSMC change their 
phenotype from quiescent, contractile cells into a synthetic form and start to excessively 
secrete growth factors and the components of the extracellular matrix. These changes are 
summarized in the Fig. 1. 
 
Media
Intima
VSMC hypertrophy Rearrangement
of VSMC
Media
Endothelial damage
Cell proliferation Cell migration
EC
VSMC
Adhesion molecules
A
B
 
 
 
 
Figure 1. Cellular changes during vascular remodeling 
A) Endothelial (EC) and vascular smooth muscle cells (VSMC) in the normal, non-diseased vessel. B) 
Cellular changes resulting in vascular remodeling. 
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Various cardiovascular diseases such as atherosclerosis, diabetes mellitus and hypertension 
are associated with vascular remodeling. Vascular remodeling is also a main pathogenic 
determinant of pulmonary hypertension (PH). This disease is characterized by elevations in 
pulmonary artery pressure and pulmonary vascular resistance which are primarily due to 
extensive vascular remodeling leading to thickening and muscularization of the vessel wall 
with subsequent stiffening and vasoconstriction of the vessels3, 4. In addition, disordered 
endothelial cell proliferation and migration, along with neoangiogenesis as well as 
proliferation of VSMC and their transformation into myofibroblasts can lead to the formation 
of so-called plexiform lesions resulting in luminal narrowing5, 6. Plexiform lesions are present 
in about 30% of lung-biopsy specimens, and are mostly located near the origin of a small 
pulmonary artery7, 8. 
 
1.1.1 Humoral factors in the pathogenesis of vascular remodeling 
 
Altered production of different humoral factors influences cellular physiology by affecting 
growth, proliferation and migration of EC and VSMC leading to structural remodeling of the 
vasculature. Among them, vasoactive peptides such as endothelin (ET-1), angiotensin II 
(AngII), atrial natriuretic peptide (ANP) and urotensin-II (U-II) as well as activation of the 
coagulation cascade play a major role in mediating functional and structural changes in the 
vasculature9-14.  
 
1.1.1.1 Vasoactive peptides in vascular remodeling 
In addition to AngII which has been shown to affect vascular tone and remodeling processes 
in the systemic and pulmonary vasculature11, 13, ET-1 has been suggested to play a 
prominent role in pulmonary vascular remodeling11, 14.  
ET-1 is composed of 21 amino acids and is secreted from endothelial cells15. It binds to two 
distinct G protein-coupled receptors (GPR), endothelin receptor A (ETA) and endothelin 
receptor B (ETB)16,17, 18. When activated by binding of endothelin-1, the ETA receptors located 
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in VSMC mediate a potent vasoconstrictive response17, while ETB receptors on EC mediate 
vasodilation via increased production of nitric oxide and prostacyclin19-21. However, ET-1 acts 
not only as a vasoactive peptide, but it is also a potent growth-promoting agent leading to 
proliferation of VSMC and EC, therefore being associated with vascular remodeling14, 22, 23. 
In recent years, the structurally related peptide urotensin-II has been found to also act as a 
vasoconstrictor and it was declared as the “new endothelin”, as initial studies suggested 
similarities between the two peptides in structure, receptor molecule and contractile actions 
within the cardiovascular system24, 25. Urotensin-II is a phylogenetically ancient peptide that 
was initially isolated from Gillichthys mirabilis, the fish also known as goby, where it is 
involved in the control of vascular tone and osmoregulation26,27. This peptide is highly 
conserved across the species, from goby till humans. It is composed of 11 amino acid 
residues with a cyclic hexapeptide region important for binding to its receptor molecule (Fig. 
2)25. 
 
 
Val Cys
Tyr
Lys
TrpPheCysAspProThrGlu
Ala
Val Cys
Tyr
Lys
TrpPheCysAspAlaThrGly
Human urotensin-II
Goby urotensin-II
 
 
 
 
Figure 2. The structure of the human and goby urotensin-II 
Explanations are given in the text. 
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Human U-II (hU-II) has been identified as endogenous ligand for the G-protein coupled 
receptor GPR1428, recently renamed as urotensin-II receptor. Both, hU-II and its receptor are 
expressed in different cardiovascular tissues including smooth muscle and endothelium29, 30. 
Several studies compared the contractile potency of hU-II relative to ET-1. hU-II was shown 
to be more potent than ET-1, with the strongest effect within the pulmonary vasculature 
(Table 1)28. In the pulmonary artery, the potency of hU-II was 28 times higher than the one of 
ET-1 (Table 1).  
Human U-II has been suggested to contribute to several cardiovascular diseases associated 
with vascular remodeling, such as pulmonary hypertension. Elevated hU-II levels have been 
found in rats with pulmonary hypertension and have been associated with pulmonary artery 
hypertrophy31. In addition, pulmonary arteries from animals with pulmonary hypertension 
showed significantly increased maximal contractive responses to hU-II compared with 
controls32. However, the signaling pathways and functional consequences of hU-II action in 
the vasculature are not defined. 
 
 
 
 
Vessel 
 
Human urotensin-II 
-log (EC) 
 
 
Endothelin-1 
-log (EC) 
 
 
Relative 
potency 
Left anterior descending coronary artery 
 
 9.39+0.40 8.20+0.32 15 
Mesenteric artery 
 
 9.35+0.26 8.24+0.28 13 
Pulmonary artery 
 
9.29+0.16 7.84+0.06 28 
Renal artery 
 
 9.59+0.36 8.83+0.24 6 
 
 
Table 1. Relative contractile potency of human hU-II compared to ET-1 in non-human primates 
Table was modified from Ames et al28. Relative potency shows how many times hU-II is more potent 
than ET-1. 
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1.1.1.2 Prothrombotic state in vascular remodeling  
Endothelial injury allows the leakage of various blood-born factors and their contact with the 
underlying smooth muscle cells resulting in increased coagulability and thrombogenicity 
within the vessel wall33. 
The primary link between vascular cells and the hemostatic system is provided by the cell 
surface protein TF34-36. Human TF is a 47-kDa transmembrane glycoprotein. It consists of 
263 amino acids, 219 of which form the large extracellular domain, 23 amino acids are 
integrated membraneously and the cytoplasmic tail is only 21 amino acid residues in length35, 
37. TF is differentially expressed in various vascular cell types35, 37, 38. In adult blood vessels, 
TF is abundant in adventitial fibroblasts whereas little or no TF is constitutively expressed in 
the intima or media36. Thus, cellular initiation of TF-dependent blood coagulation seems to 
require induction of TF expression on the surface of cells, which are normally or 
pathophysiologically in contact with plasmatic factors of hemostasis. The major role of TF is 
the initiation of blood coagulation by binding factor VII/VIIa with high affinity. This complex 
promotes the activation of factor X with subsequent thrombin generation (Fig. 3)39-42. 
Thrombin is produced predominantly on the surface of circulating platelets as a result of 
proteolytic activation of the 72-kDa zymogen prothrombin, which is constitutively synthesized 
in the liver and released into the circulation40, 41, 43. Thrombin exerts most of its actions on 
vascular target cells via an irreversible proteolytic activation of protease-activated receptors 
(PAR) that belong to the family of G-protein coupled receptors44, 45. Three of the four 
currently identified PAR family members (PAR-1, PAR-3, and PAR-4) have been shown to 
be cleaved and activated by thrombin46.  
Thrombin is a multifunctional serine protease that regulates the blood coagulation cascade 
by affecting a series of factors, cofactors and proteins inside the plasmatic hemostatic 
system leading to conversion of fibrinogen to fibrin40, 41. Fibrin deposition within the lumen of 
the vessel wall may serve as a provisional matrix for the invading VSMC, which proliferate 
within the arterial media and migrate towards the vascular lumen. Moreover, fibrin may 
directly stimulate proliferation of VSCM leading to vascular remodeling 47, 48.  
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Under normal conditions, fibrin deposition is counterbalanced by fibrinolysis and fibrin 
clearance. This process is mediated by urokinase or tissue type plasminogen activator (uPA 
or tPA) which catalyze the conversion of plasminogen to plasmin that degradates fibrin. 
Fibrinolytic processes are antagonized by the serine protease plasminogen activator 
inhibitor-1 (PAI-1)48. PAI-1 is a 47-kDa protein and is the primary inhibitor of uPA or tPA. 
Inhibition of uPA or tPA by PAI-1 is facilitated by vitronectin, a 75-kDa glycoprotein that binds 
the inhibitor with high affinity, stabilizes the inhibitor in its active conformation, and mediates 
the binding of the inhibitor to fibrin clots49. Therefore, by blocking uPA or tPA activity, PAI-1 is 
inhibiting fibrinolytic processes and increasing fibrin deposition (Fig. 2). 
PAI-1
u/t PA
Plasmin Plasminogen
Fibrin clearance
Tissue Factor
Thrombin
Fibrinogen Fibrin
Pulmonary endothelial injury
VII
XXa
Va
Ca2+
Phospholipids
VIIa
Prothrombin
X
V scular injury
h
 
 
 
 
Figure 3. Vascular injury induces TF release and PAI-1 expression 
Explanations are given in the text. 
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1.2 Vascular signaling cascades 
 
1.2.1 Reactive oxygen species in the vasculature 
 
Reactive oxygen species (ROS), which result from the incomplete reduction of oxygen and 
include superoxide anion radicals (O2-.), hydrogen peroxide (H2O2) and hydroxyl radicals 
(OH.) have been initially considered as toxic byproducts of the aerobic metabolism that lead 
to tissue damage50-54 .  
One electron reduction of oxygen results in the formation of O2-. which is membrane 
impermeable but can cross cell membranes via anion channels. Superoxide anion radicals 
are converted to H2O2 spontaneously or by the superoxide dismutase (SOD) (Fig. 4). 
Hydrogen peroxide is an easily diffusible molecule that has a longer half life than O2.-. 
Hydrogen peroxide is enzymaticaly metabolized by catalase or glutathione-peroxidase 
(GPx). Additionally, in a Fenton reaction with transition metals like ferrous ions (Fe2+), H2O2 
produces highly reactive hydroxyl radicals (OH-.). On the other hand, O2-. can react with NO. 
to form peroxynitrite (ONOO-) (Fig. 4).  
O2-.
H2O2
OH.
Catalase
GPx
SOD
Fe2+
Fe3+
H2O  
NO.+ ONOO-
 
Figure 4. Reactive oxygen and reactive nitrogen species in vascular cells 
The explanations are given in the text. SOD- superoxide dismutase; GPx- glutathione-peroxidase. 
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However, more recently, it has been appreciated that these molecules have many non-toxic 
functions, and evidence has been accumulated that they exert a prominent role as signaling 
molecules and second messengers in the vascular wall connecting receptor-mediated 
agonist stimulation and modulation of gene expression and proliferation of VSMC and EC55-
57. Indeed, ROS may be classified as second messengers, since they are generated at the 
time of receptor activation; they are short lived species and can transiently alter the activity of 
certain effectors. On the other hand, the specificity of ROS may be determined by the site of 
their production. In the vasculature, ROS production has been reported in endothelial, 
smooth muscle and adventitial cells56, 58, 59. 
ROS regulate vascular function by modulating cell growth, proliferation, apoptosis, migration, 
inflammation, secretion, and production of different growth factors and proteins of the 
extracellular matrix58, 60-62. Under normal physiological conditions, the oxidant formation is 
balanced by the rate of oxidant elimination. Thus, any change in this balance, where pro-
oxidants overwhelm cellular antioxidant capacity, results in oxidative stress. Oxidative stress 
and subsequent oxidative damage are mediators of vascular injury and associated with the 
development of many cardiovascular diseases12, 57, 63. Characteristically, increased ROS 
production is observed in disorders associated with a prothrombotic state58, 64-70 and 
enhanced generation of ROS has been linked to a procoagulant state71-74. Moreover, 
increased ROS levels have been associated with deterioration of endothelial function75, 76 
which is characterized by decreased bioavailability of NO.. NO. is synthesized by the enzyme 
endothelial nitric oxide synthase (eNOS), and released from EC in the direction of VSMC 
where it triggers vasodilatory responses. However, NO. can be scavenged by O2-. resulting in 
vasoconstriction. Different growth factors, mechanical stress, vasoconstrictors and 
vasoactive peptides, including ET-1 and AngII, have been reported to increase the levels of 
ROS in VSMC77, 78, further potentiating vasoconstrictive responses.  
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1.2.2 Vascular NADPH oxidases 
 
Vascular ROS production has been associated with a number of systems including the 
mitochondrial electron transport chain, lipoxygenases, cyclooxygenase, xanthine and 
glucose oxidase, NADPH oxidases, nitric oxide synthases, the cytochrome P450s, 
peroxidases and various hemoproteins79. However, NADPH oxidases which catalyze the 1-
electron reduction of oxygen using NADH or NADPH as electron donor resulting in the 
formation of superoxide anion radical (Fig. 5) have now been recognized as the most 
prominent sources of ROS generation in vascular cells55, 56, 58, 80, 81.  
The NADPH oxidase has been initially identified in phagocytes, where this multicomponent 
enzyme produces high amounts of microbicidal oxygen radicals (Fig. 5)82. 
gp91phoxp22phox
p47 phox
p67phox
O2
NAD(P)H
O2-.
NAD(P)++H+
e-
gp91phoxx
p47phox
p67phox p40phox
Rac
 
 
NAD(P)H + 2O2 → NAD(P)+ + H+ + 2O2-. 
 
 
 
Figure 5. The structure of the activated neutrophil NADPH oxidase 
The explanations are given in the text. 
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The leukocyte oxidase is composed of two membrane proteins, p22phox and gp91phox, that 
comprise the catalytical core of this enzyme, named flavocytochrome b558, as a result of its 
absorption maximum at 558 nm. Flavocytochrome b558 contains all redox components 
necessary for sequential transmembrane electron transport: two non-identical hemes and 
FAD- and NADPH-binding moieties. Regulatory components of the enzyme include the 
cytoplasmic subunits p40phox, p47phox, p67phox and the small GTP-binding protein Rac52-
54.  
The enzyme is dormant in resting cells, and p47phox, p67phox and p40phox form a 
heterotrimeric complex in the cytoplasm. However, upon stimulation with pathogens, 
activation of the enzyme is initiated by phosphorylation of the cytosolic subunits that change 
their conformation and translocate to the cytochrome b558 at the membrane. In addition, 
loading of Rac with GTP triggers its translocation to the membrane, where it interacts with 
p67phox, further positioning flavocytochrome b558 in the right direction for electron transfer. 
Subsequent activation of the oxidase complex leads to electron flow through the membrane 
and release of large amounts of O2- in the well-characterized respiratory burst (Fig. 5). 
The physiological significance of the phagocytic NADPH oxidase is illustrated by chronic 
granulomatous disease (CGD) caused by mutations in any of the genes encoding gp91phox, 
p22phox, p47phox or p67phox subunits of the NADPH oxidase83. Phagocytes of patients 
suffering from CGD are unable to produce O2-., and patients are therefore highly susceptible 
to bacterial and fungal infections.  
Recently, NADPH oxidases have been found to be expressed in various non-phagocytic 
cells, including vascular cells55, 58, 77, 81, 84. In contrast to the neutrophil oxidase, basal ROS 
levels have been observed in EC and VSMC. Stimulation of vascular cells with different 
agonists including ET-1, AngII, tumor necrosis factor α (TNFα), platelet-derived growth factor 
(PDGF), insulin growth factor-1 (IGF-1), interleukin-1 alpha (IL1-α), vascular endothelial 
growth factor (VEGF), transforming growth factor-β (TGF-β), low density lipoproteins (LDL) or 
their oxidized form (oxLDL), resulted in ROS production. However, ROS levels achieved in 
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vascular cells are substantially lower than in leukocytes, suggesting crucial differences 
between neutrophil and vascular NADPH oxidases80, 82. 
Recent studies demonstrated the presence of multiple NADPH oxidase forms in vascular 
cells. Based on homologies with each other and their apparent evolution from an ancestral 
NOX, these homologues are named NOX1, NOX2 (the former gp91phox), NOX3, NOX4 and 
NOX5 (Fig. 6)80, 85-88. NOX1, NOX3 and NOX4 share around 50-60% homology with NOX2, 
while NOX5 is distinct in its structure from NOX1-4, since it has an N-terminal extension with 
calcium binding moieties, known as EF hands82. NOX2 is mainly expressed in phagocytes 
and EC, whereas NOX1 and NOX4 are expressed in EC and VSMC80, 81, 86, 89. NOX3 protein 
has been identified in embryonic tissue, while NOX5 expression has been reported in tumor 
tissues85. In addition, two related proteins, called DUOX1 and DUOX2, mainly expressed in 
thyroid tissue, have NOX-homologous regions as well as regions with peroxidase activity 
(Fig. 6)90, 91.  
NOX1
NOX2
NOX3
NOX4
NOX5
NH2
NADPHFADTransmembrane
helixes
EF-handsTransmembrane
helix
Peroxidase
homology
NH2
NH2
NH2
NH2
NH2
NH2
DUOX 1
DUOX 2
NOX1
NOX2
NOX3
NOX4
NOX5
DUOX1
DUOX2
 
 
 
Figure 6. Homologues of the neutrophil gp91phox (NOX2) catalytic subunit 
NOX1, NOX2, NOX3 and NOX4 contain 6 transmembrane helixes, as well as FAD- and NADPH-
binding sites. In addition to these domains, NOX5 contains EF-hands which are calcium binding 
regions. DUOX1/2 homologues contain a peroxidase homology domain at the N-terminus. 
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In addition, two proteins with homology to the cytosolic components p47phox and p67phox, 
p41phox termed NOX organizer 1 (NOXO1) and p51phox named as NOX activator 1 
(NOXA1), respectively, have been discovered and shown to regulate NOX1 and NOX3 
activity92-95. These newly identified proteins might also modulate enzyme activity in either a 
tissue- and/or stimulus-specific fashion. 
 
1.2.2.1 p22phox 
p22phox is a 22-kDa membrane protein that contains 195 amino acids. p22phox together 
with gp91phox comprises the catalytical core of NADPH oxidase96, 97. Moreover, upon 
agonist stimulation, p22phox binds to p47phox to assemble the active oxidase53.  
In contrast to the NOX proteins, expression of p22phox is ubiquitous and has been shown in 
all vascular cell types underlining the essential function of this component for the assembly 
and activation of NADPH oxidases. The importance of p22phox is further supported by the 
identification of several polymorphisms in the p22phox gene. A polymorphism in the p22phox 
promoter revealed higher promoter activity and has been associated with hypertension98. 
Moreover, increased levels of p22phox and other NADPH oxidase subunits have been 
identified in the vascular wall after balloon angioplasty, as well as in atherosclerosis, 
hypertension, diabetes and other disorders and have been associated with elevated ROS 
levels in these disorders66-68, 75, 76, 99.  
 
1.2.2.2 Rac-1 
Rac-1 is a small GTPase composed of 192 amino acids with a molecular weight of 20-kDa. 
There are two isoforms of Rac identified, Rac-1 and Rac-2. Rac-2 expression is restricted to 
hematopoetic cells and it is the predominantly active isoform in human neutrophils100, 101, 
while Rac-1 is ubiquitously expressed and present in all vascular cell types.  
Rac belongs to the family of Rho GTPases. Rho proteins cycle between an inactive GDP-
bound, and active GTP-bound conformation. In the cytosol Rac is trapped in an inactive, 
GDP-bound state, by binding of guanine nucleotide exchange inhibitors (GDIs). Upon 
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stimulation, conversion of Rac in the active state is tightly regulated by guanine nucleotide 
exchange factors (GEFs) which allow the release of GDP and binding of GTP (Fig. 7). 
Subsequent Rac inactivation is regulated by GTPase activating proteins (GAPs) that 
increase the rate of GTP hydrolysis and downregulate GTPase signaling that acts as 
molecular switch and participates in a large variety of signaling events regulating processes 
such as cytoskeletal remodeling, mitogenesis, cell adhesion, cell-cycle progression and cell 
survival102-104. In addition, active Rac is necessary for the activation of the NADPH oxidase 
complex. Upon activation, Rac-1 translocates to the plasma membrane where it associates 
with p67phox to assemble with the oxidase complex. Furthermore, Rac-1 is geranyl-
geranylated at the C-terminus which enables its interaction with the plasma membrane82, 105.  
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Figure 7. Rac activation 
Rac-1/2 is trapped in an inactive, GDP-bound conformation, by binding of guanine nucleotide 
exchange inhibitors (GDIs). Activation of Rac-1/2 in response to stimuli is catalyzed by guanine 
nucleotide exchange factors (GEFs), and Rac-1/2 inactivation through hydrolysis of GTP is catalysed 
by GTPase activating proteins (GAPs). 
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1.2.3 Protein kinases and reactive oxygen species 
 
Protein kinases are the common participants in signal transduction pathways that transfer the 
extracellular signals from activated membrane-associated receptors to downstream effectors 
by catalyzing the phosphorylation of their substrates.  
Mitogen activated protein kinases (MAPKs) are serine/threonine kinases that are activated 
by a number of signaling pathways and are directly phosphorylated by another kinase, MAP-
kinase-kinase (MAPKK). The MAPKK is activated by a MAP-kinase-kinase-kinase 
(MAPKKK), which is thought to be activated by the binding of activated Ras106.  
MAP kinases play a crucial role in vascular signaling, since they influence gene expression 
and proliferation of vascular cells. There are three families of MAPKs, p41/42 extracellular 
signal regulated kinases (ERK), c-jun N-terminal kinases (JNK) and p38 MAP kinase 
(p38MAPK). ERK is mainly associated with proliferation and differentiation, while JNK and 
p38MAPK regulate responses to cellular stresses. Moreover, enhanced activation of MAPKs 
has been observed in different cardiovascular diseases associated with vascular 
remodeling62, 107.  
Another group of protein kinases important for signal transduction is the serine/threonine 
protein kinase B (PKB, also called Akt) and its upstream kinase phosphatidyl-inositol-(3) 
kinase (PI3K). Subsequent to the activation of PI3K, Akt is recruited to the membrane where 
it is activated via the phosphorylation by phosphoinositide-dependent kinase 1 (PDK1). Akt is 
an important relay to control metabolic activity, growth and proliferation of vascular cells108. 
Another important class of protein kinases is p21-activated kinase (PAK). The PAK family 
consists of six isoforms, PAK1, PAK2 and PAK3 and the recently discovered PAK4, PAK5 
and PAK6. PAK1-3 (so called PAK group A) are similar in the catalytic domain to PAK4-6 
(PAK group B), but have significantly different structural organization109. PAK is a 
serine/threonine protein kinase which was one of the first Cdc42/Rac effectors identified. As 
an important mediator of Rac activity, PAK plays a significant role in modulating a range of 
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biological activities, including cytoskeleton reorganization, cell survival and cell 
proliferation110. 
It has been suggested that redox homeostasis plays an important role in the proper 
functioning of protein kinases. Several studies showed that ROS can activate protein kinases 
including MAPK and PI3K/Akt107. The mechanisms proposed for the ROS-induced activation 
of protein kinases include receptor clustering and protein tyrosine phosphatase inhibition111. 
The inactivation of tyrosine phosphatases is due to the reversible oxidation of cysteine 
residues that participate in dephosphorylation of protein kinases112. 
 
1.2.4 Redox-sensitive transcription factors 
 
The proliferative activity of vascular cells and other remodeling processes are mediated by 
modulation of gene expression, thus requiring the activation of specific transcription factors.  
 
1.2.4.1. NFκB transcription factor 
Nuclear factor kappa B (NFκB) is known to mediate gene expression in response to many 
stimuli, including oxidative stress 111, 113. It is a basic-leucine-zipper transcription factor and a 
member of the Rel-related transcription factor family. The predominant form of NFκB is a 
dimer composed of p50 and p65 subunits. In resting cells, the NFκB complex is trapped in 
the cytosol by binding to the inhibitory κB proteins (IκBα or IκBβ) (Fig. 8). Upon stimulation, 
phosphorylation of the IκB proteins by kinases (IκBKα or IκBKβ) marks them for destruction 
in the proteasome. The NFκB complex dissociates, translocates into the nucleus and binds 
DNA at specific motifs (Fig. 8).  
NFκB is involved in the control of inflammatory responses, cellular growth or apoptosis as 
well as in the pathogenesis of cardiovascular diseases111, 114, 115. ROS have been initially 
implicated in stimulation of NFκB transcriptional activity, although the mechanisms of 
activation are controversial and appear to be cell-type specific115, 116.  
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Figure 8. The regulation of NFκB transcriptional activity 
The explanations are given in the text. 
 
1.2.4.2. HIF-1 transcription factor 
Another redox-sensitive transcription factor is the hypoxia-inducible factor (HIF), which 
mediates adaptive changes including proliferation in response to reduced O2 
bioavailability117.  
HIF is a heterodimer composed of two subunits, α and β, which are helix-loop-helix PAS 
proteins (Fig. 9)111. There are 3 different α-isoforms described: HIF-1α which appears to be 
ubiquitously expressed, HIF-2α which has been described to be predominantly expressed in 
vascular cells and HIF-3α whose role has not been clarified to date. While the HIF-1β subunit 
(also termed ARNT for arylhydrocarbon receptor nuclear translocator) is constitutively 
expressed, the level of the HIFα subunits is strongly regulated by the cellular O2 
concentration. In normoxia, HIF-1α is hydroxylated by prolyl hydroxylases (PHD), allowing 
the physical interaction with the tumor suppressor von Hippel-Lindau protein (pVHL). pVHL is 
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a recognition component for the E3 ubiquitin-protein ligase that ubiquitinylates HIF-1α and 
targets its degradation by the 26S proteasome118-120. In addition, hydroxylation of an 
asparagine in the C-terminal transactivation domain by hydroxylase termed factor inhibiting 
HIF-1 (FIH-1), prevents binding of the coactivator p300/CBP121. Under hypoxic conditions, 
hydroxylases are inactive, and non-hydroxylated HIF-1α escapes the proteasomal 
degradation, accumulates in the cells, and translocates to the nucleus. In the nucleus, HIF-
1α subunit binds p300/CBP coactivators and dimerizes with its partner proteins from the 
ARNT family, which allows binding to specific response elements named hypoxia-responsive 
elements (HRE) in the promoters of target genes such as PAI-1 or VEGF (Fig. 9).  
Very recently, it has been recognized that HIF-1α can be induced and activated also in 
response to certain stimuli in non-hypoxic conditions113 122-125. 
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Figure 9. The regulation of HIF-1 transcriptional activity 
The explanations are given in the text. PHD- prolyl hydroxylase; pVHL- von Hippel-Lindau protein; 
FIH-1-factor inhibiting HIF-1; p300/CBP-HIF-1 coactivators. 
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1.3 Aim of the study 
 
Thrombotic events and proliferation play an important role in vascular remodeling in the 
systemic as well as in the pulmonary vasculature. Coagulation factors and vasoactive 
peptides have been shown to activate endothelial and smooth muscle cells.  
ROS have been suggested to play an important role in vascular signaling, and NADPH 
oxidases have been identified as vascular sources of ROS. 
It was therefore hypothesized that ROS derived from NADPH oxidases could initiate 
common signaling pathways in response to coagulation factors and vasoactive peptides, 
thereby activating proliferation and procoagulant activity. 
 
The aim of the study was therefore to investigate: 
 
A) how thrombin induces NADPH oxidase-derived ROS production and proliferation of 
vascular cells. 
B) how NADPH oxidase-derived ROS and the GTPase Rac-1 influence the expression 
of the prothrombotic genes tissue factor and PAI-1 in pulmonary artery smooth 
muscle cells, the major cell type involved in pulmonary vascular remodeling. 
C) whether the vasoactive peptide urotensin-II could activate NADPH oxidases and 
ROS-derived signaling cascades and proliferation of pulmonary artery smooth muscle 
cells. 
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2. Materials and methods 
 
2.1 Materials 
 
2.1.1 Chemicals 
 
Chemicals Company 
Acetic acid Roth 
Actinomycin D Sigma 
Agar Agar Roth 
Agarose NEEO Roth 
Alamar Blue Biosource 
Ammoniumpersulfat Roth 
Ampicilin Calbiochem 
Antihuman PAI antiobody Loxo 
BAPTA-AM Sigma 
Bovine serum albumin Sigma 
Calcium chloride Merck 
Chloroform Merck 
Coumaric acid Sigma 
Cycloheximide Sigma 
Diaminofluorescein –2 Diacetate Alexis 
5-(and-6)-chloromethyl-2‘,7‘-dichlorodihydrofluorescein 
diacetate 
MoBiTec 
DEPC Roth 
Dihydroethidium MoBiTec 
Dihydrorhodamine 123 MoBiTec 
Diphenyleneiodonium chloride Alexis 
Dimethylsulfoxide Roth 
Dithiothreitol Roth 
EDTA Roth 
EGTA Roth 
Ethanol Merck 
Ethidium bromide Roth 
Formaldehyd Merck 
Glucose Merck 
Glycerol Roth 
Glycin Roth 
Guanidinethiocyanate Roth 
Hank’s balanced salt solution Gibco 
Hydrochloric acid JT Baker 
HEPES buffer Gibco 
Hydrogen peroxide Merck 
Isoamilalcohol Merck 
Isopropanol JT Baker 
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Kanamycin Calbiochem 
Luminol Sigma 
LY294002 Calbiochem 
Magnesium chloride Roth 
Maleic Acid Sigma 
MOPS Roth 
N-Acetyl-Cysteine Sigma 
N-Lauryl-Sarcosine Sigma 
N-Nitro-L-Arginine Calbiochem 
Non-fet dry milk powder  Merck 
PAK-1 PBD Biomol 
PBS Tablets  Gibco 
PD98059 Calbiochem 
Phorbol 12-Myristate 13 Acetate Sigma 
PIM Calbiochem 
PMSF Calbiochem 
Ponceau S Sigma 
Potassium chloride Merck 
Roti-Aqua-Phenol Roth 
Rotiphorese Gel  Roth 
S-2238 Haemochrom Dignostik 
SB 220025 Calbiochem 
SDS ultra pure Roth 
SH-5 Alexis 
Shingosine1 Phosphate Alexis 
Sodium acetate Merck 
Sodium chloride Roth 
Sodium citrate Roth 
Sodium dihydrogen phosphate Sigma 
Sodium fluorid Merck 
Sodium ortovanadat Merck 
SP600125 Biomol 
Sulfuric acid Roth 
TEMED Roth 
Thrombin Haemochrom Dignostik
Triton®X-100 Sigma 
Tris Roth 
Tryptone Roth 
Tween 20 Sigma 
Ovalbumin Sigma 
Urotensin-II PolyPeptide 
Vitamin C Sigma 
Wortmannin Calbiochem 
Xylencyanol Roth 
Yeast extract Roth 
β-Mercaptoethanol Roth 
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Cell culture media and additives Company 
Dulbecco's Modified Eagl’s Med.( glucose 1000mg) Gibco 
Fetal calf serum Pan Biotech 
HAT Supplement Gibco 
MCDB 131-Medium Gibco 
Penicillin /Streptomycin Gibco 
SmBm-2 medium Cambrex 
SmGm-2 Single Q Cambrex 
Trypsin EDTA Gibco 
 
 
Kits Company 
Dual-Luciferase Reporter Assay System Promega 
BrdU proliferation assay Roche 
QIAprep Spin Miniprep Kit Quiagen 
Quiagen Plasmid Maxi Kit Quiagen 
Rac activity pull down assay Biomol 
Quick Change mutagenesis kit Stratagene 
Nucleo Seq sequencing clean-up kit  Macherey-Nagel 
 
 
Restriction Enzymes Company 
EcoRI New England Biolabs 
EcoRV New England Biolabs 
BsrGI New England Biolabs 
AvaI Roche 
SmaI New England Biolabs 
Mung bean nuclease New England Biolabs 
Klenow fragment New England Biolabs 
 
 
Plastic ware Company 
T75 flasks Greiner 
10 and 6 cm dishes Sarstedt 
6-, 24- and 96-well plates Greiner 
2, 5, 10 and 25 ml pippets Sarstedt 
1.5 and 2 ml tubes Sarstedt 
15 ml and 50 ml tubes Sarstedt 
Cryovials Greiner 
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2.1.2 Plasmids 
 
2.1.2.1 Expression plasmids 
In the experiments, the following plasmids were used: 
Expression plasmids 
pcDNA3.1 
pcDNA3.1p22phoxS 
pcDNA3.1p22phoxAS 
psDNA6.1ECFP 
pcDNA6.1hp22phoxECFP 
pcDNA3.1NOX4S 
pcDNA3.1NOX4AS 
pcDNA3.1RacV12-myc 
pcDNA3.1RacN17-myc 
pRSV-NFκB-1 
pRSV-RelA 
pCMV-IκBαdn 
p-FlagCMV2-IκK-2 
PCMV-PAK-R295 
PCMV-PAK-T423 
 
To obtain pcDNA3.1p22phoxS and pcDNA3.1p22phoxAS (p22S and p2AS) the full length 
cDNA fragment encoding human p22phox derived from pBShp22phox (provided by Dr. M. 
Dinauer, Indianopolis, USA) was digested with EcoRI, blunt-ended with Mung bean nuclease 
and the fragment was ligated into pcDNA3.1 in sense and antisense direction resulting in 
p22S and p22AS. This fragment was also cloned into pcDNA6.1ECFP (provided by Dr. T. 
Kietzmann, Kaiserslautern, Germany), digested with BsrGI and filled in with Klenow fragment 
and additional nucleotides encoding a polyalanine linker were inserted using the Quick 
Change mutagenesis kit resulting in pcDNA6.1hp22phoxECFP.  
The human NOX4 full length cDNA was cut out from pCMV4-SPORT-NOX4 (RZPD, 
Accession number NM-016931) by AvaI, and blunted using Klenow fragment. It was then 
inserted into pcDNA3.1 linearised with EcoRV resulting in pcDNA3.1NOX4 sense and 
antisense constructs (NOX4S and NOX4AS).  
Plasmids encoding myc-tagged constitutively active mutant of Rac1, pcDNA3.1RacV12-myc 
(RacG12V), and myc-tagged dominant-negative mutant of Rac1, pcDNA3.1RacN17-myc 
(RacT17N) were present in the laboratory and have already been described71, 126. 
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The expression vectors p50 (pRSV-NFκB-1) and p65 (pRSV-RelA) encoding full length p50 
and p65/rel, respectively, were provided by Dr. T. Kietzmann and have been described 
previously127. The expression vector pCMV-IκBαdn (IκBdn) was purchased from Becton 
Dickinson. The expression vector p-FlagCMV2-IκK-2 (IκKdn) encoding full length IκK-2 
mutated at S177A/S181A was provided by Dr. T. Kietzmann and has been described 
previously128.  
PCMV-PAK-R295 (PAK-R295) and PCMV-PAK-T423E (PAK-T295) were kindly provided by 
Dr. T. Kietzmann. 
All constructs were confirmed by DNA sequencing using T7 and BGH primers:  
 
Sequencing primers Sequence 
T7 5'd[TAATACGACTCACTATAGGG]3 
BGH 5'd[TAGAAGGCACAGTCGAGG]3' 
 
To sequence the constructs Polymerase Chain Reaction (PCR) was performed using the 
following sequencing mix: 
Sequencing mix: 
DNA template (plasmid)  100 ng 
BigDye Terminator   3 µl 
Sequencing primers   100 µM 
Water     up to 10 µl 
The PCR products were cleaned from unincorporated dye using the Nucleo Seq sequencing 
clean-up kit and run on an ABI 3100 Genetic Analyzer. 
 
2.1.2.2 Reporter constructs 
To determine promoter activity, the promoter sequence of the gene of interest is coupled to 
the luciferase gene:  
Promoter                                                   Luciferase
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In the experiments, the following plasmids were used: 
Promoter plasmids 
pTF111 
pTF636 
pGI3 hPAI-1 
 
pTF111 contains the minimal human TF promoter (-111 to +121 bp) linked to the luciferase 
gene of the pgl2 basic vector. It was present in the lab and has been described previously129.  
pTF636 was obtained by PCR from the full length human TF promoter construct p19Luc 
(kindly provided by Dr. Nigel Mackman, La Jolla, USA). The fragment encompassing the 
sequence from –636 to -111 bp was inserted into the SmaI site from pTF111.  
The pGI3 hPAI-1 promoter construct containing the human PAI-1 promoter from -796 to +13 
was provided by Dr. T. Kietzmann. 
 
2.1.2.3 Enhancer plasmids 
To study the transactivation potential of transcription factors, copies of transcription factor 
binding sites were inserted as enhancer elements in front of a non-specific promoter and the 
luciferase gene: 
 
Enhancer elements                           SV40             Luciferase
 
 
In the experiments, the following plasmids were used: 
Enhancer plasmids 
pNFκB-Luc 
pGL3-EPO-HRE 
 
pNFκB-Luc containing 5 NFκB sites in front of the SV40 promoter linked to the luciferase 
gene was from Clontech. 
pGL3-EPO-HRE vector containing 3 hypoxia responsive elements (HRE) in front of the SV40 
promoter was present in the laboratory and has already been described122.
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2.1.2.4 Transformation and purification of plasmids 
 
Bacterial Transformation: To transform and enrich the plasmids, the E. coli strains DH5α and 
XL-10 Gold were used:  
 
Competent cells Company 
XL-10 Gold  Invitrogen 
DH5α  Stratagen 
An aliquot of 100 µl of competent cells was gently mixed with 1 µg of plasmid DNA, and 
incubated on ice for 30 min. Cells were subjected to 42°C for 30 seconds (sec),1 ml of SOC 
medium was added and the cell suspension was gently rocked for 1 hour (h) at 37°C. 
Thereafter, 100 and 50 µl of the bacterial suspension was spread on LB plates containing 
either 1% ampicilin or 1% kanamycin. 
SOC medium        Final (%) in H2O 
Yeast extract    0.5% 
Tryptone    2% 
NaCl     0.05% 
After dissolving in 950 ml of water, 10 ml of 250 mM KCl solution (final concentration 2.5 
mM) were added and the pH was adjusted to 7.0. The solution was then autoclaved and 
thereafter 20 ml of sterile 1 M solution of glucose (final concentration 5 mM) and 5 ml of 
sterile 2 M MgCl2 (final concentration 0.5 mM) were added. 
 
LB medium        Final (%) in H2O 
Yeast Extract    0.5% 
Tryptone    1% 
NaCl     1% 
The pH was adjusted to 7.2 and the solution was autoclaved. 
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LB plates        Final concentration in prepared LB medium 
Agar      1.5% 
Antibiotic (Ampicilin or Kanamycin)  1% 
 
Minipreps and Maxipreps: Plasmids were purified by miniprep or maxiprep using QIAprep 
Spin Miniprep Kit and Qiagen Plasmid Maxi Kit.  
 
Transfection of the plasmids: To deliver plasmid DNA to cells, the following transfection 
reagents were used: 
 
Transfection reagents Company 
Effectene Qiagen 
FuGENE 6 Roche 
SuperFect Qiagen 
 
 
2.1.3 Antibodies 
 
Primary antibodies were prepared in 5% non-fat dry milk powder or 5% bovine serum 
albumin (BSA) diluted in Tris buffered salt solution containing 0.3% Tween 20 (TBS-T). 
 
TBS-T                                      Final concentration 
Tris     50 mM 
NaCl     150 mM 
“Smoky” HCl    0.3% 
Tween     0.3% 
The pH was adjusted to 7.5. 
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The monoclonal antibody against p22phox (mAb 44.9) was kindly provided by Dr. D. Roos, 
Amsterdam, and was used in a concentration of 1:250 in 5% milk in TBS-T. 
The antibody against NOX4 was generated by immunizing rabbits with the peptides 
CAYLRGSQKVOSRRT and CSYGTKFEYNKESFS representing amino acids 81-95 and 566-
578, respectively, of the rat NOX4 protein, and was kindly provided by Dr. Pfeilschifter 
(Frankfurt am Main). The NOX4 antibody was used in a concentration of 1:500 in 5% milk in 
TBS-T. 
All other antibodies were commercially available. 
 
Antibodies Company Concentation 
Actin Santa Cruz 1:1000 in 5% milk 
c-myc Santa Cruz 1:1000 in 5% milk 
HIF-1 alpha BD Transduction laboratories 1:1000 in 5% milk 
PAI-1 American Diagnostica 1:200 in 5% milk 
p-PAK(Thr) Cell Signaling 1:500 in 5% BSA 
p-p38MAPK Cell Signaling 1:1000 in 5% BSA 
p-JNK Cell Signaling 1:1000 in 5% BSA 
p-ERK Cell Signaling 1:1000 in 5% BSA 
p-Akt Cell Signaling 1:1000 in 5% BSA 
Rac-1 BD Transduction laboratories 1:1000 in 5% milk 
TF American Diagnostica 1:200 in 5% milk 
 
Anti-mouse or anti–rabbit horseradish peroxidase-conjugated secondary antibodies were 
purchased from Calbiochem, and used in a concentration of 1:10000 in 5% milk or BSA.  
                                                                                                                 Materials and methods 
____________________________________________________________________________ 
29
2.1.4. Solutions 
 
2.1.4.1 Solutions for Northern blot 
 
DEPC Water 
500 µl DEPC was added to 900 ml dH2O and left overnight with slightly opened lit at room 
temperature. The solution was then autoclaved. 
GT      Final concentration  
Guanidine thiocyanate    4 M 
Na-citrate     25 mM 
N-Lauryl Sarcosine    0.3% 
The solution was prepared in DEPC-H20 and heated at 65°C.  
The lysis buffer GT-DTT was prepared by adding 7 µl of 375 mM DTT to 1 ml of GT solution 
(final concentration 2.62 mM) just before use. 
 
MOPS buffer (10X)   Final concentration 
MOPS     0.2 M 
Sodium acetate   80 mM 
EDTA     10 mM 
The pH was adjusted to 7.0. 
500 µl DEPC was added to 900 ml 10X MOPS water and left overnight with slightly opened 
lit. The solution was then autoclaved. 
 
SSC (20X)   Final concentration 
NaCl      3 M  
Sodium citrate   0.3 M 
500 µl DEPC was added to 900 ml 20X SSC and left overnight with slightly opened lit. The 
solution was then autoclaved. 
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Premix for RNA probes 
Formamid    10 ml 
Formaldehyd 37%   3.5 ml 
10 X MOPS    2.0 ml 
Ethidium Bromide   0.03 µg 
The solution was aliquoted and stored at - 20°C. 
 
Blue marker for RNA probes (10 X) 
Glycerin    1 ml 
Bromphenolblue   1.6 mg 
Xylenecyanol    1.6 mg 
EDTA     1 mM 
DEPC H20     2 ml 
The solution was stored at 4 °C. 
 
Hybridisation solution (for 250 ml)   Final concentration 
20 X SSC      25% 
Formamid      50% 
10 X Blocking reagent    5% 
N-Lauryl Sarcosinat     1% 
SDS       0.02% 
 
Washing solution    Final concentration 
Maleic acid     0.1 M 
NaCl      0.15 M 
The pH was adjusted to 7.5. 
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Blocking solution 
10X Blocking solution (Roche) was diluted 1:9 in washing solution. 
 
Detection solution    Final concentration 
Tris       0.1 M 
NaCl       5 M 
The pH was adjusted to 9-9.5. 
 
 
2.1.4.2 Solutions for Western blot 
 
Running gel  
Percentage     8%  10%  12% 
H20 (ml)     3.4   2.8  2.1 
30% acrylamid (Rotiphorese gel) (ml) 2.7  3.3  4 
1M trisHCl pH 8.8 (ml)   3.7  3.7  3.7 
10% SDS (µl)     100  100  100 
To initiate polymerization, 80 µl ammoniumpersulfate and 10 µl of TEMED were added. 
 
 
Stacking gel 
Percentage         5%   
H20 (ml)     2.14 
30% acrylamid (ml)    0.488 
1M trisHCl pH 6.8 (ml)   0.375 
10% SDS     30 
To initiate polymerization, 15 µl ammoniumpersulfate and 3 µl of TEMED were added. 
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Laemmli buffer (3X)      Final concentration 
Tris (pH 6.8)     187 mM 
SDS       6% 
Glycerol     30% 
Bromphenol blue    0.06% 
DTT      15 mM 
EDTA      60 mM 
 
 
Running buffer      Final concentration 
Tris      25 mM  
Glycin      200 mM 
SDS      0.5% 
 
 
Transfer buffer       Final concentration 
Tris      25 mM  
Glycin      200 mM 
Methanol     20% 
 
 
Stripping buffer       Final concentration 
SDS      2% 
Tris pH 6.8     62.5 mM 
β-Mercaptoethanol    0.07% 
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Enhanced chemiluminescent reagent 1 
ECL 1         Final concentration 
Tris pH 8.8     100 mM 
Luminol     2.5 mM 
Coumaric acid    0.4 mM 
Enhanced chemiluminescent reagent 2 
ECL 2         Final concentration 
Tris pH 8.8     100 mM  
H2O2      0.15% 
Before use, ECL1 and ECL2 reagents were mixed in a 1:1 ratio. 
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2.2 Cell culture 
 
2.2.1 Endothelial cells 
 
The human endothelial cell line Ea.hy 926 (kindly provided by Dr. U. Foerstermann, Mainz, 
Germany) is a permanent cell line established by hybridization of human umbilical vein 
endothelial cells with the permanent human cell line A549130. This cell line is well 
characterized for its endothelial phenotype and biology, and expresses markers of highly 
differentiated vascular endothelium, including factor VIII-related antigen, which is maintained 
for more than 100 cumulative populations130. Cells were grown in DMEM medium with 1 g/l 
glucose, containing 10% heat-inactivated fetal calf serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Since Ea.hy 926 cells need to be cultured in selective medium to maintain the 
endothelial phenotype, medium was supplemented with 1.5 X Hypoxanthine, Aminopterin, 
Thymidine (HAT) and cells were maintained at 37°C under the humidified atmosphere of 5% 
CO2. Cells were cultured in T75 flasks and passaged twice a week by trypsinisation. First, 
cells were briefly rinsed and then incubated with 2 ml of 0.05% trypsin containing 0.53 mM 
EDTA•4Na for 1-2 minutes (min) at 37°C. The digestion was stopped by adding complete 
medium and cells were subcultured in the ratio 1:3 in T75 flasks or in 10 cm dishes and 
plates. Prior to stimulation cells were starved from serum in DMEM medium containing 0.1% 
serum albumin, 1.5x HAT, 100 U/ml penicillin and 100 µg/ml streptomycin for 24 h.  
 
2.2.2 Smooth muscle cells 
 
Pulmonary artery smooth muscle cells (PASMC) were purchased from Cambrex and grown 
in the provided SmBm medium. PASMC were maintained at 37°C under the humidified 
atmosphere of 5% CO2. Cells were passaged twice per week by trypsinisation, as already 
described for endothelial cells. PASMC were used only up to passage 12 in order to maintain 
the phenotypic characteristics of PASMC in vivo, as confirmed by monitoring the expression 
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of smooth muscle α-actin in all experiments. Cells were deprived from serum for 16 to 24 h 
before stimulation.  
Rat smooth muscle cells (rSMC) derived from embryonic rat aorta, (kindly provided by Dr. 
H.H.H. Schmidt, Giessen, Germany) were cultured in DMEM medium supplemented with 
10% fetal calf serum, 1 g/l glucose, 100 U/ml penicillin and 100 µg/ml streptomycin. For 
subculturing, cells were trypsinised twice per week, and grown to confluency. Before 
experiments, cells were serum-starved for 16 h.  
 
2.2.3 Other cell types 
 
HepG2 cells (ATCC, Cat. No. HB-8065) were cultured in DMEM medium supplemented with 
1 g/l glucose, 10% heat inactivated fetal calf serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin and grown at 37°C under an atmosphere of 5% CO2. Cells were passaged 
twice per week in a subcultivation ratio of 1:4. 
 
2.2.4 Storage of the cells 
 
To store the cells in liquid nitrogen, confluent cells were detached by trypsinisation and 
centrifuged at 1000 rpm for 5 min. Cells were then resuspended in precooled culture medium 
containing 10% DMSO and transferred to cryovials. To allow gradual freezing, vials were 
then placed in a cold isopropanol freezing box and kept for one day at -70°C. Thereafter, 
cells were frozen at -70°C and kept for at least 24 h to acclimate to extreme cold. Finally, 
cells were transferred to and stored in liquid nitrogen (-196°C). 
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2.3 Transfection experiments 
 
2.3.1 Transfection of endothelial cells 
 
Ea.hy 926 cells were transfected using the Effectene transfection reagent. The Effectene 
reagent is a non-liposomal lipid formation that spontaneously forms micelle structures that 
show no variations in size or batch. In the first step of transfection, DNA is highly condensed 
by interaction with DNA-condensation buffer (Buffer EC). Thereafter, Effectene reagent is 
added in order to coat condensed DNA molecules and produce Effectene-DNA complexes, 
thus allowing transfer of DNA into eukaryotic cells. When performing transfections, Ea.hy 926 
cells were seeded one day before the experiments in 96-well plates or 10 cm dishes to 
achieve 50-70% confluency on the next day. Per one well of 96 well plates 35 ng of plasmid 
DNA was diluted in DNA-condensation buffer EC to a total volume of 5 µl, and 0.5 µl of 
Effectene reagent was added. For a 10 cm dish 3.5 µg of DNA, 500 µl of EC buffer and 50 µl 
of Effectene reagent were used. The mixture was incubated 10 min at room temperature to 
allow the formation of the transfection complex. Thereafter, the growth medium from the 
plate was gently aspirated, 100 µl of serum containing media per one well of a 96 well plate 
or 10 ml per 10 cm dish was added to the transfection complex, mixed by pipetting and 
immediately added to the cells. The transfection efficiency was about 60%.  
 
2.3.2 Transfection of smooth muscle cells 
 
To transfect PASMC, the FuGENE 6 transfection reagent was used. FuGENE 6 is a non-
liposomal transfection reagent composed of a blend of lipids supplied in 80% ethanol. When 
transfecting PASMC, cells were cultured for 24 h to a density of 70% and transfections were 
performed using 6 µg of plasmid DNA and 36 µl FuGENE 6 reagent per 10 cm dish. 
FuGENE 6 was diluted in serum-free MCDB medium, mixed with plasmid DNA and the 
transfection complex was incubated for 15 min at room temperature. The growth medium of 
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the cells was changed and the transfection complex was then added to the cells. The day 
after, medium was changed and cells were serum-deprived for 16 to 24 h prior to stimulation.  
rSMC were transfected using the SuperFect reagent. SuperFect transfection reagent is an 
activated dendrimer with a defined spherical architecture, with branches radiating from a 
central core and terminating at positively charged amino groups. Net positive charge allows 
them to bind to negatively charged receptors on the surface of eukaryotic cells (e.g. 
sialylated glycoproteins). Once inside the cell, SuperFect reagent buffers the lysosome after 
it has fused with the endosome, leading to pH inhibition of lysosomal nucleases and stability 
of SuperFect–DNA complexes. For transfection experiments, cells were plated in 24-well 
plates (25000 cells/ well) one day before transfection. A ratio of a total of 1 µg of DNA to 5 µl 
Superfect per well was used in each transfection. After 2 h of incubation with the transfection 
complex, the medium was changed, and the cells were further cultured for 5 h. Cells were 
then washed and serum-starved for 16 h.  
 
2.3.3 Transfection of other cell types 
 
HepG2 cells were transfected using FuGENE 6 reagent as described for PASMC. HepG2 
cells were plated onto 3.5 cm glass bottom dishes with a glass thickness of 0.17 mm (Willco 
Wells) the day before the transfection to achieve 40-60% of confluence on the next day. For 
transfection, 18 µl of FuGENE 6 reagent was mixed with 3 µg plasmid DNA. Transfection 
efficiency was about 70%. 
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2.4 Luciferase reporter gene assay 
 
2.4.1 Principle of the assay 
 
The Dual-Luciferase Reporter Assay System was used to determine reporter gene activity. 
Plasmids containing promoter or enhancer elements in front of the luciferase gene have 
been described (2.1.2.2 and 2.1.2.3). The expression of the luciferase is driven by promoter 
or enhancer sequences of genes of interest (Fig. 10).  
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Figure 10. Scheme presenting the principle of the Luciferase reporter gene assay 
Explanations are given in the text. 
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Firefly luciferase is a monomeric, 61kDa-enzyme that catalyzes luciferin oxidation using ATP 
Mg2+ as a cosubstrate. Light is produced by converting chemical energy of luciferin oxidation 
through an electron transition, forming oxyluciferin.  
Transfection efficiency was controlled by cotransfection of 0.25 µg Renilla Luciferase 
expression vector (pRLSV40, Promega). Activity of the co-transfected reporter enzyme 
Renilla provides an internal control that serves as the baseline response. Thus, the activity of 
the experimental reporter after substracting background was normalized to the activity of the 
Renilla internal control or standardized to the protein content.  
 
2.4.2 Luciferase assay 
 
When performing luciferase assays, rSMC were used since these cells are transfectable with 
high efficiency. Cells were transfected with different reporter or enhancer constructs that are 
coupled to the luciferase gene as described (2.3.2). Transfected and serum-starved rSMC 
were treated as described in respective legends. At the end of the experiment, cells were 
washed 2 times with cold PBS and lysed with 150 µl of passive lysis buffer (PLB, Promega). 
PLB is specifically formulated to promote rapid lysis of cultured mammalian cells, to provide 
optimum performance and stability of the firefly and Renilla luciferase reporter enzymes, and 
to minimize autoluminescence. After shaking the cells for 10 min in PLB, 75 µl of total cell 
lysate was transferred to tubes. The chemiluminescence was measured in a Berthold 
Luminometer (Berthold Technologies) by automatically injecting 100 µl of the substrate 
luciferin. Finally, protein content of the total lysate was determined by performing Bradford 
assay.  
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2.5 Measurements of ROS production 
 
2.5.1 DCF fluorescence in the plate reader 
 
The generation of reactive oxygen species (ROS) was measured using the fluoroprobe 5-
(and-6)-chloromethyl-2‘,7‘-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA 
(DCF)). Fluorescent dyes, like fluorescein, are chemically reduced to colorless, 
nonfluorescent products that are in the presence of ROS easily oxidized back to fluorescent 
compounds. Dichlorodihydrofluorescein diacetate passively diffuses into the cells where its 
diacetate groups are cleaved by cellular esterases, giving a more polar compound that stays 
trapped in the cells. The carboxylated analogue of H2DCFDA passes even easier through the 
membranes and has better retention in the cells, since it has two negative charges at 
physiological pH. Moreover, thiol-reactive chloromethyl groups react with gluthatione and 
other thiols, further preventing the leakage of the dye from the cells (Fig. 11).  
 
Esterases
Thiol reactive group
 
          
Figure 11. Structure of the 5-(and-6)- chloromethyl-2',7'- dichlorodihydrofluorescein diacetate, 
acetyl ester (CM-H2DCFDA) 
Explanations are given in the text. 
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Subsequent oxidation of DCF gives a fluorescent product that stays trapped in the cells and 
indicates ROS production. DCF is sensitive to H2O2, but it also detects peroxynitrite (ONOO-) 
that is formed in a reaction between NO. and O2.-. Endothelial cell express eNOS and 
produce high amounts of NO.. Therefore, when measuring ROS in endothelial cells, the 
contribution of ONOO--dependent DCF oxidation was excluded by preincubating the cells for 
30 min with the eNOS inhibitor N-ω-nitro-L-arginine methyl ester (L-NAME,10 µM), and by 
adding L-NAME to HBSS.  
To determine DCF fluorescence in a microplate reader (Tecan), EC or PASMC were grown 
in 96-well plates to 80% confluence, or transfected as described (2.3), and made quiescent 
in serum free medium for 24 h. Cells were then treated, washed with HBSS and incubated in 
the dark with DCF (8.5 µM) dissolved in HBSS for 10 min at 37°C. Cells were then washed 
with HBSS to remove excess dye, and fluorescence was monitored using 480 nm excitation 
and 540 nm emission wavelength. In some experiments, cells were preincubated with 
various inhibitors or antioxidants for 30 min and then exposed to stimuli.  
To evaluate ROS levels, background fluorescence of unloaded cells was subtracted from 
DCF fluorescence. Moreover, DCF fluorescence was standardized to the number of viable 
cells using the alamarBlue test. Continued cellular growth maintains a reduced environment 
in the cells, and therefore causes the redox indicator from alamarBlue to change from the 
oxidized, nonfluorescent, blue form to the reduced, fluorescent, red form. Therefore, to 
determine the number of viable cells, cells were incubated with alamarBlue in phosphate-
buffered saline (PBS), pH 7.4 at 37°C to allow the indicator to change from blue to the fully 
reduced red form. The absorbance was then measured at the wavelength of 580 nm.  
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2.5.2 Flow cytometric analyses using DCF fluorescence 
 
Alternatively, ROS production was assessed by flow cytometric analysis of DCF stained 
cells. Flow cytometry is a method where a fluidic system carries the suspended cells from the 
sample tube to the laser intercept point allowing differentiation and counting of the cells. 
When the cells are loaded with the fluorescent dye, fluorescence analysis makes it possible 
to quantify fluorescence from single cells. 
To confirm the validity of the method, detection of ROS production was tested by using 
freshly isolated leukocytes (1x106 cells/ml) loaded with 8.5 µM DCF and treated with phorbol 
12-myristate 13 acetate (PMA, 100 nM) for 5 min. PMA is known to induce respiratory burst 
in phagocytes. After performing measurements, the fluorescence peak of PMA-stimulated 
leukocytes was significantly shifted to higher fluorescent signal than in unstimulated 
leukocytes (Fig. 12). The quantification was done using the arithmetic mean of the peak. 
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Figure 12. ROS generation from freshly isolated leukocytes 
Leukocytes were loaded with 8.5 µM DCF and left untreated (-----), or stimulated with 100 nM PMA for 
5 min (____). ROS levels were detected by performing flow cytometric analyses. Counts on the y-axis 
represent relative number of cells investigated and FL1 on the x-axis relative intensity of fluorescence. 
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EC or PASMC were grown to 80% confluence and made quiescent in serum free media for 
24 h. Thereafter, cells were treated as described in respective figure legends. To evaluate 
ROS production, cells were detached and harvested by trypsinisation, collected by 
centrifugation at 1000 rpm for 5 min and resuspended in HBSS at a concentration of 1x106 
cells/ml. 
When performing experiments with endothelial cells, L-NAME (10 µM) was added to the 
buffers. Cells were then loaded with 8.5 µM DCF for 15 min in the dark at 37°C before 
stimulation. The DCF fluorescence was monitored by analyzing 10 000 cells using 480 nm 
excitation and 540 nm emission wavelength in a flow cytometer (Partec). 
 
2.5.3 Dihydroethidium staining 
 
Generation of ROS was visualized by the fluoroprobe dihydroethidium (DHE), which is also 
called hydroethidine. DHE passively diffuses into the cells exhibiting blue fluorescence. After 
oxidation, predominantly with O2.-, DHE is oxidized to ethidium, giving a more polar 
compound that intercalates within DNA and stains the nucleus in fluorescent red (Fig. 13). 
+
O2-.
Dihydroethidium Ethidium
 
 
 
Figure 13. Structure of the dihydroethidium 
After oxidation with O2.-, DHE is converted to the polar compound ethidium that intercalates into the 
DNA. 
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To evaluate the levels of ROS, EC or PASMC were grown in 96-well plates to 80% 
confluence, and growth-arrested in serum free media for 24 h. Cells were then stimulated, 
washed with HBSS and incubated in the dark with DHE (50 µM) for 10 min at 37°C. Cells 
were washed with HBSS again to remove excess dye. Fluorescence was monitored in a 
fluorescence microscope (Olympus) and images were obtained using the Openlab Modular 
Software for Scientific Imaging (Improvision). 
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2.6. Single cell two photon confocal laser microscopy 
 
Two photon confocal microscopy is a technique invented by Denk et al in 1990131. In 
conventional confocal laser scanning fluorescence microscopy, absorption of a single photon 
delivers energy for the fluorophore to reach the excited state from which it returns to the 
ground state by emitting a photon of fluorescence (Fig. 14A). Interestingly, the excited state 
can also be reached by the near simultaneous absorption of two longer wavelength photons 
(Fig. 14B). This absorption results in the squared dependence on laser light intensity in 
contrast to the linear light dependence of conventional, single-photon fluorescence imaging. 
This gives this technique the possibility of high contrast, three-dimensional resolution of 
fluorescence within living cells, reduced specimen photodamage and enhanced penetration 
depth of the light.  
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Figure 14. Principle of two photon confocal microscopy 
A. Single photon absorption and fluorescence emission B. Simultaneous absorption of two 
photons and fluorescence emission. 
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The possibility of two photon confocal microscopy to simultaneously excite different 
fluorophores allows the detection of two different fluorescent colors without any cross-talk. 
When performing experiments, HepG2 cells were used, since Ea.hy 926 cells did not adhere 
to the experimental glass dishes. Moreover, transfection efficiency of HepG2 cells is much 
higher, further increasing the sensitivity of the method. Cells were plated onto 3.5 cm glass 
bottom dishes with a glass thickness of 0.17 mm (Willco Wells) and transfected with 3 µg of 
either pcDNA6.1ECFP or pcDNA6.1hp22phoxECFP. After 24 h, the transfected cells were 
transferred to a culture chamber equipped with a thermostat, enabling observation at 37°C at 
constant pO2. Cells were loaded with DHR using 30 µM DHR solution in DMEM for 5 min and 
washed with DMEM. Then RH123 fluorescence in single cells was recorded using 2-photon 
confocal laser scanning microscopy (2P-CLSM) and an excitation wavelength of 850 nm was 
applied to colocalize RH123 (emission 530 nm) and ECFP fluorescence (emission 580 nm) 
as described132. Fluorescence was registered by a photomultiplier using a 60-fold water 
immersion objective (Plan Achromat, Nikon), digitized and visualized by the EZ2000 software 
(Version 2.1.4 Coord Automatisering). The signal-to-noise ratio was determined and images 
were deconvoluted with the Huygens System software (Version 2.2.1, Scientific Volume 
Imaging) using the Maximum Likelihood Estimation (MLE) method. The data were 
reconstructed and isosurfaces were calculated with the Application Visualisation System 
(AVS Waltham) as described133.  
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2.7 Northern blot analysis 
 
2.7.1 Preparation of total RNA  
 
Total RNA from EC or PASMC was purified using guanidine thiocyanate-acid phenol 
extraction. For RNA extraction, cells were plated in 10 cm dishes. At the end of the 
experiment, cells were washed with ice cold serum free medium and plates were frozen on 
liquid nitrogen. Thereafter, cells were lysed in 800 µl GT-DTT buffer, which denatures cellular 
and nucleoprotein complexes and releases RNA. The lysate was incubated for 30 min on ice 
with 800 µl phenol and 200 µl chloroform-isoamyl alcohol (24:1) to remove contaminating 
chromosomal DNA from the RNA preparation. Moreover, 80 µl of 2 M sodium-acetate buffer 
(pH 4) was added to maintain the pH of the denatured cell lysate during acid extraction and 
to provide the salt necessary for RNA precipitation with isopropanol. After centrifugation for 
30 min at 13000 rpm, DNA and proteins remained in the lower organic phase, while RNA 
was present in the upper aqueous phase. After separation of phases, RNA was purified by 
two isopropanol precipitations at -20 °C for 2 h. Finally, the pellet of RNA was diluted in 
DEPC treated H2O, heated at 65 °C for 10 min and RNA concentration was measured in a 
Hitachi spectrophotometer model U-2000 (Colora). 
 
2.7.2 Electrophoresis and detection 
 
10 µg of total RNA was mixed with RNA Premix in a 1:1 ratio and 10X RNA blue marker was 
added to the mix. The samples were then heated at 65°C for 10 min and loaded on prepared 
1.3% agarose gels. The gel was run in 1X MOPS buffer on 40 V for 4 h. After separation, 
RNA was transferred from the gel to a nylon membrane (Porablot) for 24 h using capillary 
transfer in 20X SSC buffer. After the transfer was checked by UV detection of incorporated 
ethidium bromide, transferred RNA was cross-linked by UV irradiation in Stratalinker 1800 
(Stratagen). Northern membranes were then incubated in hybridization solution for 2 h at 
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65°C. Northern hybridizations were carried out with digoxigenin-labeled antisense RNA for 
human p22phox and TF (that were present in the laboratory) or for human PAI-1 (provided 
by Dr. T. Kietzmann) at 65°C for 16 h. Thereafter, membranes were washed 2 times in 2X 
SSC solution containing 0.1% SDS and then 2 times in 0.1 SSC solution containing 0.1% 
SDS at 65°C. Membranes were blocked for 30 min in 1X blocking solution and then 
incubated for 1 h with anti-DIG antibody conjugated with alkaline phosphatase (Roche) 
diluted 1:10000 in blocking solution. After washing the membranes in washing solution, 
detection was performed by using the chemiluminescent substrate CDP-Star (Roche) diluted 
1:100 in detection buffer. Blots were scanned and analysed using GelDoc software (BioRad). 
Loading of equal amounts of RNA was confirmed by ethidium bromide staining of 18S. 
 
                                                                                                                 Materials and methods 
____________________________________________________________________________ 
49
2.8 Western blot analysis 
 
2.8.1 Preparation of protein samples 
 
Cells were washed with ice cold serum free medium and plates were frozen on liquid 
nitrogen. Cells were then lysed in GT-DTT buffer and total proteins from EC or PASMC were 
purified using guanidine thiocyanate-acid phenol extraction, as described for purification of 
total RNA (2.7.1). The proteins which remained in the lower organic phase were precipitated 
overnight at 4°C by addition of 3 ml isopropanol and 600 µl of ethanol. Thereafter, the protein 
pellet was washed in 70% ethanol and dissolved in PBS containing 1% SDS and 1 mM NaF.  
Alternatively, cells were lysed in freshly prepared buffer containing 50 mM 
tris(hydroxymethyl)aminomethane-HCl (Tris-HCl) pH 7.5, 150 mM NaCl, 25 mM NaF, 1% 
Triton, 2 mM EDTA, 2 mM EGTA, 10 mM Na2PO7, 2 mM activated Na3VO4 and 
supplemented with the mix of protease inhibitors PIM (2 µg/ml) and PMSF (44 µg/ml). After 
scraping of the cells, samples were incubated for 30 min on ice, and then centrifuged 10 min 
at 13000 rpm to remove cellular debris. This protocol was used to detect phosphorylated 
proteins.  
Before performing electrophoresis, samples were mixed with 3X Laemmli loading buffer and 
boiled at 95°C for 5 min. 
 
2.8.2 Electrophoresis and immunodetection 
 
50 µg of isolated proteins were separated by 8-12% SDS polyacrylamide gel electrophoresis 
(PAGE) in running buffer in a Mini-Protean 3 System (Biorad) and transferred to 
nitrocellulose Protran membranes (Schleicher & Schuell) using the Mini Trans-blot System 
(Biorad) in cold transfer buffer. After transfer, blots were rinsed in water and incubated in 
ponceau S solution for several minutes. Thereafter, blots were washed in water until the 
background was reduced. The membranes were placed on a transparency sheet and 
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photocopied for documentation. Thereafter, blots were rinsed for several times in TBS-T to 
remove the ponceau S. Membranes were then blocked for 2 h in TBS-T containing 5% non-
dry milk or 5% BSA and then overnight at 4°C with specific antibodies. Thereafter, 
membranes were washed 3 times for 5 min with TBS-T washing solution and incubated with 
a horseradish peroxidase-conjugated secondary antibody for 1 h. After washing the 
membranes 5 times for 5 min with TBS-T, protein bands were visualized by performing 
luminol-enhanced chemiluminescence. Blots were scanned and analysed using GelDoc 
software (BioRad).  
 
2.8.3 Stripping and reprobing 
 
Equal loading of proteins was confirmed by reprobing the membranes with an antibody 
against actin. To remove bound antibodies, membranes were incubated in stripping buffer for 
30 min at 50°C. Thereafter, membranes were washed 2 times for 30 min in TBS-T, blocked 
for 2 h in TBS-T containing 5% non-dry milk and then incubated with respective antibody. 
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2.9 Rac-1 pull down assay 
 
2.9.1 Principle of the assay 
 
Rac-1 activity was evaluated by using Rac-1 pull down activity assay. This assay uses a 
affinity precipitation method to detect active Rac-1. The assay reagent is a fusion-protein of 
the Rac-1 substrate, PAK-1, where the p21-binding domain of PAK (PBD, residues 67-150) 
is fused to glutathione S-transferase and then bound to glutathione agarose beads. 
Therefore, the beads interact only with active Rac-1 (Rac-1-GTP), and precipitate the whole 
complex. To confirm the validity of the method, lysates were loaded with either GTPγS or 
GDP before precipitation with PAK-PDB agarose. The signal from these cells confirmed that 
beads precipitate only Rac-1-GTP, which is the active form of Rac-1 (Fig. 15). 
 
 
Rac-1
GTPγS     GDP
Total Rac-1  
 
 
 
Figure 15. Validation of Rac-1 activity assay 
Cell lysates were incubated with 100 µM GTPγS or 1mM GDP in the presence of 10 mM EDTA for 15 
min at 30°C. The reaction was terminated by placing lysates on ice and adding MgCl2 to a final 
concentration of 60 mM. Thereafter, lysates were incubated with the beads and the assay was 
performed as described. Western blot analysis was performed by using an antibody against Rac-1. 
Only Rac-1 from lysates loaded with GTP (active form of Rac-1: Rac-1-GTP) was detected. 
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2.9.2 Rac-1 pull-down assay 
 
Serum-starved PASMC were stimulated with thrombin (3 U/ml) for the indicated time. Cells 
were lysed in buffer containing 25 mM HEPES, 150 mM NaCl, 1% Igepal CA-630, 10% 
glycerol, 25 mM NaF, 10 mM MgCl2, 1 mM EDTA, 1 mM sodium orthovanadate, 10 µg/ml 
leupeptin, 10 µg/ml aprotinin and incubated for 30 min on ice. Thereafter, the lysate was 
centrifuged at 13 000 rpm for 15 min to remove cellular debris. The supernatant was then 
transferred to another tube and 5 µg of PAK-PBD-bound agarose beads was added. The 
mixture was rocked for 60 min at 4°C. Thereafter, beads were collected by pulsing, washed 3 
times with lyses buffer, resuspended in 2X Laemmli buffer and boiled for 5 min. Levels of 
active Rac-1 were evaluated by SDS-PAGE and subsequent immunoblot analysis using a 
Rac-1 antibody. The supernatant after removal of the beads was also analysed by Western 
blot in order to determine levels of total Rac-1 protein. 
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2.10 Procoagulant activity  
 
PASMC were plated in 24 well plates and starved from serum for 16 h. Cells were then 
stimulated with thrombin (1 U/ml) for 6 h. Thereafter, the culture medium was removed and 
cells were washed 3 times with 1 ml prewarmed (37°C) HEPES buffer. Platelet poor plasma 
(PPP, 480 µl) was then added to the cells. PPP was isolated from freshly taken blood which 
was mixed 1:10 with sodium citrate buffer (3.8%), and centrifuged at 2100 U/min for 30 min. 
The upper phase was then separated and added to the cells together with 120 µl Buffer A. 
The formation of thrombin was initiated by the addition of 120 µl 0.1 M CaCl2 (pH 7.35; final 
concentration 16.7 mM). Every second minute from the beginning of the reaction, 20 µl 
aliquots were taken and mixed with prewarmed (37°C) Buffer B (480 µl) that contained 0.2 
mM chromogenic substrate S-2238. S-2238 is cleaved by thrombin thereby changing color 
into yellow whose optical densities are a quantitative measure of thrombin formation. After 3 
min, the reaction was stopped by adding 300 µl of concentrated acetic acid and the 
absorbance at 405 nm was measured in a spectrophotometer.  
 
Buffer A    Final concentration 
Tris      0.05 M 
NaCl      0.1 M 
The pH was adjusted to 7.35. 
 
Buffer B    Final concentration 
Tris      0.05 M 
NaCl      0.1 M 
EDTA      20 mM 
Ovalbumin     0.05 mg/ml 
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2.11 Proliferation assay 
 
2.11.1 Principle of the BrdU incorporation assay 
 
Cellular proliferation requires DNA replication. Therefore, monitoring of DNA synthesis is an 
indirect marker of the rate of proliferation in response to different stimuli.  
To asses proliferative activity of EC and PASMC we used 5-bromo-2‘deoxyuridine (BrdU) 
labeling. BrdU is an analogue of the DNA nucleoside thymidine, and is incorporated in newly 
synthesized DNA of proliferating cells. The incorporated BrdU is detected by an 
immunoassay, using a peroxidase-conjugated antibody that specifically recognizes BrdU 
bound to denaturated DNA. The bound antibody is detected by a peroxidase-catalysed 
colorimetric reaction, using tetramethyl-benzidine (TMB) as a substrate. 
 
2.11.2 Proliferation assay 
 
Cells were seeded in 96 well plates to achieve 50% of confluency. In the experiments where 
DNA synthesis of transfected cells was investigated, cells were transfected on the following 
day with corresponding vectors, and starved from serum overnight. On the next day, cells 
were exposed to stimuli as described in the respective legends. Alternatively, when analyzing 
PAI-1-dependent proliferation of PASMC, cells were stimulated with thrombin (3 U/ml) for 8 
h. The culture medium was then removed and another set of serum-starved PASMC seeded 
in 96 well plates was incubated with the supernatant in the presence of an inhibitory antibody 
that binds PAI-1 (Loxo) or mouse IgG (Santa Cruz) as a control. 
To asses proliferation, cells were then incubated with BrdU (10 µM) for 16 h. Thereafter, cells 
were fixed for 30 min and then incubated for 1 h with the peroxidase-conjugated antibody 
against BrdU. Immunodetection was performed by adding the colorimetric substrate TMB. 
When the blue color developed, the reaction was stopped with 1 M H2SO4. Absorbance was 
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measured in an ELISA reader (Tecan Safire) at 450 nm with a reference wavelength at 690 
nm. 
 
2.12 Statistical analysis 
 
Values presented are means ± standard deviation. All experiments are performed at least 3 
times (n>3). To calculate significance, Student-Newman-Keuls t-test was performed. P<0.05 
was considered statistically significant.  
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3. Results 
 
3.1 p22phox regulates ROS production and proliferation of endothelial cells in 
response to thrombin  
The mechanisms linking thrombosis to ROS production in the endothelium are not well 
understood. Endothelial cells are described to generate ROS, but the underlying 
mechanisms are still unclear. Therefore the role of thrombin in regulating NADPH oxidase-
dependent ROS production and expression of its subunit p22phox, as well as p22phox-
dependent proliferation of the endothelial cell line Ea.hy 926 were investigated. 
 
3.1.1 Thrombin activates ROS production and increases p22phox expression 
 
To evaluate the effects of thrombin on ROS production in endothelial cells, Ea.hy 926 cells 
were stimulated with thrombin and ROS production was measured by DCF fluorescence in a 
flow cytometer. Exposure to thrombin resulted in significantly increased ROS production 
peaking after 15 min and thereafter declining again (Fig. 16A). Furthermore, prolonged 
exposure to thrombin for more than 1 h also increased ROS production peaking at 3 h of 
stimulation (Fig. 16A). Since NADPH oxidases have been shown to contribute to endothelial 
ROS production, it was determined whether elevated ROS production in response to 
prolonged thrombin stimulation would be associated with increased mRNA and protein levels 
of the NADPH oxidase subunit p22phox. Ea.hy 926 cells were stimulated with thrombin (3 
U/ml) for increasing time periods, and p22phox mRNA and protein levels were measured by 
Northern blot and Western blot analyses, respectively (Fig.16B,C). Thrombin stimulation 
resulted in an upregulation of p22phox mRNA by 3-fold after 1 h followed by a 3.8 fold-
increase in p22phox protein levels at 3 h (Fig.16B,C) thus closely accompanying the kinetics 
of thrombin-stimulated ROS production (Fig.16A) suggesting that increased ROS production 
in response to prolonged thrombin stimulation may be allowed by upregulation of p22phox. 
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Figure 16. Thrombin stimulates ROS production and p22phox expression 
A) Ea.hy 926 cells were treated with 3 U/ml thrombin for 5, 15 and 30 min. DCF fluorescence was 
monitored by flow cytometry. Additionally, Ea.hy 926 cells were stimulated with thrombin from 1 to 6 h 
and DCF fluorescence was monitored in a microplate reader. Data are presented as relative increase 
compared to control at time 0 (100%) (n=3, *p<0.05 versus non-stimulated cells (Ctr)). B) Ea.hy 926 
cells were exposed to 3 U/ml thrombin for the indicated time points (from 1 to 8 h) and Northern blot 
and C) Western blot analyses were performed. Lysates of polymorphonuclear leukocytes (PMN) were 
used as a positive control. In each experiment the p22phox mRNA or protein levels at time 0 were set 
equal to 100% (n=3, *p<0.05 versus non-stimulated cells (Ctr)). Representative Northern and Western 
blots are displayed. 
                                                                                                                                          Results 
____________________________________________________________________________ 
58
3.1.2 Expression of p22phox colocalizes with intracellular ROS production 
 
To determine whether enhanced expression of the NADPH oxidase subunit p22phox is 
linked to increased ROS production, human p22phox fused to the enhanced cyan fluorescent 
protein ECFP was overexpressed and intracellular ROS production was measured using 
DHR fluorescence by 2- photon confocal laser scanning microscopy (2P-CLSM) (Fig. 17A). 
2P-CLSM allows the simultaneous detection of the blue fluorescence from transfected ECFP 
vectors and of the red fluorescence, from the conversion of non-fluorescent DHR to 
fluorescent rhodamine123 (RH123) by ROS, without any cross-talk due to the emission filter 
settings. Overlap of ECFP fluorescence with RH123 fluorescence after deconvolution and 
reconstruction indicates the sites of ROS generation and p22phox expression. Since 
transfected Ea.hy 926 cells did not attach to the specific wells required for the optical 
analysis, HepG2 cells were used in this experiment. Transfection of ECFP control plasmid 
resulted in disseminated blue fluorescence but almost no red RH123 fluorescence (Fig. 17A). 
In contrast, in pcDNA6.1hp22phoxECFP transfected cells, blue fluorescence was clearly 
localized to intracellular structures surrounding the nucleus and colocalized with elevated 
RH123 fluorescence, indicating that expression of this NADPH oxidase subunit is associated 
with intracellular ROS production (Fig. 17A). Furthermore, overexpression of p22phox 
increased ROS production in Ea.hy 926 cells as was quantified by DCF fluorescence in a 
microplate reader (Fig. 17B), indicating that increased levels of p22phox are associated with 
enhanced ROS production. Whereas stimulation with thrombin did not significantly enhance 
ROS production in p22phox overexpressing cells compared to control cells, depletion of 
p22phox by transfecting an antisense vector completely abrogated thrombin-stimulated ROS 
production (Fig. 17B,C). These findings confirm that p22phox is required for ROS production 
and that thrombin stimulation is mimicking the situation with enhanced p22phox expression. 
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Figure 17. Expression of p22phox is linked to intracellular ROS production 
A) HepG2 cells were transfected with pcDNA6.1hp22phoxECFP (p22phoxECFP) or control vector 
(ECFP) and loaded with 30 µM DHR for 5 min. RH123 fluorescence showing ROS generation and 
ECFP fluorescence showing the expression of the p22phox fusion protein were recorded 
simultaneously by 2-photon confocal laser scanning microscopy. Overlapping of ECFP fluorescence 
(blue fluorescence) with RH123 fluorescence (red fluorescence) after deconvolution indicates the sites 
of p22phox expression and ROS production, respectively. B) Ea.hy 926 cells were transfected with 
control vector (Ctr) or a p22phox sense (pS) or antisense vector (pAS) and stimulated with thrombin (3 
U/ml) for 3 h. ROS levels were evaluated by performing DCF measurements. Data are presented as 
relative increase to control (100%) (n=3, *p<0.05 versus cells transfected with control vector (Ctr); 
#p<0.05 versus thrombin-stimulated cells transfected with control vector (Ctr)). C) Ea.hy 926 cells 
were transfected with control vector (Ctr) or a p22phox sense (pS) or antisense vector (pAS) and the 
expression was confirmed by performing Western blot analyses using an antibody against p22phox. 
The loading of equal amounts of proteins was confirmed by reprobing the membranes with a β-actin 
antibody. A representative Western blot is shown (n=3).  
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3.1.3 Thrombin regulates p22phox expression in a redox-sensitive manner 
 
Since thrombin induced a biphasic elevation of ROS whereby the delayed phase of ROS 
production correlated with an upregulation of p22phox, and overexpression of p22phox 
significantly increased intracellular levels of ROS, the hypothesis was investigated whether 
thrombin stimulation of p22phox protein expression is redox-sensitive. Ea.hy 926 cells were 
exposed to the antioxidant vitamin C (VitC, 100 µM) or the flavin inhibitor 
diphenyleneiodonium (DPI, 10 µM) for 30 min prior to stimulation with thrombin for 3 h, and 
generation of ROS as well as expression levels of p22phox mRNA and protein were 
determined. Treatment with VitC as well as DPI did not only inhibit thrombin-stimulated ROS 
production (Fig. 18A) but also prevented upregulation of p22phox mRNA and protein levels 
(Fig. 18B) further suggesting that thrombin regulates p22phox expression via a redox-
sensitive pathway. 
To further support redox-sensitivity of p22phox expression, Ea.hy 926 cells were exposed to 
50 µM H2O2 for increasing time periods and p22phox mRNA levels were determined (Fig. 
19A). H2O2 transiently increased p22phox mRNA levels by 2.9-fold at 2 h of stimulation, 
corresponding to elevated ROS levels at this time as determined by dihydroethidium (DHE) 
fluorescence (Fig. 19B). Quantitative analysis of ROS production by DCF fluorescence in 
response to treatment with H2O2 for 3 h revealed a dose-dependent increase in DCF 
fluorescence peaking at 10 to 50 µM (Fig. 19C) which was accompanied by a significant 
increase in p22phox protein levels (Fig. 19C) further supporting that p22phox expression is 
redox-sensitive. 
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Figure 18. Thrombin-induced p22phox expression is redox-sensitive 
Ea.hy 926 cells were exposed to the antioxidant vitamin C (VitC, 100 µM) or the flavin inhibitor 
diphenyleneiodonium (DPI, 10 µM) for 30 min prior to stimulation with 3 U/ml thrombin for 3 h. A) ROS 
levels were assessed by performing DCF measurements in a microplate reader. Data are presented 
as relative increase to control (100%) (n=3, *p<0.05 versus non stimulated cells (Ctr), #p<0.05 versus 
thrombin-stimulated cells (Ctr)). B) p22phox mRNA and protein levels were evaluated by performing 
Northern blot or Western blot analyses, respectively. Equal loading was controlled by 18S staining or 
probing with an actin antibody, respectively. In each experiment the p22phox mRNA or protein levels 
under non-stimulated, untreated conditions were set equal to 100% (n=3, *p<0.05 versus non-
stimulated cells (Ctr), #p<0.05 versus thrombin-stimulated cells (Ctr)). Representative Northern and 
Western blots are displayed.  
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Figure 19. H2O2 increases ROS production and p22phox expression 
A) Ea.hy 926 cells were stimulated with 50 µM H2O2 for increasing time points (from 1 to 8 h) and 
p22phox mRNA levels were determined by Northern blot analyses. In each experiment the p22phox 
mRNA levels under non-stimulated conditions were set equal to 100% (n=3, *p<0.05 versus non-
stimulated cells (Ctr)). B) Ea.hy 926 cells were treated with H2O2 (10 or 50 µM) for 3 h, washed with 
HBSS and incubated with DHE (50 µM) for 10 min in the dark at 37°C. Representative images from a 
total of 3 experiments are shown. C) Ea.hy 926 cells were stimulated with increasing concentrations of 
H2O2 (10, 50 or 100 µM) for 3 h. DCF fluorescence was monitored in a microplate reader. Data are 
presented as relative increase to control (100%) (n=3, *p<0.05 versus non-stimulated cells). 
Concomitantly, p22phox protein levels were evaluated by Western blot analysis using an antibody 
against p22phox. In each experiment the p22phox protein levels under non-stimulated conditions were 
set equal to 100% (n=3, *p<0.05 versus non-stimulated cells (Ctr)). A representative Western blot is 
shown. 
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3.1.4 Thrombin-stimulated ROS production and p22phox expression require kinase 
activation 
 
To investigate the signaling pathways involved in thrombin-stimulated ROS production and 
p22phox expression, Ea.hy 926 cells were stimulated with thrombin (3 U/ml) and 
phosphorylation of protein kinase B (Akt), p38 MAP kinase (p38MAPK) and p42/44 MAP 
kinase (ERK) was evaluated by Western blot analysis (Fig. 20A). Thrombin transiently 
increased the phosphorylation of all three kinases peaking at 1 min for Akt and ERK and at 5 
min for p38MAPK. To further evaluate the involvement of these protein kinases in thrombin-
stimulated ROS production, Ea.hy 926 cells were preincubated with the p38MAPK inhibitor 
SB220025 (20 µM), the inhibitor of the ERK upstream kinase MEK1, PD98059 (20 µM), or 
the phosphatidylinositol-3 kinase (Pl3K) inhibitor LY294002 (10 µM). Treatment with 
SB220025 and LY294002, but not with PD98059, significantly decreased thrombin-
stimulated ROS production (Fig. 20B). Moreover, application of SB220025 or LY294002 
inhibited upregulation of p22phox mRNA by thrombin (Fig. 20B) suggesting that the 
p38MAPK and Pl3 kinase/Akt pathways are involved in the regulation of p22phox expression 
and NADPH oxidase activity in response to thrombin in endothelial cells.  
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Figure 20. p38 MAP kinase and Pl3 kinase mediate increased ROS production and p22phox 
expression in response to thrombin 
A) Ea.hy 926 cells were exposed to 3 U/ml thrombin for different time points (from 1 to 30 min) and 
Western blot analysis was performed using antibodies against the phosphorylated forms of Akt (p-
Akt), p38 MAP kinase (p-p38) and ERK (p-ERK). In each experiment protein levels under non-
stimulated conditions were set equal to 1 (n=3, *p<0.05 versus non-stimulated cells (Ctr)). B) Ea.hy 
926 cells were preincubated for 30 min with the p38MAPK inhibitor SB220025 (SB, 20 µM), the MEK1 
inhibitor PD98059 (PD, 20 µM), and the Pl3 kinase inhibitor LY294002 (LY, 10 µM). After stimulation 
with 3 U/ml thrombin for 3 h, ROS generation was assessed in a microplate reader using DCF 
fluorescence. Data are presented as relative increase to control (100%) (n=3, *p<0.05 versus non-
stimulated cells (Ctr), #p<0.05 versus thrombin-stimulated cells). After exposure to 3 U/ml thrombin for 
1 h, p22phox mRNA levels were determined by Northern blot analyses. In each experiment the 
p22phox mRNA levels under non-stimulated conditions were set equal to 100% (n=3, *p<0.05 versus 
non-stimulated cells (Ctr), #p<0.05 versus thrombin-stimulated cells).  
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3.1.5 H2O2 induces ROS production and p22phox expression via kinase activation 
 
To further evaluate the signaling pathways activated by H2O2, cells were stimulated with 
H2O2 (50 µM) and phosphorylation of Akt, p38MAPK and ERK was determined by performing 
Western blot analysis (Fig. 21A). Similar to thrombin, H2O2 increased the phosphorylation of 
all three kinases in a time-dependent manner starting between 1 to 5 min of exposure, but 
staying elevated over the whole observation period (30 min). To investigate the role of these 
kinase pathways in H2O2-stimulated ROS production, cells were pretreated with SB220025, 
PD98059 or LY294002. Application of SB220025 and LY294002, but not of PD98059, 
significantly decreased H2O2-stimulated ROS generation (Fig. 21B). Similar to the results 
obtained with thrombin, pretreatment with SB220025 and LY294002 prevented upregulation 
of p22phox mRNA levels in response to H2O2 (Fig. 21B) indicating the involvement of 
p38MAPK and Pl3 kinase/Akt in the regulation of p22phox expression and NADPH oxidase 
activity in response to low levels of H2O2 in endothelial cells.  
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Figure 21. p38 MAP kinase and PI3 kinase mediate increased ROS production and p22phox 
expression in response to H2O2 
A) Ea.hy 926 cells were stimulated with 50 µM H2O2 from 1 to 30 min. Western blot analysis using 
antibodies against the phosphorylated forms of Akt (p-Akt), p38 MAP kinase (p-p38MAPK) and ERK 
(p-ERK) was performed. Protein levels under non-stimulated conditions were set equal to 1 (n=3, 
*p<0.05 versus non-stimulated cells (Ctr)). B) Ea.hy 926 cells were preincubated for 30 min with the 
p38MAPK inhibitor SB220025 (SB, 20 µM), the MEK1 inhibitor PD98059 (PD, 20 µM), and the Pl3 
kinase inhibitor LY294002 (LY, 10 µM). After stimulation with 50 µM H2O2 for 3 h, ROS generation was 
assessed in a microplate reader using DCF fluorescence. Data are presented as relative increase to 
control (100%) (n=3, *p<0.05 versus unstimulated cells (Ctr), #p<0.05 versus H2O2-stimulated cells). 
After treatment with 50 µM H2O2 p22phox mRNA levels were detected by Northern blot analysis. 
p22phox mRNA levels under non-stimulated, untreated conditions were set equal to 100% (n=3, 
*p<0.05 versus non-stimulated cells (Ctr), #p<0.05 versus H2O2 -stimulated cells).  
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3.1.6 Thrombin and H2O2 regulate p22phox via transcription and de novo synthesis 
 
To further investigate the mechanisms involved in the regulation of p22phox expression by 
thrombin and H2O2, Ea.hy 926 cells were preincubated with actinomycin D (5 µg/ml), an 
inhibitor of gene transcription, or cycloheximide (100 µM), an inhibitor of protein synthesis, for 
30 min, and then exposed to thrombin (3 U/ml) or H2O2 (50 µM) for 1 or 2 h, respectively. 
mRNA levels were evaluated by Northern blot analyses. Actinomycin D significantly blocked 
the thrombin- or H2O2-mediated increase in p22phox mRNA whereas cycloheximide did not 
prevent the induction of p22phox mRNA (Fig. 22A). These results indicate that thrombin- or 
H2O2-stimulated p22phox mRNA involves transcriptional activation of the p22phox gene. 
In addition, preincubation with actinomycin D or cycloheximide for 30 min decreased 
thrombin- or H2O2–stimulated p22phox protein levels (Fig. 22B) suggesting that also de novo 
protein synthesis is involved in the response to thrombin and H2O2.  
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Figure 22. p22phox expression by thrombin and H2O2 is regulated at the transcriptional and 
post-transcriptional levels 
A) Ea.hy 926 cells were exposed to actinomycin D (5 µg/ml) or cycloheximide (100 µM) for 30 min 
prior to stimulation with thrombin (3 U/ml) or H2O2 (50 µM) for 1 or 2 h, respectively. p22phox mRNA 
levels were evaluated by performing Northern blot analysis. In each experiment the p22phox mRNA 
levels under non-stimulated, untreated conditions were set equal to 100% (n=3, *p<0.05 versus non-
stimulated cells (Ctr), #p<0.05 versus thrombin- or H2O2-stimulated cells). B) Ea.hy 926 cells were 
preincubated with actinomycin D (5 µg/ml) or cycloheximide (100 µM) for 30 min and thereafter 
stimulated with thrombin (3 U/ml) or H2O2 (50 µM). p22phox protein levels were evaluated by Western 
blot analysis using an antibody against p22phox. Loading of equal amounts of proteins was confirmed 
by reprobing the membranes with a β-actin antibody. In each experiment the p22phox protein levels 
under non-stimulated, untreated conditions were set equal to 100% (n=3, *p<0.05 versus non-
stimulated cells (Ctr), #p<0.05 versus thrombin- or H2O2-stimulated cells).  
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3.1.7 Low levels of H2O2 or thrombin stimulate NADPH oxidase-dependent proliferative 
activity 
 
Low levels of ROS have been suggested to promote proliferation. We therefore determined 
the effects of increasing concentrations of H2O2 and thrombin on the proliferative activity of 
Ea.hy 926 cells by BrdU incorporation. Stimulation with H2O2 at concentrations between 0.1 
and 50 µM for 72 h significantly increased the proliferative activity whereas 100 µM H2O2 had 
no effect and higher concentrations such as 500 and 1000 µM significantly decreased the 
proliferative activity (Fig. 23A). Similarly, exposure to 3 U/ml of thrombin, but not to 5 U/ml, 
significantly increased proliferation of Ea.hy 926 cells (Fig. 23B). Depletion of p22phox by 
transfecting an antisense vector completely abrogated thrombin- and H2O2-stimulated 
proliferation (Fig. 23C). 
 
In summary, the data support a model whereby activation of the NADPH oxidase by thrombin 
leads to a rapid increase in endothelial ROS production which, via activation of p38MAPK 
and the PI3 kinase/Akt pathway, elicits p22phox expression, subsequently promoting 
sustained generation of ROS and proliferation of endothelial cells.  
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Figure 23. H2O2 or thrombin treatment stimulate p22phox-dependent cell proliferation 
A) Ea.hy 926 cells were starved from serum for 24 h and then exposed for 72 h to H2O2 (0.1 to 1000 
µM). Proliferative activity was assessed by using 5-bromo-2’-deoxyuridine (BrdU) incorporation. Data 
are presented as relative increase to control (100%) (n=3, *p<0.05 versus non-stimulated cells). B) 
Ea.hy 926 cells were starved from serum for 24 h and then exposed for 72 h to thrombin (3 or 5 U/ml). 
Proliferation was assessed by using BrdU incorporation. Data are presented as relative increase to 
control (100%) (n=3, *p<0.05 versus non-stimulated cells). C) Cells were transfected with a p22phox 
antisense vector (pAS) or control vector (Ctr), starved from serum for 24 h and then stimulated with 10 
µM H2O2 or 3 U/ml thrombin for 72 h. Proliferation was assessed by using BrdU incorporation. Data 
are presented as relative increase to control (100%) (n=3, *p<0.05 versus non-stimulated cells 
transfected with control vector (Ctr), #p<0.05 versus H2O2- or thrombin-stimulated cells). 
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3.2 Rac-1 regulates ROS production and proliferation of pulmonary artery 
smooth muscle cells in response to thrombin 
 
Thrombosis, ROS generation and proliferation of smooth muscle cells are features of 
(pulmonary) vascular remodeling. Whereas thrombin has been shown to increase ROS 
production by activating NADPH oxidases in aortic smooth muscle cells122, the role of 
thrombin in the regulation of ROS production and proliferation of PASMC, the primary cell 
type involved in pulmonary vascular remodeling, is not well understood. Since Rac-1 is an 
important regulator of NADPH oxidase activity, and can also act as a molecular switch 
involved in different signaling pathways, it was investigated whether Rac-1 is involved in 
ROS production and proliferation in response to thrombin in PASMC. Moreover, the effect of 
Rac-1 on proliferation of PASMC was evaluated. 
 
3.2.1 Rac-1 modulates ROS production in response to thrombin  
 
To investigate the role of Rac-1 in thrombin-stimulated ROS production, PASMC were 
transfected with expression vectors encoding constitutively active RacG12V or dominant-
negative RacT17N or with control vector (Ctr) and stimulated with thrombin for 2 h. 
Generation of ROS was evaluated by DCF fluorescence. Treatment with thrombin 
significantly enhanced levels of ROS in PASMC (Fig. 24). Expression of RacG12V further 
increased ROS production which was abolished by the antioxidant N-acetyl-cysteine (NAC) 
(Fig. 24). On the other hand, expression of RacT17N prevented thrombin-stimulated ROS 
generation, suggesting an important role of Rac-1 in controlling ROS production in response 
to thrombin in PASMC.  
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Figure 24. Rac-1 modulates thrombin-stimulated production of reactive oxygen species 
PASMC were transfected with control vector (Ctr) or expression vectors for either a constitutively 
active RacG12V (V12) or a dominant-negative RacT17N (N17) form of Rac-1 and/or preincubated with 
NAC (10 mM) and exposed to thrombin (3 U/ml) for 2 h. DCF fluorescence was monitored in a 
microplate reader (n=3; *p<0.05 versus Ctr (unstimulated); #p<0.05 versus Ctr (thrombin-stimulated) 
$p<0.05 versus V12 transfected cells stimulated with thrombin (V12)). 
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3.2.2 Rac-1 expression and activity are increased in response to thrombin 
 
Since thrombin-stimulated ROS generation was Rac-1-dependent, it was investigated 
whether thrombin is able to influence Rac-1 expression and activity. To this end, PASMC 
were stimulated with thrombin for different time points and Rac-1 protein levels were 
evaluated by Western blot analyses. Thrombin transiently enhanced Rac-1 protein 
expression by 1.5 -fold peaking after 2 h of application (Fig. 25A). Moreover, thrombin 
stimulation for 15 sec resulted in significantly increased activity of Rac-1 to levels about 2-
fold higher than in the respective control (Fig. 25B). 
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Figure 25. Rac-1 expression and activity are increased in response to thrombin 
PASMC were exposed to thrombin (3 U/ml) for different time points and A) Rac-1 protein levels were 
determined by Western blot analysis. B) Levels of active Rac-1 or total Rac-1 proteins were evaluated 
by performing a Rac-1 pull down assay. Representative blots are shown. Equal loading of proteins 
was confirmed by reprobing the membranes with an actin antibody. In each experiment protein levels 
under non-stimulated conditions were set equal to 100 % (n=4, *p<0.05 versus non-stimulated cells 
(Ctr)). 
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3.2.3 Rac-1 activity and ROS production in response to thrombin are dependent on 
calcium 
 
Since thrombin is known to influence calcium currents in smooth muscle cells, it was 
investigated whether Ca2+ could play a role in ROS generation and Rac-1 activation by 
thrombin. Therefore, PASMC were preincubated with the calcium chelator BAPTA-AM or the 
antioxidant NAC and treated with thrombin. Application of BAPTA-AM or NAC completely 
abrogated thrombin-stimulated ROS production (Fig. 26A). Moreover, thrombin-induced 
activation of Rac-1 was prevented by application of BAPTA-AM (Fig. 26B). 
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Figure 26. Thrombin-stimulated ROS production and Rac-1 activation are Ca2+ sensitive 
PASMC were preincubated with the Ca2+ chelator BAPTA-AM (BAPTA, 7.5 µM) or the antioxidant 
NAC (10 mM) for 30 min and A) exposed to thrombin (3 U/ml) for 2 h and ROS production was 
assessed by DCF fluorescence. Data are presented as relative increase to control (100%) (n=3, 
*p<0.05 versus unstimulated cells (Ctr); #p<0.05 versus thrombin-stimulated cells (Ctr)) or B) exposed 
to thrombin for 15 sec, and levels of active Rac-1 were evaluated by performing Rac pull down assay. 
Data are presented as relative increase to control (100%) (n=3, *p<0.05 versus unstimulated cells 
(Ctr)). 
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3.2.4 Rac-1 modulates cell proliferation in response to thrombin 
 
To elucidate the role of Rac-1 in cell proliferation, PASMC were transfected with expression 
vectors encoding constitutively active RacG12V or dominant-negative RacT17N or with 
control vector and were exposed to thrombin for 24 h. Thrombin stimulation resulted in a 
significant increase in proliferative activity of PASMC that was completely abrogated by the 
antioxidant NAC and the Ca2+ chelator BAPTA-AM (Fig. 27). In addition, proliferation of 
PASMC was further elevated by RacG12V and decreased by treatment with NAC (Fig 27). 
Overexpression of RacT17N completely prevented proliferation of PASMC in response to 
thrombin (Fig. 27). 
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Figure 27. Rac-1 modulates cell proliferation by thrombin 
PASMC were transfected with control vector (Ctr), the constitutively active RacG12V (V12) or the 
dominant-negative RacT17N (N17). On the following day cells were pretreated with the Ca2+ chelator 
BAPTA-AM (7.5 µM) or the antioxidant NAC (10 mM) for 30 min and thereafter stimulated with 
thrombin (3 U/ml) for 24 h. Proliferative activity was assessed by BrdU incorporation (n=3, *p<0.05 
versus unstimulated control cells (Ctr), #p<0.05 versus thrombin-stimulated control cells (Ctr), $p<0.05 
versus V12 transfected cells stimulated with thrombin (V12)).  
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In summary, thrombin enhanced ROS production in PASMC via the activation and 
upregulation of Rac-1. Rac-1 activity as well as Rac-1 protein levels, ROS production and 
cell proliferation were dependent on calcium. Similar to the situation in endothelial cells (3.1), 
these findings support a model whereby activation of Rac-1 by thrombin could lead to a fast 
increase in ROS production, while upregulation of Rac-1 may be responsible for prolonged 
and sustained generation of ROS and proliferation of pulmonary artery smooth muscle cells 
as observed in vascular remodeling. 
 
                                                                                                                                          Results 
____________________________________________________________________________ 
77
3.3 Rac-1 regulates redox-sensitive tissue factor expression by thrombin in 
pulmonary artery smooth muscle cells: Role of the NFκB pathway 
 
Since thrombin levels are regulated by activation of TF and the coagulation cascade, and TF 
expression has been shown to be sensitive to ROS and thrombin, it was hypothesized that 
Rac-1 could play a role in regulation of TF expression in PASMC.  
 
3.3.1 Thrombin enhances tissue factor expression and promoter activity 
 
PASMC were exposed to thrombin for increasing time intervals and TF expression was 
determined by Northern and Western blot analysis. Thrombin transiently enhanced TF 
mRNA levels by 4-fold peaking after 2 to 4 h of incubation (Fig. 28A). Elevated TF mRNA 
levels were followed by enhanced TF protein levels which were continuously increasing to 
levels about 4-fold higher than in the respective controls after 16 h of exposure to thrombin 
(Fig. 28B).  
To further confirm the transcriptional activation of TF by thrombin, cells were transfected with 
two human TF promoter luciferase constructs (Fig. 28C). The plasmid pTF111 contained the 
minimal promoter sequence (-111 to +121 bp) including a proximal enhancer with three 
overlapping Egr1 and Sp1 sites. The plasmid pTF636 contained the sequence from –636 to 
+121 bp and harbored in addition a distal enhancer containing a NFκB and two AP1 
consensus sequences. Stimulation with thrombin increased luciferase activity of pTF636 by 
about 4-fold, whereas pTF111-dependent luciferase activity was only elevated by about 2-
fold, suggesting that pTF636 contains thrombin-sensitive DNA binding consensus sequences 
which are not present in pTF111. 
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Figure 28. Thrombin stimulates tissue factor expression and promoter activity 
PASMC were stimulated with thrombin (3 U/ml) for different time points. A) Tissue factor (TF) mRNA 
levels were evaluated by Northern blot analysis using a cDNA probe for human TF or for 18S to 
determine loading efficiency. These blots are representative for three independent experiments. B) TF 
protein levels were determined by Western blot analysis using an antibody against human TF or 
against actin. These blots are representative for three independent experiments. C) rSMC were 
transfected with the human TF promoter luciferase constructs pTF636 and pTF111. After 16 h of serum 
starvation, cells were stimulated for 8 h with thrombin (3 U/ml). In each experiment, the luciferase 
activity of the control vector measured under unstimulated conditions was set equal to 100% 
(represented by the dotted line). Values ± SD represent the % induction by thrombin of luciferase activity 
of three independent experiments (n=3, *p<0.05 versus control (unstimulated)).  
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3.3.2. Tissue factor expression in response to thrombin is redox-sensitive 
 
To investigate whether ROS are involved in thrombin-stimulated TF expression, PASMC 
were pretreated with the antioxidant vitamin C or the non-specific NADPH oxidase inhibitor 
DPI and then stimulated with thrombin for 4 h. Production of ROS was evaluated by using 
DCF fluorescence. Moreover, TF protein expression was determined by Western blot 
analysis (Fig. 29). Pretreatment with the antioxidants decreased ROS levels and TF 
expression by thrombin, indicating that TF expression in response to thrombin is redox-
sensitive.  
 
 
Ctr Ctr VitC DPI
Thrombinα-Actin
TF Protein
0
50
100
150 *
#
#
Thrombin
R
el
. D
C
F 
flu
or
es
ce
nc
e
[%
co
nt
ro
l]
R
el
. D
C
F 
flu
or
es
ce
nc
e
[%
co
nt
ro
l]
 
 
 
Figure 29. Thrombin-stimulated tissue factor expression is redox-sensitive 
PASMC were preincubated with DPI (10 µM) or the antioxidant VitC (100 µM) for 30 min and then 
exposed to thrombin (3 U/ml) for 4 h. ROS production was assessed by DCF fluorescence. Data are 
presented as relative increase to control (100%) (n=3, *p<0.05 versus unstimulated cells (Ctr); 
#p<0.05 versus thrombin-stimulated cells (Ctr)). TF protein levels were determined by Western blot 
analysis using an antibody against human TF or against actin. These blots are representative for three 
independent experiments. 
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3.3.3 Rac-1 mutants modulate thrombin-induced tissue factor expression and 
procoagulant activity 
 
Since thrombin-stimulated TF expression was redox-sensitive and decreased by the non-
specific NADPH oxidase inhibitor DPI, the role of Rac-1 in this pathway was evaluated. 
Therefore, human PASMC were transfected with expression vectors encoding constitutively 
active RacG12V (V12) or dominant-negative RacT17N (N17) or with control vector (Ctr) and 
stimulated with thrombin for 4 h for Northern blot analysis and for 16 h for Western blot 
analysis. In control cells, stimulation with thrombin resulted in a 2.8-fold increase in TF 
mRNA levels (Fig. 30A). This response was further enhanced in RacG12V-expressing cells, 
but was significantly diminished in RacT17N-expressing PASMC. Similarly, TF protein levels 
were enhanced by 3-fold in control cells after thrombin stimulation, and were further elevated 
in RacG12V-expressing cells (Fig. 30B). By contrast, in RacT17N-expressing PASMC, TF 
protein levels were abrogated to levels similar to those from the unstimulated controls.  
Since TF protein levels in smooth muscle cells do not necessarily reflect active TF, the role 
of Rac-1 in modulating surface procoagulant activity derived from PASMC under control 
conditions and in the presence of thrombin was evaluated using a chromogenic assay (Fig. 
30C). PASMC were transfected with RacG12V or RacT17N expression vectors or with 
control vector and exposed to thrombin for 8 h. Thrombin treatment resulted in a significant 
increase in surface procoagulant activity. In the presence of RacG12V, procoagulant activity 
was enhanced under control conditions and further potentiated in the presence of thrombin. 
In contrast, transfection of RacT17N abrogated thrombin-stimulated surface procoagulant 
activity. Since addition of an inhibitory antibody against human TF inhibits basal as well as 
thrombin-stimulated procoagulant activity as was shown previously71, these data suggest that 
Rac-1 is involved in regulating TF expression as well as TF activity in response to thrombin 
in PASMC.  
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Figure 30. Rac-1 modulates thrombin-induced tissue factor expression and activity 
PASMC were transfected with control vector (Ctr) or expression vectors for either the constitutively 
active RacG12V (V12) or the dominant-negative RacT17N (N17). A) Transfected PASMC were 
stimulated with thrombin (3 U/ml) for 4 h. Northern blot analyses were performed with a human tissue 
factor (TF) cDNA or 18S cDNA probe (n=3; *p<0.05 versus Ctr (unstimulated); #p<0.05 versus Ctr 
(thrombin-stimulated)). B) TF protein levels were determined in transfected PASMC stimulated for 16 
h with thrombin (3 U/ml) by Western blot analysis using an antibody against human TF. The 
expression of the Rac-1 constructs was controlled by Western blot analysis with an antibody against 
the c-myc epitope (n=3; *p<0.05 versus Ctr (unstimulated); #p<0.05 versus Ctr (thrombin-stimulated)). 
C) Surface procoagulant activity was investigated in human PASMC transfected with control vector 
(Ctr) or expression vectors encoding RacG12V (V12) or RacT17N (N17) and exposed to thrombin (3 
U/ml) for 8 h. The formation of thrombin was evaluated using a chromogenic assay (n=3; *p<0.05 
versus Ctr (unstimulated); #p<0.05 versus Ctr (thrombin-stimulated)).  
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3.3.4 Rac-1 modulates tissue factor promoter activity via the nuclear factor kappa B 
pathway 
 
To investigate the role of Rac-1 in thrombin-stimulated TF expression, reporter gene 
experiments using the two TF promoter constructs pTF111 and pTF636 were performed. 
Cotransfection of the RacG12V mutant with pTF636 resulted in about 2.8-fold increased 
luciferase activity compared to control cells, while in RacT17N-expressing cells pTF636-
derived luciferase activity was abrogated (Fig. 31A). pTF111-mediated luciferase activity was 
only increased by 1.5-fold in RacG12V-expressing cells and was not significantly decreased 
in the presence of RacT17N, suggesting that pTF636 contains DNA sequences sensitive to 
Rac-1 which are not present in pTF111.  
Since the pTF636, but not the pTF111 construct contains a consensus sequence for the 
redox-sensitive transcription factor NFκB, the role of this transcription factor in Rac-1-
regulated human TF promoter activity was determined. In order to evaluate whether Rac-1 is 
able to modulate NFκB-mediated transcriptional activity, a luciferase construct containing 5 
NFκB consensus sites in front of the SV40 promoter was cotransfected with the mutant Rac-
1 vectors (Fig. 31B). In the presence of active RacG12V, luciferase activity was significantly 
enhanced by 1.8-fold while expression of dominant-negative RacT17N resulted in a 
significant decrease in reporter gene activity compared to control cells. Moreover, exposure 
to thrombin for 8 h resulted in about 7-fold increased NFκB-dependent luciferase activity 
(Fig. 31C). These findings demonstrate that thrombin and Rac-1 are able to activate NFκB 
transcriptional activity in smooth muscle cells.  
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Figure 31. Rac-1 modulates tissue factor promoter activity and nuclear factor kappa B 
mediated transcriptional activity 
A) rSMC were cotransfected with expression vectors encoding constitutively active RacG12V (V12) or 
dominant-negative RacT17N (N17) or control vector (Ctr) and the human TF promoter luciferase 
constructs pTF636 or pTF111. Luciferase activity was measured 24 h after transfection. In each 
experiment the luciferase activity determined in the presence of control vector was set equal to 100%. 
Values ± SD represent the % induction of luciferase activity of three independent experiments (n=3; 
*p<0.05 versus Ctr). B) rSMC were cotransfected with expression vectors encoding constitutively 
active RacG12V (V12) or dominant-negative RacT17N (N17) or control vector (Ctr) and a luciferase 
construct containing five nuclear factor-κB (NFκB) elements (NFkappaB-Luc) in front of the SV40 
promoter. Luciferase activity was measured 24 h after transfection. In each experiment the luciferase 
activity measured in the presence of control vector was set equal to 100%. Values ± SD represent the 
% induction of luciferase activity of three independent experiments. (n=3; *p<0.05 versus Ctr). C) rSMC 
were transfected with the NFkappaB-Luc reporter gene. Cells were then serum-deprived for 16 h and 
stimulated with thrombin for 8 h. In each experiment the luciferase activity measured under 
unstimulated conditions was set equal to 100%. Values ± SD represent the % induction of luciferase 
activity of three independent experiments. (n=3; *p<0.05 versus Ctr).  
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To evaluate whether NFκB contributes to TF promoter activity, cells were transfected with 
expression vectors encoding for the NFκB subunits p50 and p65 together with the TF 
promoter constructs pTF636 or pTF111, respectively. Coexpression of p50/p65 and pTF636 
resulted in about 3.5-fold increased luciferase activity (Fig. 32A). Transfection of p50/p65, 
however, did not significantly influence reporter gene activity of the minimal TF promoter 
construct pTF111.  
To evaluate whether Rac-1 acts on the TF promoter via the NFκB pathway, cells were 
transfected with the RacG12V expression vector and vectors encoding for either dominant-
negative mutant of inhibitory κB protein (IκBdn) or inhibitory κB protein kinase (IκKdn) as well 
as with pTF636 or pTF111 (Fig. 32B). RacG12V-stimulated luciferase activity of pTF636 was 
completely abolished in the presence of dominant-negative IκB or IκBK. In contrast, pTF111-
dependent luciferase activity in RacG12V-expressing cells was not significantly reduced by 
dominant-negative IκB or IκBK. These findings indicate that Rac-1 activates NFκB leading to 
TF upregulation by thrombin. 
 
In summary, thrombin was able to increase redox-sensitive TF expression and activity in 
PASMC. Upregulation of TF was modulated by Rac-1-dependent ROS generation. Finally, 
Rac-1 stimulated TF expression involved activation of the NFκB pathway. 
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Figure 32. The nuclear factor kappa B pathway is involved in Rac-1-dependent tissue factor 
promoter activity 
A) rSMC were cotransfected with expression vectors encoding the NFκB subunits p50 and p65 or with 
control vector (Ctr) and the human TF promoter luciferase constructs pTF636 or pTF111. Luciferase 
activity was measured 24 h after transfection (n=3; *p<0.05 versus Ctr). B) rSMC were cotransfected 
with the RacG12V expression vector or control vector (pcDNA3) and the pTF636 or pTF111 human 
TF promoter luciferase constructs and expression vectors encoding for dominant-negative IκB (IKdn) 
or IκBK (IKKdn). Luciferase activity was measured 24 h after transfection (n=3; *p<0.05 versus Ctr 
(pcDNA3); #p<0.05 versus RacG12V transfected cells). 
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3.4 Rac-1 regulates redox-sensitive PAI-1 expression by thrombin in pulmonary 
artery smooth muscle cells: Role of hypoxia-inducible factor-1 
 
PAI-1 has been associated with tissue remodeling processes in vascular diseases 
characterized with a prothrombotic state. However, the link between enhanced levels of 
thrombin and PAI-1 expression has not been determined. Since thrombin enhanced ROS 
production and Rac-1 activity in PASMC (3.2), it was investigated whether Rac-1 could play 
a role in the regulation of PAI-1 in PASMC.  
 
3.4.1 Thrombin enhances PAI-1 mRNA and protein levels 
 
PASMC were exposed to thrombin for increasing time intervals and PAI-1 expression was 
determined by Northern and Western blot analysis. Thrombin significantly enhanced PAI-1 
mRNA levels after 4 and 8 h of stimulation (Fig. 33A). Elevated PAI-1 mRNA expression was 
followed by increased PAI-1 protein levels to about 3-fold higher than in the respective 
control (Fig. 33B).  
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Figure 33. Thrombin stimulates the expression of PAI-I 
A) PASMC were stimulated with thrombin (3 U/ml) for 4 and 8 h and PAI-1 mRNA was evaluated by 
Northern blot analysis. B) PAI-1 protein levels from culture supernatants were determined by Western 
blot analysis. (n=4, *p<0.05 versus non-stimulated cells (Ctr)). 
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3.4.2 Thrombin induces PAI-1 by activation of HIF-1 
 
PAI-1 expression has been shown to be dependent on the activation of the transcription 
factor HIF-1 under hypoxia134. To evaluate if thrombin is increasing HIF-1α protein levels, 
PASMC were stimulated with 3 U/ml thrombin for different time points and Western blot 
analyses using an antibody against HIF-1α were performed. Thrombin significantly enhanced 
HIF-1α protein, staying continuously elevated up to 24 h of stimulation (Fig. 34A). To 
determine the role of HIF-1 in thrombin-stimulated PAI-1 expression, rSMC were transfected 
with a promoter construct containing the human PAI-1 promoter or a similar construct where 
the HIF-1 binding site was mutated. Thrombin significantly increased PAI-1 promoter activity 
(Fig. 34B). However, thrombin-stimulated luciferase activity was completely abrogated after 
transfection of the mutated plasmid which is unable to bind HIF-1 (Fig.34B), confirming the 
central role of HIF-1 in PAI-1 expression by thrombin. 
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Figure 34. HIF-1 mediates thrombin-induced PAI-1 promoter activity 
A) PASMC were stimulated with thrombin for the indicated time points and HIF-1α protein levels were 
evaluated by Western blot analysis. A representative blot is shown (n=5). B) rSMC were transfected 
with the human PAI-1 promoter luciferase construct (WT) or a mutated PAI-1 construct (M) and 
stimulated with thrombin for 8 h. Luciferase activity was measured 24 h after transfection. In each 
experiment the luciferase activity determined in the presence of control or mutated vector under 
unstimulated conditions was set equal to 100%. Values ± SD represent the % induction of luciferase 
activity of three independent experiments (n=3; *p<0.05 versus Ctr (unstimulated WT); #p<0.05 versus 
Ctr (unstimulated M)). 
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3.4.3 PAI-1 and HIF-1α expression are redox- and calcium-sensitive 
 
Since thrombin induced ROS production dependent on Ca2+, it was determined whether ROS 
and Ca2+ could play a role in PAI-1 regulation. PAI-1-derived luciferase activity and protein 
levels induced by thrombin were prevented in PASMC treated with the calcium chelator 
BAPTA-AM or the antioxidant NAC (Fig. 35A). In addition, thrombin-stimulated HIF-1-
dependent luciferase activity and HIF-1α protein levels were significantly decreased after 
pretreatment with BAPTA-AM and NAC (Fig. 35B), further supporting an important role of 
Ca2+ and ROS in this pathway. 
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Figure 35. Thrombin-stimulated HIF-1α and PAI-1 expression are redox-sensitive 
A) PASMC were preincubated with BAPTA-AM (BAPTA, 7.5 µM) or the antioxidant NAC (10 mM) for 
30 min and then exposed to 3 U/ml thrombin for 4 h. HIF-1α protein levels were evaluated by 
performing Western blot analyses. In addition, rSMC were transfected with the EPO-HRE luciferase 
construct. Luciferase activity was measured after preincubation with the Ca2+ chelator BAPTA-AM (7.5 
µM) or the antioxidant NAC (10 mM) for 30 min and stimulation with thrombin for 8 h. B) PASMC were 
preincubated with BAPTA-AM (BAPTA, 7.5 µM) or the antioxidant NAC (10 mM) for 30 min and then 
exposed to 3 U/ml thrombin for 4 h. Western blot analyses were performed to determine PAI-1 protein 
levels. Additionally, rSMC were transfected with the human PAI-1 promoter luciferase construct. 
Luciferase activity was measured after preincubation with the Ca2+ chelator BAPTA-AM (7.5 µM) or 
the antioxidant NAC (10 mM) for 30 min and stimulation with thrombin for 8 h. In each experiment the 
luciferase activity determined in the presence of control vector was set equal to 100% (n=3; *p<0.05 
versus Ctr (unstimulated); #p<0.05 versus Ctr (thrombin-stimulated)). 
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3.4.4 Rac-1 modulates thrombin-induced PAI-1 promoter activity and PAI-1 expression 
 
To evaluate whether Rac-1 is involved in PAI-1 expression by thrombin, rSMC were 
transfected with the human PAI-1 promoter construct and cotransfected with expression 
vectors encoding constitutively active RacG12V or dominant-negative RacT17N or with 
control vector and stimulated with thrombin for 8 h. Thrombin significantly increased PAI-1 
promoter activity (Fig. 36). Moreover, cotransfection of the RacG12V mutant resulted in 
about 3.5-fold increased PAI-1 promoter activity compared to control cells, while in 
RacT17N-expressing cells PAI-1 promoter activity was abrogated.  
To evaluate whether Rac-1 mutants modulate PAI-1 mRNA and protein expression after 
stimulation with thrombin in human PASMC, Northern blot and Western blot analyses were 
performed. PAI-1 mRNA and protein levels were enhanced by 3-fold in control cells after 
thrombin stimulation, and were further elevated in RacG12V-expressing cells (Fig. 36). By 
contrast, in RacT17N-expressing PASMC, PAI-1 mRNA and protein levels were abrogated 
(Fig.36), further suggesting that Rac-1 is involved in regulating PAI-1 promoter activity and 
expression in response to thrombin in PASMC.  
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Figure 36. Rac-1 modulates thrombin-induced PAI-1 expression and promoter activity 
rSMC were transfected with control vector (Ctr) or expression vectors for either the constitutively 
active RacG12V (V12) or the dominant-negative RacT17N (N17) and the human PAI-1 promoter 
luciferase construct. Luciferase activity was measured 24 h after transfection. In each experiment 
luciferase activity determined in the presence of control vector was set equal to 100%. Values ± SD 
represent the % induction of luciferase activity of three independent experiments (n=3; *p<0.05 versus 
Ctr (unstimulated); #p<0.05 versus Ctr (thrombin-stimulated)). PASMC were transfected with control 
vector (Ctr) or expression vectors for either the constitutively active RacG12V (V12) or the dominant-
negative RacT17N (N17). Transfected PASMC were stimulated with thrombin (3 U/ml) for 4 h and 
mRNA levels were evaluated by performing Northern blot analyses. PAI-1 protein levels were 
determined in transfected PASMC stimulated for 4 h with thrombin (3 U/ml) by Western blot analysis 
using an antibody against human PAI-1. Representative blots are shown.  
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3.4.5 Rac-1 modulates HIF-1α protein levels and HIF-1 activity 
 
To evaluate the role of Rac-1 in thrombin-stimulated HIF-1 activity, the constitutively active 
RacG12V mutant or the dominant-negative RacT17N were cotransfected with the pGl3-EPO-
HRE luciferase construct containing 3 HIF-1-binding sites (Hypoxia Responsive Elements 
(HRE)) in front of the SV40 promoter. Luciferase activity was 2-fold increased in RacG12V-
expressing cells, but remained unchanged in RacT17N-expressing cells (Fig. 37). In 
thrombin-stimulated cells, RacG12V further enhanced HIF-1-dependent luciferase activity, 
whereas this response was abrogated in the presence of RacT17N. Similarly, HIF-1α protein 
levels were increased in cells expressing RacG12V and were further enhanced after 
thrombin stimulation. However, transfection of RacT17N abrogated HIF-1α expression in 
response to thrombin (Fig. 37). 
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Figure 37. Rac-1 modulates HIF-1 activity and HIF-1α protein levels 
rSMC were transfected with control vector (Ctr) or expression vectors for either the constitutively 
active RacG12V (V12) or the dominant-negative RacT17N (N17) and the human EPO-HRE promoter 
luciferase construct (pglEPO-HRE). Luciferase activity was measured 24 h after transfection and after 
stimulation with thrombin for 8 h. In each experiment the luciferase activity determined in the presence 
of control vector was set equal to 100%. Values ± SD represent the % induction of luciferase activity of 
three independent experiments (n=3; *p<0.05 versus Ctr (unstimulated); #p<0.05 versus Ctr 
(thrombin-stimulated)).  
PASMC were transfected with control vector (Ctr) or expression vectors for either the constitutively 
active RacG12V (V12) or the dominant-negative RacT17N (N17). Transfected PASMC were 
stimulated with thrombin (3 U/ml) for 4 h and HIF-1α protein levels were determined by Western blot 
analysis using an antibody against human HIF-1α. Representative blots are shown.  
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3.4.6 Rac-1 activates HIF-1 and increases PAI-1 promoter activity via the activation of 
PAK in response to thrombin 
 
Since p-21-activated kinase (PAK) is a known downstream effector of Rac-1, it was 
investigated whether PAK is involved in thrombin-induced PAI-1 expression. To this end, 
PASMC were exposed to thrombin for different time points and phosphorylation of PAK was 
determined by Western blot analysis. Thrombin stimulation resulted in rapid PAK 
phosphorylation peaking at 1 min (Fig. 38). Then, to investigate the effect of Rac-1 on PAK 
activation by thrombin, PASMC were transfected with RacG12V or RacT17N and exposed to 
3 U/ml thrombin for 1 min. In the presence of RacG12V, basal and thrombin-induced 
phosphorylation of PAK was increased, but was abolished in the presence of RacT17N (Fig. 
38). 
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Figure 38. PAK activation by thrombin depends on Rac-1 
A) PASMC were stimulated with thrombin (3 U/ml) for the time indicated and levels of pPAK were 
evaluated by performing Western blot analysis. B) PASMC were transfected with control vector (Ctr) 
or expression vectors for either the constitutively active RacG12V (V12) or the dominant-negative 
RacT17N (N17) and stimulated with 3 U/ml thrombin for 1 min. p-PAK protein levels were evaluated 
by performing Western blot analysis. Representative blots are shown (n=3).  
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To further evaluate the role of PAK in the regulation of HIF-1, an active PAK mutant (PAK-
T423) or a dominant-negative mutant of PAK (PAK-R295), which increased or decreased 
PAK phosphorylation, respectively, were expressed with the luciferase construct pGl3-EPO-
HRE. PAK-T423 increased HIF-1-dependent luciferase activity (Fig. 39A). Moreover, PAK-
T423 also enhanced PAI-1 promoter activity whereas PAK-R295 diminished thrombin-
induced PAI-1 promoter activity (Fig. 39B). 
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Figure 39. PAK induces HIF-1 activity and PAI-1 promoter activity in a redox-sensitive manner 
in response to thrombin 
rSMC were transfected with expression vectors for either the active PAK-T423 (T432) or the 
dominant-negative PAK-R295 (R295) and A) the human EPO-HRE or B) PAI-1 promoter luciferase 
construct. Luciferase activity was measured 24 h after transfection and after preincubation with NAC 
(10 mM) for 30 min and stimulation with thrombin for 8 h. In each experiment the luciferase activity 
determined in the presence of control vector was set equal to 100%. Values ± SD represent the % 
induction of luciferase activity of three independent experiments (n=3; *p<0.05 versus Ctr 
(unstimulated); #p<0.05 versus Ctr (thrombin-stimulated)). 
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Application of the antioxidant NAC significantly decreased PAK-T423-induced HIF-1 activity 
and PAI-1 promoter activity (Fig. 39), indicating that PAK-mediated responses are redox-
sensitive and that PAK could be upstream of ROS production. To test this hypothesis, the 
effect of PAK mutants on ROS production was evaluated. Active PAK significantly increased 
ROS production under control conditions as well as after thrombin stimulation (Fig. 40), 
whereas the dominant-negative mutant prevented thrombin-stimulated ROS generation.  
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Figure 40. PAK modulates thrombin-stimulated ROS production 
PASMC were transfected with expression vectors for either active PAK-T423 (T432) or the dominant-
negative PAK-R295 (R295) and stimulated with thrombin for 4 h. ROS production was assessed by 
performing DCF measurements. Data are presented as relative increase compared to control (100%) 
(n=3, *p<0.05 versus non-stimulated cells (Ctr), #p<0.05 versus Ctr (thrombin-stimulated), $p<0.05 
versus thrombin-stimulated PAK-T423-transfected cells)). 
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3.4.7 PAI-1 regulates cell proliferation in response to thrombin 
 
Finally, to determine the role of secreted PAI-1 in regulating proliferation of PASMC, cells 
were stimulated with thrombin for 8 h. The conditioned cell culture medium was then 
transferred to another set of serum-starved PASMC. In order to deplete PAI-1, a PAI-1 
inhibitory antibody or control mouse IgG were added and PASMC were incubated for 16 h. 
The conditioned medium from thrombin-stimulated PASMC increased the proliferation of 
PASMC, whereas in the presence of the inhibitory antibody against PAI-1 this response was 
decreased (Fig. 41), confirming the important role for PAI-1 in proliferation of PASMC.  
 
In summary, Rac-1 modulates ROS-dependent PAI-1 expression in PASMC in response to 
thrombin by the activation of its substrate PAK and HIF-1 in a Ca2+-dependent manner. 
Moreover, PAI-1 secretion promoted PASMC proliferation in response to thrombin.  
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Figure 41. PAI-1 modulates cell proliferation by thrombin 
PASMC were stimulated with thrombin (3 U/ml) for 8 h. The conditioned medium was transferred to 
another set of serum-starved PASMC. An antibody directed against PAI (PAI-Iab) or mouse IgG as a 
control were added to the supernatant. Cells were further incubated for 16 h in the presence of BrdU 
(10 µM). Proliferative activity was assessed by evaluating BrdU incorporation. Stimulated proliferative 
activity in control cells was set equal to 100% (n=3; *p<0.05 versus Ctr (unstimulated IgG treated); 
#p<0.05 versus Ctr (thrombin-stimulated IgG treated)) 
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3.5 p22phox and NOX4 regulate redox-sensitive PAI-1 expression and 
proliferation of pulmonary artery smooth muscle cells in response to the 
vasoactive peptide urotensin-II 
 
Urotensin-II (hU-II) has been suggested to play a role in the pathogenesis of several 
cardiovascular diseases, including pulmonary hypertension135. However, the signaling 
mechanisms linking hU-II to vascular remodeling are unclear. Since enhanced levels of ROS 
and PAI-1 expression may play a role in promoting vascular remodeling, the role of hU-II in 
the formation of ROS by NADPH oxidases, in the regulation of PAI-1 expression and in the 
control of proliferation of PASMC was investigated.  
 
3.5.1 Urotensin-II elevates ROS  
 
To investigate whether the vasoactive peptide hU-II can increase ROS levels, PASMC were 
exposed to 100 nM hU-II for 2 h and stained with dihydroethidium (DHE). A strong increase 
in fluorescence in stimulated PASMC compared to controls indicated increased ROS levels 
(Fig. 42A). Alternatively, PASMC were treated with hU-II (100 or 200 nM) for 2 h and ROS 
levels were measured by DCF fluorescence in a flow cytometer. Significantly increased 
levels of ROS compared to control cells were observed after challenging with both 
concentrations (Fig. 42B). Pretreatment with the flavin inhibitor diphenyleneiodonium (DPI, 
10 nM) for 30 min significantly decreased hU-II-induced ROS levels, as was measured by 
DCF fluorescence in a microplate reader (Fig. 42C).  
 
                                                                                                                                          Results 
____________________________________________________________________________ 
99
Ctr Ctr DPI
0
50
100
150
200
hU-II
Control Urotensin II 
A
B
C
R
el
. D
C
F 
flu
or
es
ce
nc
e
[%
 c
on
tr
ol
]
Ev
en
ts
*
* #
----- Control
----- hU-II 100 nmol/L
----- hU-II 200 nmol/L
100 101 102 103 104 
FL1-H
100
80
60
40
20
3
20
50
R
el
. D
C
F 
flu
or
es
ce
nc
e
[%
 c
on
tr
ol
]
Ev
en
ts
 
 
Figure 42. hU-II increases levels of ROS 
A) ROS levels were visualized in PASMC treated with 100 nM hU-II for 2 h by dihydroethidium staining 
(n=3). B) PASMC were stimulated with 100 and 200 nM hU-II for 2 h. ROS levels were assessed by 
DCF fluorescence using flow cytometry (n=3). C) PASMC cells were exposed to 10 µM 
diphenyleneiodonium (DPI) for 30 min prior to hU-II stimulation for 2 h. ROS levels were evaluated by 
DCF fluorescence in a microplate reader. Data are presented as relative increase compared to control 
(100%) (n=3, *p<0.05 versus unstimulated cells (Ctr), #p<0.05 versus hU-II-stimulated cells (Ctr)). 
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3.5.2 p22phox and NOX4 contribute to urotensin-II-induced ROS levels 
 
Since DPI is known to (unspecifically) inhibit NADPH oxidases, we evaluated the role of 
p22phox and NOX4 in ROS generation in response to hU-II. PASMC were transfected with 
sense or antisense vectors for p22phox or NOX4 and exposed to hU-II for 2 h. Depletion of 
p22phox or NOX4 abolished the hU-II-stimulated increase in ROS, whereas ROS levels were 
slightly enhanced in p22phox- and NOX4-overexpressing PASMC (Fig. 43A). Transfection of 
p22phox or NOX4 antisense constructs prevented the increase of both subunits in response 
to hU-II (Fig. 43A, B). 
To further investigate the mechanisms underlying p22phox- and NOX4-dependent ROS 
production by hU-II, PASMC were stimulated with 100 nM hU-II for increasing time periods 
(from 1 to 16 h) and the protein levels of the NADPH oxidase subunits p22phox and NOX4 
were determined by Western blot analysis (Fig. 44). Application of hU-II resulted in strong 
upregulation of p22phox and NOX4 protein levels peaking at 2 h after stimulation.  
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Figure 43. hU-II increases ROS production dependent on p22phox and NOX4 
A) PASMC were transfected with control vector (Ctr), p22phox or NOX4 sense (S) or antisense (AS) 
vectors. Transfection efficiency was controlled by Western blot using antibodies against p22phox and 
NOX4. After treatment with hU-II (100 nM) for 2 h, ROS levels were assessed by DCF fluorescence. 
(n=3, *p<0.05 versus unstimulated controls (Ctr), #p<0.05 versus hU-II stimulated cells (Ctr)). B) 
PASMC were transfected with control vector (Ctr), p22phox antisense (p22AS) or NOX4 antisense 
(N4AS) constructs and exposed to hU-II (100 nM) for 2 h. Western blot analysis was performed using 
antibodies against p22phox and NOX4 (n=4, *p<0.05 versus unstimulated cells (Ctr)). All data are 
presented as relative increase compared to control (100%). 
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Figure 44. hU-II increases p22phox and NOX4 protein levels 
PASMC were stimulated with 100 nM hU-II for increasing time points and Western blot analysis was 
performed. Lysates of polymorphonuclear leukocytes (PMN) were used as control (n=4, *p<0.05 
versus unstimulated cells (Ctr)). Western blot analysis was performed using antibodies against 
p22phox and NOX4 (n=4, *p<0.05 versus unstimulated cells (Ctr)). All data are presented as relative 
increase compared to control (100%). 
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3.5.3 Urotensin-II increases protein kinase activity  
 
To investigate the signaling pathways activated by hU-II, PASMC were treated with hU-II 
(100 nM) for increasing time periods. Phosphorylation of ERK, p38 MAP kinase (p38MAPK), 
c-Jun N-terminal kinase (JNK) and protein kinase B (Akt) was determined by Western blot 
analysis. hU-II increased the phosphorylation of all kinases peaking at 5 min (Fig. 45). 
Phosphorylation of all kinases was observed with 10 nM and stayed elevated up to 100 or 
500 nM of hU-II, while higher concentrations of this peptide decreased kinase 
phosphorylation (Fig. 46).  
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Figure 45. hU-II activates protein kinases  
PASMC were exposed to 100 nM hU-II from 1 to 30 min and Western blot analysis using antibodies 
against the phosphorylated forms of ERK (p-ERK), p38 MAP kinase (p-p38), c-Jun N-terminal kinase 
(p-JNK) and Akt (p-Akt) were performed. Equal loading was confirmed by reprobing the membranes 
with an anti-α-actin antibody. In each experiment the protein levels of protein kinases under non-
stimulated conditions were set equal to 100% (n=4, *p<0.05 versus non-stimulated cells (Ctr)). 
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Figure 46. Different concentrations of hU-II activate protein kinases 
PASMC were exposed to different concentrations of hU-II (1-1000 nM) for 5 min. Western blot 
analysis using antibodies against the phosphorylated forms of ERK (p-ERK), p38 MAP kinase (p-p38), 
c-Jun N-terminal kinase (p-JNK) and Akt (p-Akt) were performed. Equal loading was confirmed by 
reprobing the membranes with an anti-α-actin antibody. In each experiment the protein levels of 
protein kinases under non-stimulated conditions were set equal to 100% (n=4, *p<0.05 versus non-
stimulated cells (Ctr)). 
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3.5.4 p22phox and NOX4 are involved in urotensin-II-stimulated protein kinase activity 
 
To test the role of NADPH oxidases in the activation of kinases by hU-II, PASMC were 
treated with DPI (10 µM) or transfected with p22phox or NOX4 antisense vectors prior to 
stimulation with hU-II. DPI as well as depletion of p22phox or NOX4 abrogated hU-II-induced 
phosphorylation of ERK, p38MAPK, JNK and Akt (Fig. 47A, B), indicating that hU-II can 
stimulate MAP kinases and Akt in PASMC via a redox-sensitive pathway involving NADPH 
oxidases. 
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Figure 47. The NADPH oxidase mediates protein kinase activation by hU-II  
PASMC were A) pretreated with diphenyleneiodonium (DPI, 10 µM) for 30 min or B) transfected with 
sense (S) or antisense (AS) vectors against p22phox or NOX4 and stimulated with hU-II (100 nM) for 
5 min. Western blot analysis using antibodies against the phosphorylated forms of ERK (p-ERK), p38 
MAP kinase (p-p38), c-Jun N-terminal kinase (p-JNK) and Akt (p-Akt) were performed. In each 
experiment the protein levels under non-stimulated conditions were set equal to 1 (n=4, *p<0.05 
versus non-stimulated cells (Ctr); #p<0.05 versus hU-II stimulated cells). 
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3.5.5 Urotensin-II induces PAI-1 expression 
 
Since hU-II has been suggested to contribute to vascular remodeling and has been 
associated with cardiovascular diseases such as PH, the role of hU-II in the regulation of 
PAI-1 was investigated. 
Exposure to 100 nM hU-II increased PAI-1 mRNA levels peaking at 4 h and PAI-1 protein 
levels, determined in culture supernatants, after 4 and 8 h (Fig. 48), suggesting that hU-II is 
able to stimulate gene expression in PASMC. 
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Figure 48. hU-II stimulates the expression of PAI-I 
PASMC were stimulated with hU-II (100 nM) and PAI-1 mRNA levels were evaluated by Northern blot 
analysis and PAI-1 protein levels from the culture supernatants were determined by Western blot 
analysis. Equal loading of proteins was confirmed by Ponceau S staining. In each experiment the 
mRNA or protein levels under non-stimulated conditions were set equal to 100% (n=4, *p<0.05 versus 
non-stimulated cells (Ctr); #p<0.05 versus hU-II stimulated cells). 
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3.5.6 Urotensin-II induces PAI-1 expression by MAP kinases and the Pl3 kinase/Akt 
pathway involving NADPH oxidases 
 
The involvement of MAPK and Pl3K/Akt pathway, as well as the role of p22phox and NOX4 
in PAI-1 expression was then evaluated. Application of inhibitors of p38MAPK (SB220025, 
20 µM), MEK1 (PD98059, 20 µM or U0126, 20 µM), Pl3 kinase (PI3K) (LY294002, 10 µM), 
Akt (SH-5, 10 µM)136 or JNK (SP600125, 25 µM) or pretreatment with DPI decreased hU-II-
induced PAI-1 protein levels (Fig. 49A). Since in test experiments all inhibitors prevented the 
phosphorylation of their respective target kinases, these data suggest that hU-II regulates 
PAI-1 expression by stimulating NADPH oxidase-dependent ROS generation and 
subsequent activation of MAP kinases and the PI3 kinase/Akt pathway. In support of these 
findings, transfection of p22phox or NOX4 antisense vectors prevented the increase in PAI-1 
protein by hU-II (Fig. 49B). 
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Figure 49. hU-II stimulates the expression of PAI-I involving NADPH oxidases, MAP kinases 
and Pl3 kinase/Akt 
A) PASMC were pretreated with the p38 MAP kinase inhibitor SB220025 (SB, 20 µM), the MEK1 
inhibitors PD98059 (PD, 20 µM) or U0126 (U, 20 µM), the c-Jun N-terminal kinase inhibitor SP600125 
(SP, 25 µM), the Pl3 kinase inhibitor LY294002 (LY, 10 µM) or the Akt inhibitor SH-5 (SH, 10 µM), or 
exposed to diphenyleneiodonium (DPI, 10 µM) for 30 min prior to stimulation with hU-II for 4 h, or B) 
transfected with control vector (Ctr), p22phox or NOX4 sense (S) and antisense (AS) vectors. PAI-1 
protein levels from the culture supernatants were determined by Western blot analysis. Equal loading 
of proteins was confirmed by Ponceau S staining. In each experiment the mRNA or protein levels 
under non-stimulated conditions were set equal to 100% (n=4, *p<0.05 versus non-stimulated cells 
(Ctr); #p<0.05 versus hU-II stimulated cells). 
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3.5.7 Urotensin-II stimulates proliferation via protein kinases and NADPH oxidases 
 
To evaluate whether hU-II can regulate proliferation of PASMC, cells were stimulated with 
100 and 1000 nM hU-II and the proliferative activity of PASMC was determined using BrdU 
incorporation. Stimulation with hU-II for 48 h significantly increased proliferative activity of 
PASMC (Figure 50A). In addition, specific inhibition of MAP kinases and the PI3K/Akt 
pathway completely blocked proliferation of PASMC in response to hU-II (Fig. 50B). 
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Figure 50. hU-II stimulates cell proliferation involving MAP kinases and PI3 kinase/Akt 
A) PASMC were exposed to hU-II (100 or 1000 nM) for 48 h. Proliferative activity was assessed by 
labeling with BrdU (n=3, *p<0.05 versus unstimulated cells (0 nM)). B) PASMC were pretreated with 
the inhibitors of p38MAP kinase (SB220025 (SB), 20 µM), MEK1 (PD98059 (PD), 20 µM or U0126 
(U), 20 µM), c-Jun N-terminal kinase (SP600125 (SP), 25 µM), Pl3 kinase (LY294002 (LY), 10 µM) or 
Akt (SH-5 (SH), 10 µM) 30 min prior to stimulation with hU-II for 48 h. Proliferative activity was 
assessed by labeling with BrdU (n=3, *p<0.05 versus unstimulated cells (Ctr), #p<0.05 versus hU-II 
stimulated control cells (Ctr)). 
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To determine whether proliferation of PASMC by hU-II is mediated by NADPH oxidases, 
p22phox and NOX4 were depleted by using antisense vectors. Depletion of p22phox or 
NOX4 specifically abrogated hU-II-stimulated proliferation of PASMC (Fig. 51A), whereas the 
proliferation in response to sphingosine-1-phosphate (S1P, 1 µM), known to promote 
proliferation of smooth muscle cells137, was not significantly reduced by depletion of p22phox 
or NOX4 (Fig. 51B). 
 
In summary, these findings identify hU-II as a novel agonist of NADPH oxidases in PASMC 
and demonstrate that enhanced levels of ROS and the subsequent redox-sensitive activation 
of MAP kinases and Akt increases PAI-1 expression and PAI-1-dependent proliferation.  
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Figure 51. hU-II stimulates cell proliferation involving NADPH oxidases 
A) PASMC were transfected with control vector (Ctr), p22phox or NOX4 sense and antisense vectors. 
After stimulation with hU-II for 48 h, proliferative activity was assessed by BrdU incorporation (n=3, 
*p<0.05 versus unstimulated control cells (Ctr), #p<0.05 versus hU-II stimulated control cells (Ctr)). B) 
PASMC were transfected with control vector (Ctr), p22phox or NOX4 antisense (AS) vectors and 
stimulated with hU-II or sphingosine-1-phosphate (S1P, 1 µM) for 48 h. Proliferative activity was 
assessed by BrdU incorporation. Stimulated proliferative activity in control cells was set equal to 100% 
(n=3, #p<0.05 versus stimulated control cells (Ctr)).  
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4. Discussion 
 
4.1. Thrombin induces NADPH oxidase-dependent ROS production in 
endothelial and pulmonary artery smooth muscle cells 
 
4.1.1 p22phox mediates thrombin-stimulated sustained elevation of ROS and 
proliferation of endothelial cells 
 
Endothelial dysfunction is one of the early events in vascular remodeling. It is characterized 
by an imbalance between nitric oxide (NO) and superoxide anion radical production leading 
to a decrease in NO bioavailability and is frequently associated with enhanced thrombin 
formation and a procoagulant state75. Whereas in smooth muscle cells thrombin has been 
shown to potently increase ROS production via activation and/or induction of NADPH 
oxidases122, the role of thrombin in regulating endothelial ROS production is less clear.  
In the first part of the study, it was demonstrated that thrombin is able to induce a biphasic 
increase in ROS production in the endothelial cell line Ea.hy 926. A rapid but transient 
elevation in ROS generation peaking at 15 min was followed by a delayed response peaking 
at 3 to 4 h of stimulation. This delayed response was caused by a redox-sensitive, 
p38MAPK- and PI3 kinase-dependent increase in the expression of the NADPH oxidase 
subunit p22phox since a) exposure to thrombin resulted in a time-dependent increase in 
ROS production which was closely matched by an increase in p22phox mRNA and protein 
levels, b) antioxidants or the flavin inhibitor DPI decreased ROS production as well as 
p22phox mRNA and protein levels induced by thrombin, c) exposure to low concentrations of 
H2O2 resulted in an increase in ROS production and concomitantly elevated p22phox 
expression, d) increased levels of p22phox achieved by overexpression of p22phox elevated 
intracellular ROS production, and e) redox-sensitive activation of p38MAPK and the PI3 
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kinase/Akt pathway was involved in ROS production and upregulation of p22phox in 
response to thrombin and H2O2.  
NADPH oxidases have now been established as important sources of ROS production in the 
vascular wall. In endothelial cells, a functionally active NADPH oxidase closely resembling 
the leukocyte NADPH oxidase has been described81, 138. Indeed, the results of the present 
study show that overexpression of p22phox increased ROS production in endothelial cells 
indicating that enhanced levels of this NADPH oxidase subunit allow increased ROS 
generation. Expression of a p22phox fusion protein was found perinuclear and was closely 
linked to sites of intracellular ROS production, as shown by 2 photon confcal microscopy. 
This is in contrast to the situation in neutrophils where it is generally accepted that p22phox 
is mainly located at the plasma membrane52. However, in support of our findings, it was 
shown that p22phox is present in nuclear-enriched fractions and localized in a perinuclear 
zone in endothelial cells139. Moreover, part of the enzyme was found to be present as a 
preassembled intracellular complex in endothelial cells139 suggesting that a) low levels of 
ROS production may occur under unstimulated conditions and b) stimulation with agonists 
may allow a rapid activation of the NADPH oxidase. Indeed, exposure to thrombin resulted in 
a fast increase in endothelial ROS production, starting at 5 min and peaking after 15 min of 
stimulation, thereafter declining again. Similarly, thrombin has been shown to rapidly elicit 
ROS formation in rat aortic smooth muscle cells within 10 min of exposure122, 140, whereas in 
endothelial cells, angiotensin II stimulation evoked a rapid activation of ROS production by 
the NADPH oxidase141. Interestingly, in smooth muscle cells, NADPH oxidase-dependent 
production of ROS in response to angiotensin II was shown to be biphasic142. The first phase 
peaked at 30 sec and was dependent on PKC, whereas the second phase started at 1 min 
and was sustained for 30 min and more. 
Whereas a rapid increase in ROS production may be sufficient to initiate a primary cellular 
response to injury, many cardiovascular disorders including pulmonary hypertension are 
characterized by a chronic dysfunction of the endothelium and sustained elevation of ROS 
levels62. Indeed, prolonged exposure to thrombin resulted in a delayed, time-dependent 
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increase in ROS production. This response was closely accompanied by an elevation of 
p22phox mRNA and protein levels. Moreover, depletion of p22phox by transfection of an 
antisense vector diminished thrombin-induced ROS production, confirming that p22phox is 
required for thrombin-stimulated ROS production. The importance of p22phox is further 
confirmed by in vivo studies showing increased p22phox protein levels in the endothelium 
and in the smooth muscle cell layer of atherosclerotic vessels compared to non-
atherosclerotic vessels143. These findings also support the view that a hypercoagulant state 
as it is frequently observed in cardiovascular diseases may contribute to ROS generation, 
and that upregulation of p22phox may participate in this response. 
In addition to p22phox, thrombin has also been shown to increase the levels of p47phox 
protein in VSMC, and this has been associated with increased ROS production73. In 
preliminary studies we also observed increased p47phox protein levels in endothelial cells in 
response to thrombin, suggesting that elevated levels of more than one subunit may 
contribute to the delayed response to thrombin in endothelial cells and that the regulation of 
the different subunits may be controlled in a complex manner. 
To date only limited information is available with regard to the signaling mechanisms involved 
in the regulation of NADPH oxidase subunits. Inhibition of ROS formation by the antioxidant 
vitamin C or the flavin inhibitor DPI prevented thrombin-induced p22phox mRNA and protein 
expression suggesting a redox-sensitive mechanism involved in the regulation of p22phox in 
endothelial cells. Consistently, exposure to low doses of H2O2 up to 50 µM increased ROS 
production and p22phox mRNA and protein levels. 
Our findings that pretreatment with actinomycin D blocks p22phox expression by thrombin or 
H2O2 indicated that p22phox is regulated at the transcriptional level. This is further supported 
by recent studies reporting the presence of functional polymorphisms in the p22phox 
promoter that resulted in higher transcriptional activity of the p22phox gene in hypertensive 
rats144. Moreover, NADPH-derived ROS generation has been shown to be blocked by 
actinomycin D and cycloheximide145, 146. Consistent with these observations, pretreatment 
with cycloheximide prevented upregulation of p22phox by thrombin and H2O2, whereas 
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application of cycloheximide after treatment with thrombin or H2O2 did not increase p22phox 
protein levels suggesting the involvement of de novo protein synthesis rather than altered 
stability in this response.  
To further evaluate the signaling pathways mediating redox-sensitive regulation of p22phox, 
we investigated the role of MAP kinases and the Pl3 kinase/Akt pathway in this response. 
Exposure to thrombin transiently enhanced phosphorylation of p38MAPK, ERK and Akt, 
while treatment with H2O2 resulted in increased phosphorylation of the same kinases over the 
whole observation period, indicating sustained activation of the Pl3 kinase/Akt pathway and 
MAP kinases. Similar observations have been made in smooth muscle cells140 and may 
relate to differences between receptor-mediated activation of kinases as for thrombin 
compared to "redox-sensitive" activation of kinases occurring in the presence of elevated 
ROS levels as for H2O2. These findings are also in agreement with our suggestion that 
thrombin causes a rapid induction of NADPH oxidase activity whereas H2O2 causes a 
sustained increase in NADPH oxidase-mediated ROS production. Furthermore, inhibition of 
p38MAPK or Pl3 kinase, an upstream kinase of Akt, prevented thrombin- and H2O2-
stimulated ROS production and p22phox upregulation whereas inhibition of ERK was not 
effective. Consistently, in smooth muscle cells thrombin-induced stimulation of ROS 
production via the NADPH oxidase was able to specifically activate p38MAPK and Akt, but 
not ERK71, 122, 140.  
These findings support the view that ROS are involved in the regulation of p22phox 
expression and suggest that activation of the NADPH oxidase by thrombin stimulates specific 
redox-dependent pathways leading to the upregulation of p22phox and thus to a sustained 
generation of ROS in endothelial cells. Very recently, it has been shown that antioxidants 
reduced ROS production and p22phox protein levels in response to intermittent high glucose 
treatment in endothelial cells147 further supporting a prominent role of ROS in regulating 
NADPH oxidase expression and activity in endothelial cells. 
The sustained ROS generation in many cardiovascular disorders, including pulmonary 
hypertension, has been described to result on one hand in a stimulatory effect on the 
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proliferation of vascular cells56, 148, on the other hand it has been associated with toxic effects 
and increased cell death149. Indeed, exposure to low concentrations of H2O2 (between 0.1 
and 50 µM) increased endothelial cell proliferation whereas doses of 100 µM or higher 
reduced or even prevented the proliferative response. Similar observations have been made 
in bovine aortic endothelial cells150. Consistently, p22phox protein levels were upregulated in 
response to H2O2 concentrations up to 50 µM whereas higher concentrations decreased 
p22phox protein levels indicating that the amount of H2O2 leading to the activation of 
signaling cascades, gene expression and proliferation is tightly regulated in endothelial cells. 
Very similar to the situation with H2O2, stimulation with 3 U/ml of thrombin, but not 5 U/ml, 
increased proliferation of endothelial cells. Moreover, depletion of p22phox diminished 
proliferation in response to H2O2 and thrombin, pointing towards an important role of the 
NADPH oxidases in regulating proliferative responses in endothelial cells. In contrast, in 
smooth muscle cells, much higher doses of H2O2 (200 µM) were required to stimulate 
NADPH oxidase-dependent ROS production suggesting that endothelial and smooth muscle 
cell NADPH oxidases may differ in their redox sensitivity and their activity151. However, in 
support of our results, depletion of p22phox resulted in decreased proliferation of vascular 
smooth muscle cells152, suggesting that NADPH oxidases play a crucial role in regulating 
proliferative responses in endothelial and smooth muscle cells. 
 
4.1.2 Rac-1 and PAK mediate thrombin-stimulated elevation of ROS in pulmonary 
artery smooth muscle cells 
 
In the second part of the study, it was demonstrated that thrombin is able to rapidly increase 
Rac-1 activity within 15 s in PASMC. Since Rac-1 is known to be required for activation of 
the NADPH oxidase, these results suggest that thrombin is, similar to the situation in 
endothelial cells, rapidly stimulating ROS production in PASMC. In support of these findings, 
NADPH oxidase-dependent production of ROS in response to angiotensin II was shown to 
be biphasic in smooth muscle cells142. The first phase peaked at 30 sec and was dependent 
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on PKC, whereas the second phase was dependent on Rac-1 activation and translocation 
and started at 1 min. The differences in the kinetics may be related to stimulus- and cell type 
specific variations as well as to different NADPH oxidase homologues.  
Moreover, thrombin also elevated Rac-1 protein levels within 2 h. Consistently, Rac-1 
mutants modulated ROS levels in response to thrombin in PASMC. Together with the results 
that thrombin induced a biphasic increase in ROS production in endothelial cells, where the 
delayed phase was paralleled by upregulation of p22phox, these findings suggest that 
thrombin elicits a biphasic production of ROS also in PASMC. 
To date only limited information is available with regard to the signaling events involved in 
the regulation of ROS production in response to thrombin. The data of the present study 
show that Rac-1 is activated by thrombin involving a Ca2+ dependent mechanism in PASMC, 
since treatment with the Ca2+ chelator BAPTA-AM decreased thrombin-stimulated Rac-1 
activity. Similarly, in prostate carcinoma cells, Rac-1 activation was shown to be dependent 
on Ca2+ levels in response to thrombin receptor activating peptide (TRAP)153. In endothelial 
cells, sphingosine-1 phosphate (S1P)-induced Rac-1 activation was mediated by Ca2+154. 
Since the increase in intracellular calcium levels is a common mechanism in coupling the 
signals from activated G protein-coupled receptors to signaling pathways, Ca2+ could be the 
messenger linking PAR signaling after thrombin stimulation to activation of NADPH oxidases. 
Indeed, BAPTA-AM prevented thrombin-induced ROS production. In addition to NOX5 and 
DUOX that contain Ca2+ binding moieties and appear to be directly activated by Ca2+ 90, 155, 
156, it has been suggested that other NOX homologues could also be regulated by Ca2+ 156, 
157. It was demonstrated that NOX2 can be activated in vitro by Ca2+-binding proteins158. 
Moreover, ROS are important regulators of intracellular Ca2+ homeostasis12, 159, suggesting 
that there is a tight regulation between levels of Ca2+ and redox status of the cells.  
Furthermore, this study showed that thrombin stimulation of PASMC resulted in PAK 
phosphorylation peaking after 1 min, and this response was modulated by Rac-1 mutants. 
These results show that PAK activation in response to thrombin is downstream of Rac-1 that 
was activated after only 15 sec. Consistently, PAK has been identified as a target of Rac-1, 
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where Rac-1 is directly binding to the PBD domain of PAK110. In support of these findings, 
PAK has been shown to be rapidly activated by thrombin and to play a central role in 
thrombin-mediated TF expression in PASMC160.  
In addition, expression of an active mutant of PAK significantly increased ROS production. In 
support to this data, PAK was shown to directly interact with p47phox and to phosphorylate 
this NADPH oxidase subunit, and to subsequently increase ROS production in endothelial 
cells161. However, in VSMC PAK phosphorylation in response to Ang-II was not only 
dependent on Ca2+ and blocked by a dominant-negative Rac mutant, but was also inhibited 
by antioxidants162, suggesting that reactive oxygen species are also involved in the upstream 
signaling of PAK. Similarly, it was reported that phosphorylation of PAK in response to PDGF 
was attenuated by inhibition of ROS163, further suggesting that PAK is not only able to 
increase ROS production, but is also sensitive to ROS. These data support the view that a 
positive feed back loop exists, where Rac-1-dependent ROS production leads to activation of 
PAK, which is able to further stimulate NADPH oxidase and additionally increase ROS levels. 
 
In summary, the data presented support a model whereby activation of the NADPH oxidase 
by thrombin in endothelial or PASMC leads to a biphasic increase in ROS production. The 
first, rapid phase is probably due to the activation of a preassembled NADPH oxidase 
complex or due to the activation of regulatory oxidase components, such as Rac-1. The 
second, prolonged phase of ROS production is allowed by the increased protein expression 
of p22phox or Rac-1, subsequently promoting sustained generation of ROS. Whereas a 
rapid increase in ROS production in response to thrombin may be beneficial for the initial 
wound healing at sites of vascular injury, the initiation of a vicious circle promoting ROS 
generation over a long time period by upregulating p22phox or Rac-1 may be important in 
promoting vascular remodeling in the pathogenesis of many cardiovascular diseases, 
including pulmonary hypertension. 
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4.2 NADPH oxidases mediate cell proliferation and tissue factor and 
plasminogen activator inhibitor-1 expression by thrombin in pulmonary artery 
smooth muscle cells: Role of Rac-1 
 
4.2.1 Rac-1 mediates tissue factor expression involving the NFκB pathway  
 
Enhanced thrombin levels and procoagulant activity have been associated with vascular 
remodeling. In this study it was demonstrated that activation of Rac-1 by thrombin leads to 
the activation of the transcription factor NFκB and induction of tissue factor in PASMC. This 
was based on the findings that a) thrombin increased Rac-1 activity and expression, b) 
constitutively active and dominant-negative Rac-1 mutants increased or decreased, 
respectively, thrombin-induced TF expression and TF-dependent procoagulant activity, c) 
thrombin and Rac-1 were able to activate NFκB-dependent transcriptional activity, d) 
overexpression of NFκB enhanced TF promoter activity, and e) inhibition of the NFκB 
pathway prevented Rac-1-dependent TF promoter activity.  
Using constitutively active and dominant-negative Rac-1 mutants, TF expression and 
procoagulant activity in PASMC by thrombin could be enhanced or decreased, respectively, 
indicating that Rac-1 and NADPH oxidases are involved in thrombin-induced TF expression 
in PASMC. These findings also confirm previous observations in VSMC demonstrating the 
involvement of p22phox and Rac-1 in the regulation of TF by thrombin71. Moreover, in 
endothelial cells, TF expression by thrombin was decreased by treatment with statins which 
prevent activation of the RhoGTPases Rho, Rac and cdc42164 further supporting an 
important role of Rac-1 in the control of TF expression and activity by thrombin.  
Rac-1 and thrombin stimulated TF promoter activity only in the presence of a distal enhancer 
containing AP1 and NFκB sites. In contrast, in smooth muscle cells stimulated with activated 
platelets or in endothelial cells activated by VEGF, luciferase activity of the pTF111 construct 
was not significantly different to the activity of promoter constructs containing also the distal 
enhancer129, 165. However, in endothelial cells, pTF111-mediated luciferase activity in 
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response to lipopolysaccharides (LPS), TNF-α and IL-1ß was significantly reduced compared 
to the luciferase activity of constructs containing also the distal enhancer166-168. The LPS- and 
cytokine-stimulated response in endothelial cells and in monocytes has been shown to 
require constitutive AP1 DNA binding and inducible activation of the NFκB pathway166, 168. 
The involvement of NFκB in Rac-1 and thrombin-induced TF regulation was further 
demonstrated by experiments where overexpression of the NFκB subunits p50 and p65 or 
dominant-negative mutants of IκB or IκBK increased or decreased TF promoter activity, 
respectively. These findings are consistent with previous observations that RacG12V 
induced NFκB activity in HepG2 cells and that Rac-1 is involved in phosphorylation of IκB 
and nuclear translocation of NFκB126, 169. However, a role for AP1 in Rac-1-induced TF 
expression can not be completely ruled out. Possibly, the interaction of AP1 and NFκB is 
also required for maximal induction of TF in PASMC similar to the situation in endothelial 
cells35. Moreover, the modest induction of pTF111-derived luciferase activity by thrombin and 
RacG12V suggests that additional transcription factors, such as Sp1 and/or Egr1 may also 
contribute to the regulation of TF expression by thrombin and Rac-1 in PASMC. 
 
In summary, in PASMC thrombin increased TF expression and activity via Rac-1 involving 
activation of the NFκB pathway. Since enhanced NFκB activity has been observed in various 
cardiovascular diseases170, and statins which inhibit Rac and Rho kinases decrease 
procoagulant activity in the vascular wall171, Rac-1-dependent activation of the NFκB 
pathway may be a critical element promoting thrombin-induced TF activity.  
Thrombin and TF have been shown to directly interact with the vascular wall and to activate 
signaling pathways and gene expression thus being key players in promoting vascular 
remodeling37, 172. Moreover, since TF activity determines the levels of thrombin, Rac-1 and 
NFκB may promote a positive feed back loop where thrombin-induced upregulation of TF 
expression and TF-dependent procoagulant activity in PASMC lead to the increased 
thrombogenicity of the vascular wall. Such a thrombogenic cycle may then promote vascular 
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remodeling that is associated with the pathogenesis of various vascular diseases, such as 
pulmonary hypertension173, 174.  
 
4.2.2 Rac-1 mediates PAI-1 expression and cell proliferation involving HIF-1 
 
In addition to thrombin and TF, elevated levels of PAI-1 have been associated with vascular 
remodeling in vascular disorders characterized with a prothrombotic state, such as 
pulmonary hypertension. PAI-1 is a matrix protein and the major inhibitor of fibrinolysis and 
has a central role in tissue remodeling by degrading extracellular matrix and activating 
growth factors48.  
This study now demonstrates that thrombin upregulates PAI-1 expression in PASMC via a 
redox-sensitive, Ca2+-dependent pathway involving Rac-1 and the transcription factor HIF-1 
since a) PAI-1 mRNA and protein levels were elevated in response to thrombin; b) 
constitutively active and dominant-negative Rac-1 mutants increased or decreased, 
respectively, PAI-1- promoter activity as well as PAI-1 mRNA and protein expression; c) Rac-
1 mutants were able to modulate thrombin-stimulated HIF-1-dependent transcriptional 
activity and HIF-1α protein levels; d) pretreatment with the antioxidant NAC or the Ca2+ 
chelator BAPTA-AM prevented Rac-1-dependent PAI-1 and HIF-1α expression; e) HIF-1 was 
required for PAI-1-induced promoter activity by thrombin; f) constitutively active and 
dominant-negative Rac-1 mutants increased or decreased, respectively, thrombin-induced 
cell proliferation, and this response was prevented by treatment with NAC or BAPTA-AM and 
g) PAI-1 promoted proliferation of PASMC. 
Together with the findings that thrombin activated and induced Rac-1 via a Ca2+-dependent 
pathway, and Rac-1 modulated ROS generation in response to thrombin, this study now 
identifies a pathway whereby thrombin enhances proliferation of PASMC via activation of 
Rac-1, ROS generation, and HIF and PAI-1 induction.  
Our findings identify Ca2+- and Rac-1-dependent ROS as key players in thrombin-induced 
PAI-1 expression in PASMC, since BAPTA-AM or the antioxidant NAC and RacT17N 
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decreased PAI-1 mRNA and protein levels as well as PAI-1 promoter activity, whereas 
constitutively active RacG12V had opposite effects. Consistently, p22phox-dependent ROS 
generation has been shown to contribute to thrombin-induced PAI-1 expression in aortic 
smooth muscle cells122. Moreover, PAI-1 upregulation by AngII was prevented by BAPTA-AM 
in vascular smooth muscle cells175. In contrast, hypoxic induction of PAI-1 was reduced by 
RacG12V but enhanced by BAPTA-AM in HepG2 cells126, 176. Although the reasons for this 
conflicting data are not resolved to date, they may relate to cell type specific differences in 
the role of Ca2+-activated Rac-1.  
PAI-1 is known as the target gene of the transcription factor HIF-1 under hypoxia. Similarly, 
HIF-1 is also required for thrombin-induced PAI-1 expression, since mutation of a HIF-1 
binding site in the PAI-1 promoter prevented reporter gene activity by thrombin. Furthermore, 
Rac-1 regulated HIF-1α protein levels as well as HIF-1 activity by thrombin in a redox-
sensitive manner. Moreover, an active mutant of PAK, which is a downstream target of Rac-1 
(see 4.1.2) increased transcriptional activity of HIF-1 as well as PAI-1 promoter activity by 
thrombin. Supporting these findings, it was previously shown that thrombin increased HIF-1 
activity and expression in a redox-sensitive manner involving p22phox, further indicating the 
important role of NADPH oxidase in regulating HIF-1122. Similarly, AngII has been shown to 
induce HIF-1α in a redox-sensitive manner125. 
In addition, BAPTA-AM also decreased thrombin-induced HIF-1α levels. In support of these 
findings it was reported that elevation of intracellular Ca2+ by calcium ionophores leads to 
enhanced HIF-1α protein levels177 and that induction of HIF-1 transcriptional activity by 
intermediate hypoxia was prevented by BAPTA-AM178. However, it was also demonstrated 
that the Ca2+ chelators BAPTA-AM or EGTA-AM can transiently increase hypoxia-induced 
HIF-1α accumulation in HepG2 or Hep3B cells by inhibiting PHD activity and thereby the 
interaction between HIF-1α and VHL177, 179. Taken together, these data show that Ca2+ plays 
an important role in controlling HIF-1 activity by acting at different levels of regulation in a cell 
type-specific and stimulus-dependent manner. 
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The sustained ROS generation in vascular remodeling has been described to have 
stimulatory effects on the proliferation of vascular cells56, 148. This study clearly shows that 
Rac-1 activation by thrombin increases proliferation of PASMC, while a dominant-negative 
mutant of Rac-1 or treatment with the antioxidant NAC prevented thrombin-stimulated 
proliferation of PASMC. Rac-1 has been described to also play an important role in 
proliferation of tumor cells180. In a recent study, transgenic mice that express the cDNA of a 
constitutively active mutant of human Rac-1 showed accelerated wound healing associated 
with efficient proliferation of vascular cells181. Moreover, expression of a dominant-negative 
Rac-1 mutant in endothelial cells inhibited VEGF-induced ROS production and 
proliferation182, again supporting the model that NADPH oxidases play a crucial role in 
regulating proliferative responses in vascular cells. 
Interestingly, proliferation of endothelial cells treated with tumor supernatants was inhibited 
by targeting Rac-1 GTPase with small interference RNA in tumor cells183. These data would 
support the mechanism where different secreted proteins from tumor cells (such as PAI-1) 
exhibit also paracrine effects on proliferation of vascular cells.  
In addition, not only ROS production but also cell proliferation was modulated by Ca2+. 
Proliferation was inhibited after removal of Ca2+ by the Ca2+ chelator BAPTA-AM. Supporting 
these findings, it has been demonstrated that thrombin-induced proliferation of tracheal 
smooth muscle cells was modulated by Ca2+ 184 and that Ca2+ plays an important role in 
proliferative responses of PASMC185. 
Various studies reported a role for PAI-1 in proliferation of vascular cells, but results from 
these investigations have been controversial. The data of this study clearly imply that PAI-1, 
which is induced via Ca2+, Rac-1, and HIF-1-dependent pathway, is leading to increased 
proliferation of PASMC in response to thrombin, since cell proliferation after addition of 
conditioned medium from PASMC stimulated with thrombin was attenuated when incubated 
with an inhibitory antibody against PAI-1 (which decreases PAI-1 levels in the supernatant). 
Therefore, since PAI-1 is a secreted protein, our data suggest that it could exhibit an 
autocrine proliferative effect in PASMC. In support of our findings, using the rat carotid 
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balloon injury model, induction of modest, transient increase in PAI-1 was associated with 
increased cell proliferation186. In addition, PAI-1 was shown to promote neointima formation 
in mouse, rat and murine carotid arteries186-188. In contrast, Ploplis et al demonstrated that 
endothelial cells isolated from arterial trees of PAI-1-deficient mice showed increased 
proliferation in vitro and that neointima formation was attenuated following arterial injury in 
PAI-1 deficient mice189, 190. These opposite findings may be explained by differences in the 
models used and their genetic background, variations in the vascular bed as well as by 
different endogenous levels of PAI-1. However, consistent with our studies in human 
PASMC, several studies showed that enhanced levels of PAI-1 in patients were associated 
with increased remodeling of the vascular wall and increased thickening of the intimal and 
medial layers, and with the pathogenesis of vascular diseases including pulmonary 
hypertension 48, 191-194. 
 
In summary, in PASMC thrombin increased PAI-1 expression via Rac-1 by activation of its 
substrate PAK and by inducing HIF-1. PAI-1 expression was not only redox-sensitive, but 
also dependent on Ca2+. In addition, PAI-1 stimulated proliferative responses of PASMC. 
Therefore, since PAI-1 and Ca2+ have been associated with remodeling processes, these 
findings provide a mechanism that may link redox-sensitive and calcium-dependent 
expression of PAI-1 with elevated levels of thrombin and proliferation of PASMC. 
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4.3 NADPH oxidase-derived ROS mediate urotensin-II-induced signaling and 
proliferation of pulmonary artery smooth muscle cells 
 
Urotensin-II has been described as a potent vasoactive peptide and has been suggested to 
contribute to several cardiovascular diseases including pulmonary hypertension. Herein, we 
showed that hU-II increases the levels of NADPH oxidase-derived ROS leading to the 
activation of MAP kinases and Akt followed by enhanced PAI-1 expression and increased 
proliferation of PASMC. This conclusion is supported by the findings that: a) hU-II strongly 
enhanced ROS levels which were blocked by DPI or depletion of the NADPH oxidase 
subunits p22phox or NOX4, b) hU-II elevated protein levels of p22phox and NOX4, c) hU-II 
increased the phosphorylation of ERK, p38MAPK, JNK and Akt, which was prevented by 
treatment with DPI and by depletion of p22phox or NOX4, d) hU-II upregulated the 
expression of PAI-1 in a redox-sensitive, NADPH oxidase- and kinase-dependent manner, e) 
hU-II increased the proliferative activity of PASMC which was abrogated by depletion of 
p22phox or NOX4.  
 
4.3.1 Urotensin-II stimulates ROS production by NADPH oxidases 
In this study it was demonstrated that hU-II significantly increased ROS levels in PASMC. 
This response was accompanied by elevated protein levels of the NADPH oxidase subunits 
p22phox and NOX4, but was abrogated by the flavin inhibitor DPI and by depletion of 
p22phox or NOX4. These findings show that hU-II is able to activate ROS generation and 
identify the NADPH oxidases as the source of ROS in PASMC. Interestingly, depletion of 
either p22phox or NOX4 also downregulated the expression of the other subunit (NOX4 or 
p22phox, respectively), but did not affect expression levels of the p47phox subunit (data not 
shown). These findings suggest that, similar to the neutrophil NADPH oxidase, protein 
expression of p22phox or NOX4 requires concomitant expression of NOX4 or p22phox, 
respectively. 
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Whereas vasoactive peptides such as AngII and ET-1 have been shown to activate ROS 
production by NADPH oxidases in aortic smooth muscle cells and endothelial cells, 
respectively23, 77, and a role for ROS in pulmonary vascular remodeling has been 
suggested69, only limited data are available with regard to ROS production in pulmonary 
artery smooth muscle cells. In fetal pulmonary artery smooth muscle cells endothelin-1 
increased ROS production which was sensitive to treatment with the unspecific NADPH 
oxidase inhibitors DPI and apocynin195. Similarly, serotonin enhanced ROS production in 
murine pulmonary arteries which was inhibited by apocynin196 suggesting that both peptides 
may, similar to hU-II, induce ROS production via activation of NADPH oxidases. Whereas 
p22phox has been described to contribute to ROS production in pulmonary endothelial and 
airway smooth muscle cells69, the involvement of NOX4 in the ROS production of pulmonary 
vascular cells has not been reported so far. In support of our study, it was recently shown 
that NOX4 and p22phox co-localize in smooth muscle cells197. However, in contrast to our 
study where hU-II increased NOX4 protein, stimulation with AngII decreased NOX4 levels in 
rat aortic smooth muscle cells198. Although the reasons for these differences are not clear to 
date, they may relate to stimulus- and/or cell type-specific signaling mechanisms and/or 
intracellular localization as has been suggested recently197. However, in favor of our data, 
NOX4 was upregulated in vessels from hypertensive rats199. Together with the findings that 
in animals with pulmonary hypertension hU-II levels are elevated31, the data that hU-II 
increases ROS levels via the activation of NADPH oxidases in PASMC suggest that 
enhanced NADPH oxidase expression and activity in response to hU-II may contribute to the 
development of vascular remodeling processes. 
 
4.3.2 Urotensin-II activates redox-sensitive signaling cascades and PAI-1 expression 
It was further demonstrated that hU-II rapidly increases the phosphorylation of ERK, 
p38MAPK, JNK and Akt in PASMC. In vascular smooth muscle cells, hU-II has been 
reported to activate ERK200. Thus, hU-II appears to be an effective activator of PASMC since 
these kinases have been linked to various cellular processes including proliferation, 
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differentiation, cell growth and apoptosis. Activation of the kinases by hU-II was redox-
sensitive and was inhibited by depletion of p22phox or NOX4, suggesting the involvement of 
NADPH oxidase-derived ROS. Whereas p38MAPK, JNK and Akt have been shown to be 
activated by thrombin or angiotensin II in a redox-sensitive, NADPH oxidase-dependent 
manner in vascular smooth muscle cells from different beds and species, ERK has been 
found to be rather insensitive to ROS in response to thrombin71, 107, 122. However, conflicting 
data exist regarding the role of ROS in ERK activation by angiotensin II, indicating a 
stimulus-dependent involvement of the NADPH oxidase and ROS in the activation of ERK. 
Interestingly, hU-II-stimulated NADPH oxidase-dependent kinase activation was faster than 
the increase in ROS levels measured, indicating that in addition to increased ROS levels due 
to enhanced NADPH oxidase expression, hU-II may also activate the NADPH oxidase. 
Similar observations have been made with thrombin140 or angiotensin II142 in smooth muscle 
cells and endothelial cells (see 4.1.1)201. 
In this study it was further shown that hU-II strongly elevates PAI-1 expression in PASMC. 
Depletion of NADPH oxidase subunits or inhibition of MAP kinases and PI3K/Akt prevented 
this response, indicating that similar to thrombin, hU-II induces PAI-1 expression by a 
NADPH oxidase-dependent increase in ROS levels and the subsequent activation of MAP 
kinases and Akt. In vascular smooth muscle cells, MAP kinases and PI3K/Akt have been 
shown to be involved in the regulation of PAI-1 by thrombin, PDGF and angiotensin II122, 175, 
202. Since findings of the present study indicate that enhanced levels of PAI-1 stimulate 
proliferation of PASMC, this novel pathway activated by hU-II can be relevant in promoting 
vascular remodeling.  
In summary, our findings demonstrate that hU-II is a novel agonist of NADPH oxidases in 
PASMC. Elevated levels of ROS due to the increased expression of p22phox and NOX4 lead 
to the subsequent activation of MAP kinases and Akt that induce PAI-1 expression and PAI-
1-dependent proliferation of PASMC. Since PAI-1 is essentially involved in vascular 
remodeling processes possibly by facilitating migration and/or proliferation of PASMC, such a 
mechanism may be highly relevant in promoting pulmonary vascular remodeling processes.  
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5. Summary 
 
Vascular remodeling processes are characterized by increased proliferation of vascular cells 
and a prothrombotic state. Coagulation factors and vasoactive peptides have been 
suggested to contribute to these processes. Reactive oxygen species (ROS) have been 
implicated to act as vascular signaling molecules, and NADPH oxidases have been identified 
as a major source of vascular ROS production. The aims of the present study were therefore 
to identify signaling pathways linking factors promoting remodeling processes such as 
thrombin and the vasoactive peptide urotensin-II to ROS production derived from NADPH 
oxidases as well as subsequent proliferation and procoagulant activity. 
Thrombin induced a biphasic increase in ROS levels. A rapid activation of NADPH oxidases 
was followed by a second delayed response. This increase was paralleled by ROS-
dependent induction of p22phox involving p38MAPK and PI3K/Akt in endothelial cells, and 
by enhanced Rac-1 levels in pulmonary artery smooth muscle cells, and followed by 
enhanced proliferation.  
Activation of Rac-1-dependent ROS production by thrombin resulted in elevated levels of the 
prothrombotic factors tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) in 
PASMC. Rac-1-dependent induction of TF was mediated by the transcription factor NFκB 
and resulted in enhanced procoagulant activity. Since active TF results in thrombin 
generation, this pathway could play an important role in promoting a feedback loop leading to 
a thrombogenic cycle.  
Rac-1-dependent induction of PAI-1 was mediated by elevated Ca2+, the Rac-1 downstream 
target PAK and the transcription factor HIF-1. Since PAI-1 inhibition diminished proliferation 
of PASMC, these findings identify PAI-1 as an important mediator of thrombin-stimulated 
NADPH oxidase-dependent proliferation.  
Finally, the vasoactive peptide U-II was identified as a novel activator of NADPH oxidases 
and ROS-dependent activation of MAP kinases and Akt which subsequently induced PAI-1 
expression and proliferation.  
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Taken together, these findings support a model where enhanced levels of thrombotic and 
vasoactive factors, as found in an early stage of vascular remodeling, activate and induce 
NADPH oxidases and ROS generation. ROS-dependent signaling cascades link and amplify 
these signals and promote proliferative and thrombotic events which can lead to progression 
of vascular remodeling.  
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Figure 52. Summary of the pathways described in this study 
Explanations are given in the text. 
 
                                                                                                                                   References 
____________________________________________________________________________ 
130
6. References  
 
1. Stocker R, Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol 
Rev. 2004;84:1381-1478. 
2. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary 
hypertension. Circulation. 2004;109:159-165. 
3. Montani D, Jais X, Ioos V, Sitbon O, Simonneau G, Humbert M. [Treatments for 
pulmonary arterial hypertension.]. Rev Med Interne. 2004;25:720-731. 
4. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 
2004;351:1655-1665. 
5. Lopes AA, Maeda NY, Goncalves RC, Bydlowski SP. Endothelial cell dysfunction 
correlates differentially with survival in primary and secondary pulmonary 
hypertension. Am Heart J. 2000;139:618-623. 
6. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman 
BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular 
pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-
24S. 
7. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky 
EH, Brundage BH, Detre KM, et al. Histopathology of primary pulmonary 
hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 
patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary 
Hypertension Registry. Circulation. 1989;80:1198-1206. 
8. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study 
of 80 cases. Mayo Clin Proc. 1985;60:16-25. 
9. Chen YF. Atrial natriuretic peptide in hypoxia. Peptides. 2005;26:1068-1077. 
10. Kiemer AK, Furst R, Vollmar AM. Vasoprotective actions of the atrial natriuretic 
peptide. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:11-21. 
11. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic 
intervention in pulmonary hypertension. Pharmacol Ther. 2001;92:1-20. 
12. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signaling by angiotensin II and 
vascular remodeling in hypertension. Clin Exp Pharmacol Physiol. 2003;30:860-866. 
13. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor 
blockers. Am J Hypertens. 2005;18:720-730. 
14. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol. 2005;43:19-29. 
15. Vollmar AM. Endothelins. Zentralbl Veterinarmed A. 1992;39:481-493. 
16. Masaki T. The discovery of endothelins. Cardiovasc Res. 1998;39:530-533. 
                                                                                                                                   References 
____________________________________________________________________________ 
131
17. Takuwa Y, Kasuya Y, Takuwa N, Kudo M, Yanagisawa M, Goto K, Masaki T, 
Yamashita K. Endothelin receptor is coupled to phospholipase C via a pertussis toxin-
insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle 
cells. J Clin Invest. 1990;85:653-658. 
18. Benigni A. Defining the role of endothelins in renal pathophysiology on the basis of 
selective and unselective endothelin receptor antagonist studies. Curr Opin Nephrol 
Hypertens. 1995;4:349-353. 
19. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin 
receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial 
cells. J Clin Invest. 1993;91:1367-1373. 
20. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane 
JR. Pressor effects of circulating endothelin are limited by its removal in the 
pulmonary circulation and by the release of prostacyclin and endothelium-derived 
relaxing factor. Proc Natl Acad Sci U S A. 1988;85:9797-9800. 
21. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor 
antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:62S-67S. 
22. Zhang YM, Wang KQ, Zhou GM, Zuo J, Ge JB. Endothelin-1 promoted proliferation of 
vascular smooth muscle cell through pathway of extracellular signal-regulated kinase 
and cyclin D1. Acta Pharmacol Sin. 2003;24:563-568. 
23. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative 
stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial 
cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 
2005;145:323-333. 
24. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, 
Bern HA, Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog 
and human reveals intense expression of the urotensin II gene in motoneurons of the 
spinal cord. Proc Natl Acad Sci U S A. 1998;95:15803-15808. 
25. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol. 
2002;137:579-588. 
26. Pearson D, Shively JE, Clark BR, Geschwind, II, Barkley M, Nishioka RS, Bern HA. 
Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of 
fishes. Proc Natl Acad Sci U S A. 1980;77:5021-5024. 
27. Bern HA, Pearson D, Larson BA, Nishioka RS. Neurohormones from fish tails: the 
caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory 
system of fishes. Recent Prog Horm Res. 1985;41:533-552. 
28. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden 
CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, 
                                                                                                                                   References 
____________________________________________________________________________ 
132
Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, 
Shabon U, Trill JJ, Hay DW, Douglas SA, et al. Human urotensin-II is a potent 
vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282-
286. 
29. Douglas SA. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter 
or simply a fishy 'tail'? Curr Opin Pharmacol. 2003;3:159-167. 
30. Onan D, Hannan RD, Thomas WG, Douglas SA, Dhanak D, Johns DG, Takahashi K. 
Urotensin II: the old kid in town. Trends Endocrinol Metab. 2004;15:175-182. 
31. Qi J, Du J, Tang X, Li J, Wei B, Tang C. The upregulation of endothelial nitric oxide 
synthase and urotensin-II is associated with pulmonary hypertension and vascular 
diseases in rats produced by aortocaval shunting. Heart Vessels. 2004;19:81-88. 
32. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, 
Morecroft I, Polland K. Contractile responses to human urotensin-II in rat and human 
pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J 
Pharmacol. 2000;130:201-204. 
33. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman 
PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic 
pulmonary hypertension. A morphometric and immunohistochemical study. Am J 
Respir Crit Care Med. 2000;162:1577-1586. 
34. Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the 
molecular basis of the crosstalk. Life Sci. 1998;62:1817-1824. 
35. Mackman N. Regulation of the tissue factor gene. Thromb Haemost. 1997;78:747-
754. 
36. Mackman N. Gene targeting in hemostasis. tissue factor. Front Biosci. 2001;6:D208-
215. 
37. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8. 
38. Oeth P, Parry GC, Mackman N. Regulation of the tissue factor gene in human 
monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and 
lipopolysaccharide-induced expression. Arterioscler Thromb Vasc Biol. 1997;17:365-
374. 
39. Biro E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE, Sturk A, 
Nieuwland R. Human cell-derived microparticles promote thrombus formation in vivo 
in a tissue factor-dependent manner. J Thromb Haemost. 2003;1:2561-2568. 
40. Mann KG. Thrombin formation. Chest. 2003;124:4S-10S. 
41. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler 
Thromb Vasc Biol. 2003;23:17-25. 
                                                                                                                                   References 
____________________________________________________________________________ 
133
42. Osterud B. Tissue factor: a complex biological role. Thromb Haemost. 1997;78:755-
758. 
43. Overduin M, de Beer T. The plot thickens: how thrombin modulates blood clotting. 
Nat Struct Biol. 2000;7:267-269. 
44. Dugina TN, Kiseleva EV, Chistov IV, Umarova BA, Strukova SM. Receptors of the 
PAR family as a link between blood coagulation and inflammation. Biochemistry 
(Mosc). 2002;67:65-74. 
45. Trejo J. Protease-activated receptors: new concepts in regulation of G protein-
coupled receptor signaling and trafficking. J Pharmacol Exp Ther. 2003;307:437-442. 
46. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 
2000;407:258-264. 
47. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 
2003;89:601-609. 
48. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator 
inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des. 
2003;9:1545-1564. 
49. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, 
Butcher M, Weitz JI. Type 1 plasminogen activator inhibitor binds to fibrin via 
vitronectin. J Biol Chem. 2000;275:19788-19794. 
50. Babior BM. The respiratory burst oxidase. Curr Opin Hematol. 1995;2:55-60. 
51. Babior BM. NADPH oxidase: an update. Blood. 1999;93:1464-1476. 
52. Babior BM. The leukocyte NADPH oxidase. Isr Med Assoc J. 2002;4:1023-1024. 
53. Babior BM. NADPH oxidase. Curr Opin Immunol. 2004;16:42-47. 
54. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem 
Biophys. 2002;397:342-344. 
55. Bokoch GM, Knaus UG. NADPH oxidases: not just for leukocytes anymore! Trends 
Biochem Sci. 2003;28:502-508. 
56. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular 
biology and disease. Circ Res. 2000;86:494-501. 
57. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in 
hypertension. Histochem Cell Biol. 2004;122:339-352. 
58. Gorlach A, Kietzmann T, Hess J. Redox signaling through NADPH oxidases: 
involvement in vascular proliferation and coagulation. Ann N Y Acad Sci. 
2002;973:505-507. 
59. Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the 
arterial wall. J Cell Biochem. 2001;82:674-682. 
                                                                                                                                   References 
____________________________________________________________________________ 
134
60. Torres M, Forman HJ. Redox signaling and the MAP kinase pathways. Biofactors. 
2003;17:287-296. 
61. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, Galeotti T. 
Reactive oxygen species as downstream mediators of angiogenic signaling by 
vascular endothelial growth factor receptor-2/KDR. J Biol Chem. 2002;277:3101-
3108. 
62. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells -- 
implications in cardiovascular disease. Braz J Med Biol Res. 2004;37:1263-1273. 
63. Lassegue B, Griendling KK. Reactive oxygen species in hypertension; An update. Am 
J Hypertens. 2004;17:852-860. 
64. Berk BC. Redox signals that regulate the vascular response to injury. Thromb 
Haemost. 1999;82:810-817. 
65. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative 
stress in atherosclerosis. Am J Cardiol. 2003;91:7A-11A. 
66. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic 
targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478. 
67. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with 
NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin 
Aldosterone Syst. 2003;4:51-61. 
68. Brennan LA, Steinhorn RH, Wedgwood S, Mata-Greenwood E, Roark EA, Russell 
JA, Black SM. Increased superoxide generation is associated with pulmonary 
hypertension in fetal lambs: a role for NADPH oxidase. Circ Res. 2003;92:683-691. 
69. Wedgwood S, Black SM. Role of reactive oxygen species in vascular remodeling 
associated with pulmonary hypertension. Antioxid Redox Signal. 2003;5:759-769. 
70. Tracy RP. Thrombin, inflammation, and cardiovascular disease: an epidemiologic 
perspective. Chest. 2003;124:49S-57S. 
71. Herkert O, Diebold I, Brandes RP, Hess J, Busse R, Gorlach A. NADPH oxidase 
mediates tissue factor-dependent surface procoagulant activity by thrombin in human 
vascular smooth muscle cells. Circulation. 2002;105:2030-2036. 
72. Herkert O, Gorlach A. Redox control of tissue factor expression in smooth muscle 
cells and other vascular cells. Methods Enzymol. 2002;352:220-231. 
73. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, 
Brasier AR, Bode C, Runge MS. Stimulation of a vascular smooth muscle cell 
NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming 
this oxidase in vitro and in vivo. J Biol Chem. 1999;274:19814-19822. 
                                                                                                                                   References 
____________________________________________________________________________ 
135
74. Ruef J, Peter K, Nordt TK, Runge MS, Kubler W, Bode C. Oxidative stress and 
atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic 
approaches. Thromb Haemost. 1999;82 Suppl 1:32-37. 
75. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood 
vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J 
Physiol Pharmacol. 2002;53:515-524. 
76. Miller FJ, Jr., Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide 
production in vascular smooth muscle contributes to oxidative stress and impaired 
relaxation in atherosclerosis. Circ Res. 1998;82:1298-1305. 
77. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates 
NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ 
Res. 1994;74:1141-1148. 
78. Fei J, Viedt C, Soto U, Elsing C, Jahn L, Kreuzer J. Endothelin-1 and smooth muscle 
cells: induction of jun amino-terminal kinase through an oxygen radical-sensitive 
mechanism. Arterioscler Thromb Vasc Biol. 2000;20:1244-1249. 
79. Wolin MS, Ahmad M, Gupte SA. The sources of oxidative stress in the vessel wall. 
Kidney Int. 2005;67:1659-1661. 
80. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, 
expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 
2003;285:R277-297. 
81. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox 
containing NADPH oxidase selectively expressed in endothelial cells is a major 
source of oxygen radical generation in the arterial wall. Circ Res. 2000;87:26-32. 
82. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory burst 
oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol. 2004;76:760-781. 
83. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin 
Immunol. 2003;15:578-584. 
84. Brandes RP, Miller FJ, Beer S, Haendeler J, Hoffmann J, Ha T, Holland SM, Gorlach 
A, Busse R. The vascular NADPH oxidase subunit p47phox is involved in redox-
mediated gene expression. Free Radic Biol Med. 2002;32:1116-1122. 
85. Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD. Homologs of gp91phox: cloning 
and tissue expression of Nox3, Nox4, and Nox5. Gene. 2001;269:131-140. 
86. Bengtsson SH, Gulluyan LM, Dusting GJ, Drummond GR. Novel isoforms of NADPH 
oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol. 
2003;30:849-854. 
87. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, 
Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production 
                                                                                                                                   References 
____________________________________________________________________________ 
136
and expression of nox family proteins in human atherosclerosis. Circulation. 
2002;105:1429-1435. 
88. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, 
Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 
1999;401:79-82. 
89. Krause KH. Tissue distribution and putative physiological function of NOX family 
NADPH oxidases. Jpn J Infect Dis. 2004;57:S28-29. 
90. Lambeth JD. Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) 
oxidases. Curr Opin Hematol. 2002;9:11-17. 
91. De Deken X, Wang D, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE, Miot 
F. Cloning of two human thyroid cDNAs encoding new members of the NADPH 
oxidase family. J Biol Chem. 2000;275:23227-23233. 
92. Takeya R, Ueno N, Kami K, Taura M, Kohjima M, Izaki T, Nunoi H, Sumimoto H. 
Novel human homologues of p47phox and p67phox participate in activation of 
superoxide-producing NADPH oxidases. J Biol Chem. 2003;278:25234-25246. 
93. Cheng G, Lambeth JD. NOXO1, regulation of lipid binding, localization, and activation 
of Nox1 by the Phox homology (PX) domain. J Biol Chem. 2004;279:4737-4742. 
94. Banfi B, Clark RA, Steger K, Krause KH. Two novel proteins activate superoxide 
generation by the NADPH oxidase NOX1. J Biol Chem. 2003;278:3510-3513. 
95. Cheng G, Ritsick D, Lambeth JD. Nox3 regulation by NOXO1, p47phox, and 
p67phox. J Biol Chem. 2004;279:34250-34255. 
96. Quinn MT, Curnutte JT, Parkos CA, Mullen ML, Scott PJ, Erickson RW, Jesaitis AJ. 
Reconstitution of defective respiratory burst activity with partially purified human 
neutrophil cytochrome B in two genetic forms of chronic granulomatous disease: 
possible role of Rap1A. Blood. 1992;79:2438-2445. 
97. Parkos CA, Dinauer MC, Walker LE, Allen RA, Jesaitis AJ, Orkin SH. Primary 
structure and unique expression of the 22-kilodalton light chain of human neutrophil 
cytochrome b. Proc Natl Acad Sci U S A. 1988;85:3319-3323. 
98. Moreno MU, San Jose G, Orbe J, Paramo JA, Beloqui O, Diez J, Zalba G. 
Preliminary characterisation of the promoter of the human p22(phox) gene: 
identification of a new polymorphism associated with hypertension. FEBS Lett. 
2003;542:27-31. 
99. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. 
Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll 
Cardiol. 2003;41:2164-2171. 
100. Roberts AW, Kim C, Zhen L, Lowe JB, Kapur R, Petryniak B, Spaetti A, Pollock JD, 
Borneo JB, Bradford GB, Atkinson SJ, Dinauer MC, Williams DA. Deficiency of the 
                                                                                                                                   References 
____________________________________________________________________________ 
137
hematopoietic cell-specific Rho family GTPase Rac2 is characterized by 
abnormalities in neutrophil function and host defense. Immunity. 1999;10:183-196. 
101. Bokoch GM, Diebold BA. Current molecular models for NADPH oxidase regulation by 
Rac GTPase. Blood. 2002;100:2692-2696. 
102. Werner E. GTPases and reactive oxygen species: switches for killing and signaling. J 
Cell Sci. 2004;117:143-153. 
103. Ridley AJ. Rho proteins: linking signaling with membrane trafficking. Traffic. 
2001;2:303-310. 
104. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629-
635. 
105. Gregg D, Rauscher FM, Goldschmidt-Clermont PJ. Rac regulates cardiovascular 
superoxide through diverse molecular interactions: more than a binary GTP switch. 
Am J Physiol Cell Physiol. 2003;285:C723-734. 
106. English J, Pearson G, Wilsbacher J, Swantek J, Karandikar M, Xu S, Cobb MH. New 
insights into the control of MAP kinase pathways. Exp Cell Res. 1999;253:255-270. 
107. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase 
activity and gene expression by reactive oxygen species and their role in vascular 
physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20:2175-2183. 
108. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of 
phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol 
Cell Cardiol. 2004;37:449-471. 
109. Fryer BH, Field J. Rho, Rac, Pak and angiogenesis: old roles and newly identified 
responsibilities in endothelial cells. Cancer Lett. 2005;229:13-23. 
110. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem. 2003;72:743-
781. 
111. Michiels C, Minet E, Mottet D, Raes M. Regulation of gene expression by oxygen: 
NF-kappaB and HIF-1, two extremes. Free Radic Biol Med. 2002;33:1231-1242. 
112. Forman HJ, Fukuto JM, Torres M. Redox signaling: thiol chemistry defines which 
reactive oxygen and nitrogen species can act as second messengers. Am J Physiol 
Cell Physiol. 2004;287:C246-256. 
113. Haddad JJ. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-
sensitive transcription factors. Cell Signal. 2002;14:879-897. 
114. Wang T, Zhang X, Li JJ. The role of NF-kappaB in the regulation of cell stress 
responses. Int Immunopharmacol. 2002;2:1509-1520. 
115. Haddad JJ. Science review: Redox and oxygen-sensitive transcription factors in the 
regulation of oxidant-mediated lung injury: role for nuclear factor-kappaB. Crit Care. 
2002;6:481-490. 
                                                                                                                                   References 
____________________________________________________________________________ 
138
116. Zhang Y, Chen F. Reactive oxygen species (ROS), troublemakers between nuclear 
factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res. 
2004;64:1902-1905. 
117. Haddad JJ. Science review: redox and oxygen-sensitive transcription factors in the 
regulation of oxidant-mediated lung injury: role for hypoxia-inducible factor-1alpha. 
Crit Care. 2003;7:47-54. 
118. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the 
nucleus. Cell. 2001;107:1-3. 
119. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 
2001;13:167-171. 
120. Safran M, Kaelin WG, Jr. HIF hydroxylation and the mammalian oxygen-sensing 
pathway. J Clin Invest. 2003;111:779-783. 
121. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. 
Physiology (Bethesda). 2004;19:176-182. 
122. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes 
RP, Kietzmann T, Busse R. Thrombin activates the hypoxia-inducible factor-1 
signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing 
NADPH oxidase. Circ Res. 2001;89:47-54. 
123. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces 
transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. 
Embo J. 1998;17:5085-5094. 
124. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta 
and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. 
Blood. 1999;94:1561-1567. 
125. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of 
hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 
2000;275:26765-26771. 
126. Gorlach A, Berchner-Pfannschmidt U, Wotzlaw C, Cool RH, Fandrey J, Acker H, 
Jungermann K, Kietzmann T. Reactive oxygen species modulate HIF-1 mediated 
PAI-1 expression: involvement of the GTPase Rac1. Thromb Haemost. 2003;89:926-
935. 
127. Duckett CS, Perkins ND, Kowalik TF, Schmid RM, Huang ES, Baldwin AS, Jr., Nabel 
GJ. Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional 
activation, and inhibition by an I kappa B-alpha (MAD-3). Mol Cell Biol. 1993;13:1315-
1322. 
                                                                                                                                   References 
____________________________________________________________________________ 
139
128. Swantek JL, Christerson L, Cobb MH. Lipopolysaccharide-induced tumor necrosis 
factor-alpha promoter activity is inhibitor of nuclear factor-kappaB kinase-dependent. 
J Biol Chem. 1999;274:11667-11671. 
129. Gorlach A, Brandes RP, Bassus S, Kronemann N, Kirchmaier CM, Busse R, Schini-
Kerth VB. Oxidative stress and expression of p22phox are involved in the up-
regulation of tissue factor in vascular smooth muscle cells in response to activated 
platelets. Faseb J. 2000;14:1518-1528. 
130. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor 
VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A. 
1983;80:3734-3737. 
131. Denk W, Strickler JH, Webb WW. Two-photon laser scanning fluorescence 
microscopy. Science. 1990;248:73-76. 
132. Liu Q, Berchner-Pfannschmidt U, Moller U, Brecht M, Wotzlaw C, Acker H, 
Jungermann K, Kietzmann T. A Fenton reaction at the endoplasmic reticulum is 
involved in the redox control of hypoxia-inducible gene expression. Proc Natl Acad 
Sci U S A. 2004;101:4302-4307. 
133. Bestvater F, Spiess E, Stobrawa G, Hacker M, Feurer T, Porwol T, Berchner-
Pfannschmidt U, Wotzlaw C, Acker H. Two-photon fluorescence absorption and 
emission spectra of dyes relevant for cell imaging. J Microsc. 2002;208:108-115. 
134. Kietzmann T, Jungermann K, Gorlach A. Regulation of the hypoxia-dependent 
plasminogen activator inhibitor 1 expression by MAP kinases. Thromb Haemost. 
2003;89:666-673. 
135. Ong KL, Lam KS, Cheung BM. Urotensin II: Its Function in Health and Its Role in 
Disease. Cardiovasc Drugs Ther. 2005;19:65-75. 
136. Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block 
activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc. 
2003;125:1144-1145. 
137. Tanimoto T, Lungu AO, Berk BC. Sphingosine 1-phosphate transactivates the 
platelet-derived growth factor beta receptor and epidermal growth factor receptor in 
vascular smooth muscle cells. Circ Res. 2004;94:1050-1058. 
138. Bayraktutan U, Draper N, Lang D, Shah AM. Expression of functional neutrophil-type 
NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc 
Res. 1998;38:256-262. 
139. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase 
complex in cultured endothelial cells. J Biol Chem. 2002;277:19952-19960. 
140. Brandes RP, Viedt C, Nguyen K, Beer S, Kreuzer J, Busse R, Gorlach A. Thrombin-
induced MCP-1 expression involves activation of the p22phox-containing NADPH 
                                                                                                                                   References 
____________________________________________________________________________ 
140
oxidase in human vascular smooth muscle cells. Thromb Haemost. 2001;85:1104-
1110. 
141. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by 
angiotensin II. Role of the p47phox subunit. J Biol Chem. 2003;278:12094-12100. 
142. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin 
II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res. 
2002;91:406-413. 
143. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, 
Yokoyama M. Expression of NADH/NADPH oxidase p22phox in human coronary 
arteries. Circulation. 1999;100:1494-1498. 
144. Zalba G, San Jose G, Beaumont FJ, Fortuno MA, Fortuno A, Diez J. Polymorphisms 
and promoter overactivity of the p22(phox) gene in vascular smooth muscle cells from 
spontaneously hypertensive rats. Circ Res. 2001;88:217-222. 
145. Greiber S, Munzel T, Kastner S, Muller B, Schollmeyer P, Pavenstadt H. NAD(P)H 
oxidase activity in cultured human podocytes: effects of adenosine triphosphate. 
Kidney Int. 1998;53:654-663. 
146. Thannickal VJ, Fanburg BL. Activation of an H2O2-generating NADH oxidase in 
human lung fibroblasts by transforming growth factor beta 1. J Biol Chem. 
1995;270:30334-30338. 
147. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high 
glucose enhances apoptosis related to oxidative stress in human umbilical vein 
endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. 
Diabetes. 2003;52:2795-2804. 
148. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, Cheng TH. Angiotensin II 
induces endothelin-1 gene expression via extracellular signal-regulated kinase 
pathway in rat aortic smooth muscle cells. Cardiovasc Res. 2004;61:159-168. 
149. Higuchi Y. Chromosomal DNA fragmentation in apoptosis and necrosis induced by 
oxidative stress. Biochem Pharmacol. 2003;66:1527-1535. 
150. Yasuda M, Ohzeki Y, Shimizu S, Naito S, Ohtsuru A, Yamamoto T, Kuroiwa Y. 
Stimulation of in vitro angiogenesis by hydrogen peroxide and the relation with ETS-1 
in endothelial cells. Life Sci. 1999;64:249-258. 
151. Li WG, Miller FJ, Jr., Zhang HJ, Spitz DR, Oberley LW, Weintraub NL. H(2)O(2)-
induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant 
injury. J Biol Chem. 2001;276:29251-29256. 
152. Jeong HY, Kim CD. p22phox-derived superoxide mediates enhanced proliferative 
capacity of diabetic vascular smooth muscle cells. Diabetes Res Clin Pract. 
2004;64:1-10. 
                                                                                                                                   References 
____________________________________________________________________________ 
141
153. Price LS, Langeslag M, ten Klooster JP, Hordijk PL, Jalink K, Collard JG. Calcium 
signaling regulates translocation and activation of Rac. J Biol Chem. 
2003;278:39413-39421. 
154. Mehta D, Konstantoulaki M, Ahmmed GU, Malik AB. Sphingosine 1-phosphate-
induced mobilization of intracellular Ca2+ mediates rac activation and adherens 
junction assembly in endothelial cells. J Biol Chem. 2005;280:17320-17328. 
155. Banfi B, Molnar G, Maturana A, Steger K, Hegedus B, Demaurex N, Krause KH. A 
Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem. 
2001;276:37594-37601. 
156. Banfi B, Tirone F, Durussel I, Knisz J, Moskwa P, Molnar GZ, Krause KH, Cox JA. 
Mechanism of Ca2+ activation of the NADPH oxidase NOX5. J Biol Chem. 
2004;24:24. 
157. Abramov AY, Jacobson J, Wientjes F, Hothersall J, Canevari L, Duchen MR. 
Expression and modulation of an NADPH oxidase in mammalian astrocytes. J 
Neurosci. 2005;25:9176-9184. 
158. Berthier S, Paclet MH, Lerouge S, Roux F, Vergnaud S, Coleman AW, Morel F. 
Changing the conformation state of cytochrome b558 initiates NADPH oxidase 
activation: MRP8/MRP14 regulation. J Biol Chem. 2003;278:25499-25508. 
159. Touyz RM. Reactive oxygen species as mediators of calcium signaling by angiotensin 
II: implications in vascular physiology and pathophysiology. Antioxid Redox Signal. 
2005;7:1302-1314. 
160. Gorlach A, BelAiba RS, Hess J, Kietzmann T. Thrombin activates the p21-activated 
kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression. 
Thromb Haemost. 2005;93:1168-1175. 
161. Wu RF, Gu Y, Xu YC, Nwariaku FE, Terada LS. Vascular endothelial growth factor 
causes translocation of p47phox to membrane ruffles through WAVE1. J Biol Chem. 
2003;278:36830-36840. 
162. Woolfolk EA, Eguchi S, Ohtsu H, Nakashima H, Ueno H, Gerthoffer WT, Motley ED. 
Angiotensin II-Induced Activation of P21-Activated Kinase 1 Requires Ca2+ and 
Protein Kinase C {delta} in Vascular Smooth Muscle Cells. Am J Physiol Cell Physiol. 
2005. 
163. Weber DS, Taniyama Y, Rocic P, Seshiah PN, Dechert MA, Gerthoffer WT, 
Griendling KK. Phosphoinositide-dependent kinase 1 and p21-activated protein 
kinase mediate reactive oxygen species-dependent regulation of platelet-derived 
growth factor-induced smooth muscle cell migration. Circ Res. 2004;94:1219-1226. 
                                                                                                                                   References 
____________________________________________________________________________ 
142
164. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor 
expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. 
Circulation. 2002;105:1756-1759. 
165. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E. Vascular 
endothelial cell growth factor-induced tissue factor expression in endothelial cells is 
mediated by EGR-1. Blood. 1999;93:3811-3823. 
166. Hall AJ, Vos HL, Bertina RM. Lipopolysaccharide induction of tissue factor in THP-1 
cells involves Jun protein phosphorylation and nuclear factor kappaB nuclear 
translocation. J Biol Chem. 1999;274:376-383. 
167. Orthner CL, Rodgers GM, Fitzgerald LA. Pyrrolidine dithiocarbamate abrogates tissue 
factor (TF) expression by endothelial cells: evidence implicating nuclear factor-kappa 
B in TF induction by diverse agonists. Blood. 1995;86:436-443. 
168. Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in 
human endothelial cells. Arterioscler Thromb Vasc Biol. 1995;15:612-621. 
169. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of 
the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 
1997;11:463-475. 
170. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in 
atherosclerosis and thrombosis. Cardiovasc Res. 2004;61:671-682. 
171. Ferrara DE, Liu X, Espinola RG, Meroni PL, Abukhalaf I, Harris EN, Pierangeli SS. 
Inhibition of the thrombogenic and inflammatory properties of antiphospholipid 
antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003;48:3272-
3279. 
172. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: 
nonthrombotic effects of thrombin in vessel wall biology. Circ Res. 2001;88:987-997. 
173. Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagul 
Fibrinolysis. 1998;9:107-117. 
174. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G, Simonneau G. 
Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin 
Chest Med. 2001;22:451-458. 
175. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, Shimokawa H, Takeshita 
A. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced 
plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc 
Biol. 2001;21:868-873. 
176. Dimova EY, Samoylenko A, Kietzmann T. Oxidative stress and hypoxia: implications 
for plasminogen activator inhibitor-1 expression. Antioxid Redox Signal. 2004;6:777-
791. 
                                                                                                                                   References 
____________________________________________________________________________ 
143
177. Liu Q, Moller U, Flugel D, Kietzmann T. Induction of plasminogen activator inhibitor I 
gene expression by intracellular calcium via hypoxia-inducible factor-1. Blood. 
2004;104:3993-4001. 
178. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. Ca2+/calmodulin 
kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in 
cells subjected to intermittent hypoxia. J Biol Chem. 2005;280:4321-4328. 
179. Metzen E, Fandrey J, Jelkmann W. Evidence against a major role for Ca2+ in 
hypoxia-induced gene expression in human hepatoma cells (Hep3B). J Physiol. 
1999;517 ( Pt 3):651-657. 
180. Yang C, Liu Y, Leskow FC, Weaver VM, Kazanietz MG. Rac-GAP-dependent 
inhibition of breast cancer cell proliferation by {beta}2-chimerin. J Biol Chem. 
2005;280:24363-24370. 
181. Hassanain HH, Irshaid F, Wisel S, Sheridan J, Michler RE, Goldschmidt-Clermont PJ. 
Smooth muscle cell expression of a constitutive active form of human Rac 1 
accelerates cutaneous wound repair. Surgery. 2005;137:92-101. 
182. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano 
PJ, Johnson C, Alexander RW. Novel role of gp91(phox)-containing NAD(P)H 
oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. 
Circ Res. 2002;91:1160-1167. 
183. Xue Y, Bi F, Zhang X, Pan Y, Liu N, Zheng Y, Fan D. Inhibition of endothelial cell 
proliferation by targeting Rac1 GTPase with small interference RNA in tumor cells. 
Biochem Biophys Res Commun. 2004;320:1309-1315. 
184. Lin CC, Shyr MH, Chien CS, Wang CC, Chiu CT, Hsiao LD, Yang CM. Thrombin-
stimulated cell proliferation mediated through activation of Ras/Raf/MEK/MAPK 
pathway in canine cultured tracheal smooth muscle cells. Cell Signal. 2002;14:265-
275. 
185. Mauban JR, Remillard CV, Yuan JX. Hypoxic pulmonary vasoconstriction: role of ion 
channels. J Appl Physiol. 2005;98:415-420. 
186. DeYoung MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases 
neointima formation in balloon-injured rat carotid arteries. Circulation. 2001;104:1972-
1971. 
187. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and 
plasminogen activator inhibitor-1 promote neointima formation in murine carotid 
arteries. Arterioscler Thromb Vasc Biol. 2002;22:934-939. 
188. Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances 
neointima formation after oxidative vascular injury in atherosclerosis-prone mice. 
Circulation. 2001;103:3105-3110. 
                                                                                                                                   References 
____________________________________________________________________________ 
144
189. Ploplis VA, Balsara R, Sandoval-Cooper MJ, Yin ZJ, Batten J, Modi N, Gadoua D, 
Donahue D, Martin JA, Castellino FJ. Enhanced in vitro proliferation of aortic 
endothelial cells from plasminogen activator inhibitor-1-deficient mice. J Biol Chem. 
2004;279:6143-6151. 
190. Ploplis VA, Castellino FJ. Attenuation of neointima formation following arterial injury in 
PAI-1 deficient mice. Ann N Y Acad Sci. 2001;936:466-468. 
191. Martin I, Humbert M, Marfaing-Koka A, Capron F, Wolf M, Meyer D, Simonneau G, 
Angles-Cano E. Plasminogen activation by blood monocytes and alveolar 
macrophages in primary pulmonary hypertension. Blood Coagul Fibrinolysis. 
2002;13:417-422. 
192. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe 
primary pulmonary hypertension. Eur Respir J. 1998;12:1446-1449. 
193. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A 
levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary 
hypertension. Circulation. 1990;82:841-847. 
194. Altman R, Scazziota A, Rouvier J, Gurfinkel E, Favaloro R, Perrone S, Fareed J. 
Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin 
Cardiol. 1996;19:549-554. 
195. Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth 
muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung 
Cell Mol Physiol. 2001;281:L1058-1067. 
196. Liu JQ, Folz RJ. Extracellular superoxide enhances 5-HT-induced murine pulmonary 
artery vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 2004;287:L111-118. 
197. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular 
localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb 
Vasc Biol. 2004;24:677-683. 
198. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, 
Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells : nox1 
mediates angiotensin II-induced superoxide formation and redox-sensitive signaling 
pathways. Circ Res. 2001;88:888-894. 
199. Paravicini TM, Chrissobolis S, Drummond GR, Sobey CG, Ago T, Kitazono T, 
Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, Iida M. 
Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension 
is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke. 
2004;35:584-589. 
200. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. Urotensin II-
induced activation of extracellular signal-regulated kinase in cultured vascular smooth 
                                                                                                                                   References 
____________________________________________________________________________ 
145
muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci. 
2003;72:1049-1060. 
201. Djordjevic T, Pogrebniak A, BelAiba RS, Bonello S, Wotzlaw C, Acker H, Hess J, 
Gorlach A. The expression of the NADPH oxidase subunit p22phox is regulated by a 
redox-sensitive pathway in endothelial cells. Free Radic Biol Med. 2005;38:616-630. 
202. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H. Role of JNK, p38, 
and ERK in platelet-derived growth factor-induced vascular proliferation, migration, 
and gene expression. Arterioscler Thromb Vasc Biol. 2003;23:795-801. 
 
 
                                                                                                                                Abbreviations 
____________________________________________________________________________ 
146
7. Appendix 
 
Abbreviations 
 
2P-CLSM 2- photon confocal laser scanning microscopy 
Akt   Protein kinase B (PKB) 
ARNT  Arylhydrocarbon receptor nuclear translocator 
BrdU  5-bromo-2’deoxyuridine 
BSA  Bovine serum albumin 
Ca2+  Calcium 
CFP  Cyan fluorescent protein 
CGD  Chronic granulomatous disease 
DAF-2  Diaminofluorescein –2 Diacetate 
DCF  5-(and-6)-chloromethyl-2‘,7‘-dichlorodihydrofluorescein diacetate (H2DCFDA) 
DHE  dihydroethidium 
DHR  Dihydrorhodamine 123 
DMEM  Dulbecco's Modified Eagl’s Medium 
DMSO  Dimethylsulfoxide  
DPI  Diphenyleneiodonium 
DTT  Dithiothreitol 
EC  Endothelial cells  
eNOS  Endothelial nitric oxide synthase 
EPO  Erythropoietin 
ERK  p41/42 extracellular signal regulated kinase 
ET-1  Endothelin-1 
ETA  Endothelin receptor A 
ETB  Endothelin receptor B 
GAPs  GTPase activating proteins 
GDIs  Guanine nucleotide exchange inhibitors 
GEFs  Guanine nucleotide exchange factors 
GPR  G protein-coupled receptors 
GPx  Glutathione-peroxidase 
GTT  Guanidinethiocyanate 
h  Hours 
H2O2  Hydrogen peroxide 
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HAT  Hypoxanthine, Aminopterin, Thymidin 
HBSS  Hank’s balanced salt solution 
HIF-1  Hypoxia inducible factor-1 
HRE  Hypoxia-responsive elements 
hU-II  Human urotensin-II  
ICAM–1 Intercellular adhesion molecule  
IGF-1  Insulin growth factor 
IL1-α  Interleukin-1 alpha 
IκBKα  Inhibitory κB protein alpha kinase 
IκBKβ  Inhibitory κB protein beta kinase 
IκBα  Inhibitory κB protein alpha 
IκBβ  Inhibitory κB protein beta 
JNK  c-jun N-terminal kinase 
LDL  Low density lipoproteins 
L-NAME N-ω-nitro-L-arginine methyl ester 
LPS  Lipopolysaccharides 
MAPK  Mitogen activated protein kinases 
MEK1  Mitogen activated protein kinase kinase 1 
Min  Minutes 
NAC  N-Acetyl-Cysteine 
NFκB  Nuclear factor kappa B 
NO  Nitric oxide 
O2-.  Superoxide anion radical 
OH.  Hydroxyl radicals 
ONOO- Peroxynitrite 
oxLDL  Oxidised low density lipoproteins 
PAGE  Polyacrylamide gel electrophoresis 
PAI-1  Plasminogen activator inhibitor-1 
PAK  p21-activated kinase 1 
PAR  Protease-activated receptors 
PASMC Pulmonary artery smooth muscle cells 
PBS  Phosphate-buffered saline  
PCR  Polymerase chain reaction 
PDGF  Platelet-derived growth factor 
PH  Pulmonary hypertension  
Phox  Phagocytic oxidase 
PI3K  Phosphatidyl-inositol-(3) kinase 
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PKB  Protein kinase B 
PMA  Phorbol 12-Myristate 13 Acetate 
PMN  Polymorphonuclear leukocytes 
PPP  Platelet poor plasma 
pVHL  Von Hippel-Lindau protein 
RH123  Rhodamine123 
ROS  Reactive oxygen species 
rSMC  Rat smooth muscle cells 
S1P  Shingosine1 Phosphate 
SHR  Spontaneously hypertensive rats 
SOD  Superoxide dismutase 
TF  Tissue factor 
TGF-β  Transforming growth factor-beta 
TMB  Tetramethyl-benzidine 
TNFα  Tumor necrosis factor alpha 
TRAP  Thrombin receptor activating peptide 
tPA  Tissue-type plasminogen activator  
U-II  Urotensin-II 
uPA  Urokinase-type plasminogen activator 
VEGF  Vascular endothelial growth factor 
Vit C  Vitamin C 
VSMC  Vascular smooth muscle cells  
vWF  von Willebrand factor 
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